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2. Thesis abstract 
 
Background  
Dementia is a national priority for Scotland, and as such, fast and accurate diagnosis plus 
responsive and well-evidenced interventions post-diagnosis are key. Accurately estimating 
an individual’s level of premorbid functioning can be a crucial part of establishing that 
cognitive decline has taken place, enabling clinicians to be more confident and accurate in 
their diagnosis. Measures that assess premorbid ability should be able to 1) capture current 
ability in healthy controls and 2) resist the effects of cognitive decline when used in 
individuals with dementia. At the post-diagnostic stage, there is a growing evidence base for 
non-pharmacological, tailored interventions for individuals with dementia. However, the 
evidence base is limited, particularly so for Cognitive Rehabilitation.  
Objectives 
An empirical study was conducted in order to assess whether a newly developed measure 
that aims to capture lifelong cognitive reserve (the brain’s ability to withstand pathological 
change), the Cognitive Reserve Index Questionnaire (CRIq), can capture premorbid ability. 
Three research questions were addressed; 1) does the CRIq capture current ability in 
healthy controls? 2) is it resistant to cognitive decline when used with a patient group with 
dementia? and 3) how does the CRIq compare to a traditional measure of premorbid ability, 
the NART (National Adult Reading Test)? Another focus of development and innovation in 
dementia research is that of post-diagnostic interventions. A systematic review was 
therefore conducted in order to evaluate the effectiveness of Cognitive Rehabilitation for 
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mild-moderate dementia (Alzheimer disease or mixed dementia) in relation to cognitive and 
functional outcomes. Due to the limited number of RCTs in this field precluding a clear 
understanding of the evidence base, the additional contribution of non-RCTs was also 
evaluated.  
Method 
For the empirical study N=20 healthy older controls and N=13 patients with dementia were 
recruited. In order to appropriately address the three research questions both groups were 
assessed using the NART, the CRIq and the MOCA (Montreal Cognitive Assessment). In 
addition, the control group were assessed on a measure of current ability, the WAIS-IV 
Perceptual Reasoning Index. For the systematic review of Cognitive Rehabilitation the CDCIG 
Specialised Register, ALOIS, was searched in order to identify relevant studies. In addition, 
previous reviews were searched to identify studies excluded on the basis that they were not 
an RCT.  
Results 
Results for the empirical study show both CRIq and NART were strongly correlated to 
current ability (performance on WAIS-IV PRI) in controls, although both significantly over-
estimated ability. CRIq performance was not affected by the presence of dementia whereas 
NART predicted premorbid ability was. CRIq and NART showed a different pattern of results 
between controls and patients, indicating that CRIq may more resistant to the effects of 
cognitive decline. Ten studies were identified for the systematic review; five RCT and five 
non-RCT. Study quality was assessed using a well-validated quality assessment tool, and 
indicated large variability. Eight of the ten studies reported a positive effect of Cognitive 
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Rehabilitation. However, several studies were of poor quality and included aspects of other 
approaches in their intervention (e.g. Cognitive Training, Cognitive-Behaviour Therapy).  
Conclusions 
The empirical study found that CRIq over-estimated current ability in controls, but was 
resistant to cognitive decline in patients. The over-estimation of current ability may be 
accounted for by the CRIq being normed on an Italian population, thus not reflecting UK 
cultural norms (e.g. for length of schooling). When the NART and the CRIq were directly 
compared, the two measures were found to be related, but yet produced significantly 
different estimates of premorbid ability. This suggests that they may capture different facets 
of premorbid functioning, with the NART being primarily a verbal performance-based 
measure, and the CRIq capturing aspects of global cognitive functioning. Clinical implications 
include the potential utility of the CRIq for patients with language impairment. However the 
study conclusions are limited by a low N, and therefore have restricted generalisability. In 
the systematic review, the literature was exhaustively searched and evidence was found for 
the effectiveness of Cognitive Rehabilitation for mild-moderate Alzheimer disease and 
mixed dementia. Methodological limitations of the included studies are discussed, and 
clinical implications are identified. Both the empirical study and the systematic review 
highlight the need for greater research and development of methods by which dementia 
care is supported; through more effective methods of diagnosis, to a better evidence base 
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There is a growing evidence base for non-pharmacological interventions for dementia; 
however, the evidence base for Cognitive Rehabilitation is particularly limited.  
Objectives 
The current review evaluates the effectiveness of Cognitive Rehabilitation for mild-
moderate dementia (Alzheimer disease or mixed dementia) in relation to cognitive and 
functional outcomes. The limited number of RCTs in this field precludes clear conclusions, 
and so the additional contribution of non-RCTs to the evidence base is also evaluated.  
Method 
The CDCIG Specialised Register, ALOIS, was searched in order to identify relevant studies. In 
addition, previous reviews were searched to identify studies excluded on the basis that they 
were not an RCT.  
Results 
Ten studies were identified; five RCT and five non-RCT. Study quality was assessed using a 
well-validated quality assessment tool, and indicated large variability. Eight of the ten 
studies reported a positive effect of the intervention. However, several studies were of poor 
quality and included aspects of other approaches in their intervention (e.g. CT, CBT).  
Conclusions 
This review has exhaustively assessed the literature and found some evidence for the 
effectiveness of Cognitive Rehabilitation for mild-moderate Alzheimer disease and mixed 
dementia. Methodological limitations of studies are discussed, and clinical implications are 
identified. 
 






• This is the first systematic review to exhaustively examine the literature (including 
RCTs and non-RCTs) for cognitive rehabilitation interventions in mild-moderate 
Alzheimer disease and mixed dementia (vascular and Alzheimer disease); focusing on 
cognitive and functional outcomes; 
• There is some evidence to support the effectiveness of cognitive rehabilitation for 
mild-moderate Alzheimer disease and mixed dementia (vascular and Alzheimer 
disease), however, included studies vary in their methodological quality; 
• Studies are inconsistent in their interpretation of ‘cognitive rehabilitation’, the 
duration and number of sessions of the intervention, and the outcome measures 
used. Many studies did not adequately match the intervention aims to the outcome 
measure, thus compromising the likelihood of detecting relevant change; 
• Additional studies of good quality are required to develop greater understanding of 
the efficacy of cognitive rehabilitation for dementia; studies should be consistent in 
their definition of cognitive rehabilitation, should target specific goals, and should 











4.1 Introduction  
Dementia is a disorder characterised by cognitive impairment, and encompasses a variety of 
cognitive difficulties including memory loss, disorientation, language problems, and changes 
in personality (NICE, 2011). Cognitive difficulties can have a catastrophic effect on an 
individual’s ability to carry out everyday tasks, and can lead to low self-confidence, anxiety, 
apathy and low mood (Schoenmakers, Buntinx, & Delepeleire, 2010). Unfortunately, these 
symptoms can exacerbate cognitive impairment, and so magnify the psychological impact of 
receiving a diagnosis of dementia. 
 There are approximately 71,000 people with dementia in Scotland, with an 
associated annual cost of £1.7billion (The Scottish Government, 2010). With projected 
population increases skewed towards an aging population, it is estimated that this number 
will increase to 192,000 by 2040 (The Scottish Government, 2006), although recent evidence 
suggests that this is increasing at a slower rate than previously anticipated (Matthews, 
Arthur, Barnes, Bond, Jagger, Robinson et al., 2013). Nonetheless, post-diagnostic support 
has been identified as an area of service delivery that requires significant development in 
Scotland (The Scottish Government, 2010), with patients and carers awarded with the right 
to “maintain maximum independence, physical, mental, social and vocational ability”, via 
appropriate levels of “rehabilitation” (The Scottish Government, 2010, page 24). There is 
therefore a clear economic and ethical mandate for a well-developed evidence base 
regarding the range of interventions for cognitive and functional decline in dementia.  
 There is a growing evidence base for non-pharmacological interventions targeting 
cognitive and functional abilities in dementia (Spector, Orrell & Hall, 2012; Olazarán, 
Reisberg, Clare, Cruz, Peña-Casanova, del Ser et al., 2010). The underlying basis of these 
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approaches draws upon evidence that some abilities can be relatively spared in the early 
stages of dementia, such as procedural memory (Beaunieux, Eustache, Busson, de la 
Sayette, Viader, & Desgranges, 2012) and implicit memory (Vanhalle, Var der Linden, 
Belleville, & Gilbert, 1998). Imaging studies have provided additional weight to this 
argument, by demonstrating that early pathological changes in Alzheimer’s disease (AD) are 
predominantly located in the hippocampal and entorhinal cortex; the location of memory 
formation (Hodges, 2000). Techniques such as errorless learning attempt to make use of 
these relatively spared abilities to facilitate the encoding or recall of information (Anderson, 
Arens, Johnson, & Coppens, 2001). It is also hypothesised that these techniques help to re-
establish links between various representations in neocortical regions that are less severely 
atrophied in the early stages of dementia.  
 Interventions targeting cognitive decline have predominantly used three 
approaches; cognitive stimulation (CS), cognitive training (CT) and cognitive rehabilitation 
(CR). The definitions used for these approaches are detailed in Table 1.  
 
Table 1. Definition of cognitive interventions based on guidance by Clare, Woods, Moniz 




This approach uses participation in a range of activities to promote the use of cognitive processes (e.g memories of the 
past). It is aimed at general improvement in abilities through the re-retrieval of salient and relevant personal 
information, and was originally designed to overcome disorientation and confusion. Reality Orientation (RO) is the most 
widely established example of this approach, and tends to be delivered in group format. 
Cognitive These interventions focus on the rehearsal of a particular task that relates to a cognitive function (e.g memory or 
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Training (CT) attention). This taps into the theoretical assumption that increased practice of a specific cognitive ability leads to 
generalised improvement in that domain, i.e that the benefit will expand to related abilities. This can be delivered in 
numerous formats including groups (Cahn-Weiner, Malloy, Rebok , & Ott, 2003), on an individual basis (Beck, Heacock, 





This approach aims to improve ability rather than performance on specific tasks. There is more of an individual focus, 
with the targeted abilities agreed upon between the therapist, the individual and where possible, the family. This 
method attempts to draw upon an individual’s strengths and utilise relatively intact domains of memory to facilitate 
learning, through strategies such as errorless learning (Anderson et al., 2001) and spaced-retrieval (Neely, Vikstrom, & 
Josephsson, 2009), as well as develop strategies to compensate for impairments (such as external aids). 
 
 Studies examining the efficacy of CS for dementia have provided sufficient evidence 
for it to be recommended by national clinical guidelines. For example, the Scottish 
Intercollegiate Guidelines Network (SIGN 86, 2006), the National Institute for Clinical 
Excellence (NICE Guidelines 42, 2006), and the Matrix of Psychological Therapies (2011; 
which rates CS as “A”) all recommend CS for dementia. SIGN 86 recommends it based upon 
the results of two studies (Davis, Massman and Doody, 2001; and Quayhagen, Quayhagen, 
Corbeil, Hendrix, Jackson, Snyder, et al., 2000). However, these studies were excluded from 
a more recent meta-analysis of CS as aspects of the intervention meet criteria for both CS 
and CT (as defined by Clare et al., 2003). These study results were therefore confounded by 
poor fidelity to treatment. NICE guidelines (2006) also recommended CS, but note that at 
the time of publication it had not been directly compared to cholinesterase inhibitors in a 
randomised control trial, and so it was difficult to partial out the individual effect of CS on 
cognition. The Matrix (2011) recommends CS based upon the SIGN and NICE guidelines 
(SIGN 86, 2006; NICE guideline 42, 2006) as well as the results of one RCT by Spector, 
Thorgrimsen, Woods, Royan, Davies, Butterworth, et al. (2003). Spector et al. (2003) is also 
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included in a recent Cochrane review that examined all 15 RCTs that have been completed 
examining CS (Woods et al., 2012; Aguirre, Woods, Spector, & Orrell, 2013). This concluded 
that CS has a positive effect on cognition,  based upon a meta-analysis of data from over 700 
individuals, 407 of which received CS. However, some studies included in the review had 
small N’s (e.g. Bottino, Carvalho, Alvarez, Avila, Zukauskas, Bustamante, et al., 2003) and 
limited information regarding patient randomisation, meaning the studies were not all of 
high quality. In addition, the nature and severity of impairment was not consistent across all 
studies; with some only stating that participants met criteria for “dementia” (e.g. Spector et 
al., 2003), whilst others specified this further as a particular type of dementia, such as AD 
(e.g. Requena, Maestu, Fernandez & Ortiz, 2006). Even so, there was evidence to support 
more generalised improvement in communication and social interaction over and above 
medication effects, addressing the concern raised by NICE (2006). However, Woods et al. 
(2012) found limited evidence for any benefit to mood or ability to participate in activities of 
daily living. In addition, no studies included data related to caregiver burden. Another 
systematic review of RCTs examined which domains of cognition were most able to benefit 
from CS (Spector, Orrell & Hall, 2012). Again, this found evidence of general cognitive 
enhancement, but was able to specify this further and identify that memory and language 
were most amenable to enhancement through CS. Overall, there is a growing evidence base 
for CS in dementia.  
 CT is not recommended by either SIGN or NICE. A Cochrane review of CT was 
completed in 2003 (Clare et al., 2003), updated in 2008 (Clare & Woods, 2008) and again in 
2013 (Bahar-Fuchs, Clare & Woods, 2013). The 2008 review included nine RCTs, and 
examined the effect of the intervention across five domains; scores on cognitive screening 
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measures; scores on neuropsychological tests; self-reported functioning; informant report 
of participant functioning and carer’s perception of memory and behaviour problems. 
Whilst no negative effect of CT was detected, no significant benefit was identified for any 
domain. However, due to the variability of measures used between studies, the number of 
participants contributing data to each of these domains was low, even when data was 
pooled. For example, the largest meta-analysis completed in the review was for 
neuropsychological test performance (change in immediate verbal memory score). This 
consisted of data from four studies, with a total N of 137 participants, which is still a smaller 
N than many single studies examining CS (e.g. Spector et al., 2003). The most recent update 
of this meta-analysis (Bahar-Fuchs et al., 2013) found an additional two RCTs for CT, 
however, this did not alter the overall findings of the review. In conclusion, there is a 
minimal evidence base for CT in dementia.  
 A Cochrane review of CR (Clare & Woods, 2008) undertook a comprehensive search 
for papers examining CR for dementia. However, they were unable to find any RCTs. This 
was recently updated (Bahar-Fuchs et al., 2013) using an equally rigorous search strategy, 
with one RCT identified that met inclusion criteria. The outcome of this single study (Clare, 
Linden, Woods, Whitaker, Evans, Parkinson, et al., 2010) was promising, with significant 
improvement in scores on neuropsychological tests and functional ability in patients with 
AD, which was supported by changes in fMRI data. It also identified several studies of CR 
that were not RCTs (e.g. Kixmiller, 2002; Hwang, Choi, Yoon, Yoon, Suh, Lee, et al., 2012) but 
did not include them in the meta-analysis due to strict inclusion criteria for studies. The 
evidence base for the delivery of CR interventions has potential, but is extremely limited, 
and based solely on individual studies. There is therefore no published systematic review 
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(containing more than one study) or meta-analysis of CR for dementia, for either RCTs or 
non-RCTs.  
 With an aging population, the demand for interventions targeting cognitive and 
functional outcomes following dementia diagnosis is set to increase. The evidence for non-
pharmacological interventions is rather patchy, particularly for CR interventions, where 
there are few single studies and virtually no reviews (e.g Olazaran et al., 2010). Clinicians 
therefore have little evidence base to draw upon when developing post-diagnostic support 
for patients. A Cochrane review by Clare & Woods, (2008) did not identify any RCTs and so 
no review could be completed. The recent update (Bahar-Fuchs et al., 2013) was only able 
to identify one study, and so again the evidence base as a whole was unable to be 
examined. The current review will build upon these findings by examining studies excluded 
by Clare & Woods (2008) and conducting a new search for papers in order to review all 
available evidence for CR for dementia, including non-RCTs.   
 
4.2 Method 
The structure of this review follows guidance developed by the Centre for Reviews and 
Dissemination (CRD, 2009), which forms part of the National Institute for Health Research. It 






4.2.1 Inclusion criteria 
 Study design 
All studies published in English, examining the effect of CR for dementia, were included. This 
included RCTs and non-RCTs so as to comprise all relevant information and to develop a fully 
informed understanding of the evidence base. All criteria for study inclusion are based upon 
those outlined by Clare & Woods (2008), in an attempt to exclude studies of poorer quality 
(e.g with no comparison group).  
 Population 
• Participants had a medical diagnosis of dementia, according to DSM-IV (American 
Psychiatric Association, 1995), ICD-10 (World Health Organisation, 1992) or NINCDS-
ADRA (McKhann, Drachman, Folstein, Katzman, Price, & Stadlan, 1984). This could be 
further specified as AD, Vascular (VaD) or mixed dementia. These diagnostic categories 
were considered together due to limited data.  
• No limits were made regarding age of participant, due to limited data.  
• Studies were excluded if participants were identified as having a diagnosis of fronto-
temporal dementia, as this subtype of dementia is likely to require a significantly 
different intervention to that of other forms of dementia.  
• Data regarding concurrent treatment with cholinesterase inhibitors was noted if 
possible. 
• Severity of dementia was indicated if possible, preferably through performance on a 
standardised cognitive screening measure or neuropsychological tool such as the Mini-
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Mental State Examination (MMSE; Folstein, Folstein, &McHugh, 1975) or the Clinical 
Dementia Rating (CDR; Hughes, Berg, Danziger, Coben, & Martin, 1982).  
• Studies primarily targeted mild-moderate dementia (MMSE score >12 or CDR score < or 
= 2). However, a small proportion of studies (30%) did not specify the severity of 
dementia, or included participants in the severe range.  
• Participants could be residing at home or in a care home. Interventions could be offered 
in a variety of settings including; day hospital, at home, as an out-patients. However, 
participants were excluded if they were resident in a psychiatric institution, or were 
known to have a co-morbid psychiatric condition.  
 Intervention 
• Studies of CR targeting any aspect of cognitive functioning were included. This might be 
described as ‘therapy’, ‘training’, ‘stimulation’ or ‘re-training’, but was still included if it 
met Clare et al.’s (2003) definition of CR. This could include either one or both of the 
following; 
 Drawing upon preserved or remaining ability by identifying how best to take in or 
learn important information, or carrying out important tasks (e.g. Kixmiller, 
2002); 
 Using compensatory strategies such as external aids, environmental 
modifications or using techniques to facilitate learning, to reduce demand on 
memory systems. This includes techniques such as errorless learning (e.g. 
Anderson et al., 2001); 
21 
 
• Studies were included if they compared the intervention to ‘no treatment’, ‘standard 
treatment’, an alternative cognitive rehabilitation condition, a placebo treatment, or a 
control condition. ‘Standard treatment’ might include medical management, relaxation 
training, or Occupational Therapy. 
• No studies were included where the comparison group consisted only of healthy 
controls; meaning that all studies included at least one comparison group with 
dementia. 
• No limits were set on the number of sessions or duration of intervention. 
• Interventions could be delivered in individual or group format, with or without family 
caregivers.  
 Outcome measures 
Outcomes for the individual with dementia were considered in this review. This attempted 
to identify whether any changes were evident post-intervention, and whether any changes 
could be attributed to the intervention itself. Given the nature of dementia, it was unlikely 
that significant improvement on measures would be seen. Therefore, between-group 
differences in the trajectory of cognitive decline (between pre-post treatment, for 
intervention and no-intervention groups) were considered. In this instance,  a smaller 
decline in performance on cognitive measures in comparison to a non-treatment group 
would be seen as a positive outcome, and would indicate an effective intervention. 
Therefore, studies were included if at least one of the following measures were recorded 
pre and post intervention. Additional measures of performance at follow up was considered 
as desirable but not necessary for inclusion; 
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• Performance on standardised cognitive screening tests measuring global cognitive 
function or severity of dementia (e.g. MMSE, CDR); 
• Performance on standardised neuropsychological tests that evaluate aspects of 
cognitive functioning such as memory (e.g. Wechsler Memory Scale-Revised; Wechsler 
1987) or executive functioning (e.g. Trail Making Test; Reitan, 1958); 
• Performance on a cognitive or functional measure developed specifically for use in the 
study, where this was relevant to participants’ everyday functioning or reflected a core 
deficit associated with dementia (e.g. face-name recall, remembering to complete a 
task); 
• Self-reported change in cognition (e.g. memory) or health status on standardised 
measures; 
• Self-reported change in mood (e.g. anxiety or depression) on standardised measures; 
• Observer, clinician or carer rating of behaviour, everyday functioning (ability to carry out 
activities of daily living), well-being, quality of life, or neuropsychiatric symptoms. 
 
4.2.2 Search strategy 
The Cochrane Dementia and Cognitive Improvement Group Specialised Register, ALOIS 
(http://www.medicine.ox.ac.uk/alois/) was searched in order to identify studies for this 
review. ALOIS is a comprehensive register of dementia studies and contains records of RCTs, 
CCT’s and open-label studies. Studies are identified from: 
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• Monthly searches of the major healthcare databases: MEDLINE, EMBASE, PSYCHINFO, 
CINAHL and LILACS; 
• Monthly searches of numerous trial registers including: Centre Watch Clinical Trials 
Listing Service; CENTRAL (The Cochrane Library); ClinicalTrials.gov;  
• Monthly searches of grey literature sources including ISI Conference Proceedings; and 
worldwide Index to Theses.  
The ALOIS database was searched on 9th April 2013.  For full details of all sources searched 
by ALOIS see http://www.medicine.ox.ac.uk/alois/content/about-alois. This review 
therefore builds upon that of Clare & Woods (2008) by including all studies of CR (including 
RCTs and non-RCTs). Their comprehensive search identified 11 studies but all were excluded 
as they failed to meet their criterion that they be RCTs. After further examination of these 
studies, three were identified that would meet the criteria for the current review. A search 
was therefore completed in order to identify potential studies published since the search 
was completed for the Clare & Woods (2008) review. The search terms used were taken 
from Clare & Woods (2008): cognitive stimulation OR cognitive rehabilitation OR cognitive 
training OR cognitive retraining OR cognitive support OR memory function OR memory 
rehabilitation OR memory therapy OR memory aid OR memory group OR memory training 
OR memory retraining OR memory support OR memory stimulation OR memory strategy OR 
memory management. This retrieved 1014 references. After screening these references 
based on the health status of the participants, the type of intervention (pharmacological or 
non-pharmacological) and excluding those published pre-2006 (as this was when the search 
was completed for Clare & Woods, 2008), this left 117 studies. A secondary search was 
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undertaken in order to identify any new publications that had not been entered into the 
ALOIS database at the time of the search (as this is only updated monthly). Therefore, the 
above search terms were entered into EMBASE, MEDLINE and PSYCHINFO, with results 
limited to studies of human participants, in the English language, published in 2013. This 
identified an additional 205 papers. These combined searches therefore resulted in 322 
papers. After de-duplication, and a first and second assessment (removing studies based 
upon reading the title and the abstract), a total of 22 papers were read and assessed for 
inclusion or exclusion into the systematic review. This revealed a total of seven papers.  This 
therefore increased the total number of studies included in the current review to 10, and 
meant that the current review includes all RCTs, CCT’s and open-label studies examining 
Cognitive Rehabilitation in dementia. Figure 1 summarises the search strategies used and 


































3. TOTAL number of papers found meeting 
Cochrane review criteria, RCTs AND non 
RCTs, no date limit, limited to cognitive 
rehabilitation intervention 
N = 10 papers 
2.  Exclude studies based on 
reading paper. 
Exclude if intervention NOT 
Cognitive Rehabilitation 
N = 3 papers  
1. CLARE & WOODS (2008):  
No studies identified suitable for 
review, i.e. NO RCTs identified. 
Number of studies excluded 
because they were NOT an RCT 
N = 11 papers 
SEARCH TERMS USED FOR ALL LEVEL 1 SEARCHES: 
Cognitive stimulation OR cognitive rehabilitation OR cognitive training OR cognitive 
retraining OR cognitive support OR memory function OR memory rehabilitation OR 
memory therapy OR memory aid OR memory group OR memory training OR memory 
retraining OR memory support OR memory stimulation OR memory strategy OR 
memory management 
1. ALOIS Searched using search 
terms 
N = 1014 papers  
2. Refine based on health status 
of study participants: 
Include only: MCI, dementia, 
Alzheimer disease, senile 
dementia, mixed dementia, 
clinical population.  
N = 319 papers 
2. Limit search criteria to: 
HUMAN/ English Language/ 
published in 2013 
N = 205 papers 
1. PSYCHINFO, EMBASE and 
MEDLINE searched using search 
terms 
N = 17869 papers 




AND studies with both types of 
intervention 
N = 183 papers  
4. Exclude studies published pre 
2006 (as this was when Clare & 
Woods, 2008, completed their 
search) N = 117 papers 
6. Exclude studies based on title.  
N = 103 papers 
7. Exclude studies based on 
reading abstract.  
N = 22 papers  
5. COMBINE Searches 
N = 322 papers  
8. Exclude studies based on 
reading paper.  
N = 7 papers  
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Figure 1. Flow chart of search strategy and study selection process 
 
4.2.3 Assessment of study quality 
Quality assessment tools developed for use in systematic reviews, such as those proposed 
by SIGN or CRD (http://www.york.ac.uk/inst/crd/), tend to be relevant only to the 
evaluation of randomised control trials (RCTs). However, when sufficient RCTs are not 
available, clinicians and policy makers are required to turn to non-RCTs in order to be able 
to develop relevant clinical guidelines. For the present review, it is necessary to be able to 
compare mixed methodologies in order to adequately review the current available 
evidence. In order to address this problem, Deeks, Dinnes, D’Amico, Sowden, Sakarovitch, 
Song et al. (2003) evaluated 60 quality assessment tools in order to identify those that are 
suitable for non-RCTs and for reviews that include both study designs. Deeks et al. (2003) 
identified six quality assessment tools suitable for this purpose. Of these, the Downs & Black 
(1998) quality assessment tool was deemed most suitable for the current review.  
  This quality assessment tool has been cited 970 times since publication (according 
to Scopus http://www.scopus.com/home; searched 7th June 2013), and so has been well-
used for this purpose (See Appendix A1; screenshot taken 15/07/13). Downs & Black (1998) 
has been further adapted by Cahill, Barkham & Stiles (2010) specifically for use in reviews of 
psychological, practice-based research. Since its publication Cahill et al. (2010) has been 
used to systematically review psychological interventions on 11 occasions (according to 
Scopus 7th June 2013; see Appendix A1, screenshot taken 15/07/13).  The present review 
therefore uses the tool developed by Cahill et al. (2010) to assess the quality of each study.   
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 The quality assessment checklist provides an overall score derived from four 
dimensions; reporting (11 items), external validity (11 items), internal reliability of 
measurement and treatment (5 items), and internal reliability of confounding variables (5 
items). Each item is scored as present (1) or absent (0). This provides a total score out of 32 
(see Appendix A2).  
 Data extraction was completed using a standardised template. Initial coding of 
papers was completed by the author (JP), using the checklist criteria, which codes each item 
based on whether the paper addresses the item appropriately; Yes=1, No=0, Unable to 
determine=0. Secondary coding was completed by an independent doctoral level 
practitioner who was a Trainee Clinical Psychologist (BP). Initial agreement between raters 
was good at 87.5%. The majority of these differences were within the External Validity 
domain, and were resolved via discussion and re-checking of papers, which then resulted in 
100% agreement.  
 
4.3. Results 
Data from each of the 10 included studies was extracted using a standardised template. 
Synthesis of data was completed using a narrative approach. Meta-analysis was not 
undertaken due to the variation in design, outcome measures, and intervention approach 
between the studies.  
4.3.1 Quality of studies 
Study quality was assessed using the quality assessment tool developed by Cahill et al. 
(2010), see Table 2. This provides a basis upon which to compare the methodological 
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strengths and weaknesses of each study, and identified a large discrepancy between 
studies. Based upon the quality assessment, Kixmiller (2002) was the least methodologically 
sound study, scoring 10/32 whilst Clare et al. (2010) was the strongest study 
methodologically, scoring 30/32. In general, RCTs were of greater quality than non-RCTs 
(averaging 23.4/32 Vs. 18.4/32). Interestingly, there were several criteria that almost all 
studies failed to achieve. Quality criteria #13 “representative population – participants” was 
only met by one study; Clare et al. (2010). Quality criteria #15a “facilities and staff 
representative of usual treatment” was only achieved by Matsuda, Shido, Haskihai, Shibuya 
& Kouno (2010). Similarly, quality criteria #12a “representative population – invitees” was 
only achieved by Clare et al. (2010) and Neely et al. (2009). This suggests that the majority 
of studies were poor at indicating whether the participants that a) were invited or b) 
participated in the study, were representative of the sample from which they were 
recruited; whether the intervention was a variation from the usual treatment offered; and 
whether therapists were free to use multiple approaches as part of the intervention.  
4.3.2 Characteristics of studies  
Of the 10 studies included in this systematic review, five were RCTs, and five were non-RCTs 
(including one series of single cases; one ABA design; one pilot study; and one non-
randomised control study). Studies varied in terms of the primary aims, outcome measure 
(standardised or non-standardised), rehabilitation technique (e.g. errorless learning, spaced-
retrieval, mnemonics, vanishing cues) and the type of comparison group (e.g. treatment as 
usual, relaxation group, medical management, occupational therapy) and so each of these 




































Quality criteria  Does study meet criteria? Yes = 1,  No = 0, Unable to determine = 0 
1 Aims/ hypothesis 1 1 1 1 1 1 1 1 1 1 
2 Outcomes  1 1 1 1 1 0 1 1 1 1 
3 Characteristics of participants 1 1 1 1 1 1 1 1 1 1 
4 Treatment described 1 1 1 1 1 1 1 1 1 1 
5 Confounders  1 1 1 1 1 0 1 1 1 1 
6 Findings  1 1 1 1 1 0 1 1 1 1 
7 Variability  0 1 1 1 1 0 1 1 1 1 
8 Adverse events  1 1 1 1 1 0 1 1 1 1 
9 Characteristics of attrition 1 1 1 1 1 1 1 1 1 0 
10 Reporting values 0 0 1 1 1 0 1 0 0 1 
11 Effect sizes, reliability 0 0 1 1 1 0 0 1 1 0 
12a Representative population – invitees 0 0 1 0 0 0 0 0 1 0 
12b Recruitment  1 1 1 1 0 0 0 1 1 0 
13 Representative population – participants 0 0 1 0 0 0 0 0 0 0 
14a Heterogeneity of sample – demographics 0 1 1 1 0 0 1 0 0 0 
14b Heterogeneity of sample – clinical presentation 0 1 1 0 0 1 0 1 1 1 
15a Facilities, staff representative 0 0 0 0 0 0 0 1 0 0 
15b Intervention location – University setting 1 0 1 1 1 1 0 0 0 0 
15c Monitoring of intervention 0 1 1 1 1 0 1 1 1 1 
16 Experienced therapists 0 0 1 1 0 0 0 1 0 0 
17 Intervention procedure – flexibility 0 0 0 0 0 0 0 0 0 0 
18 Training of therapists 1 0 1 1 0 0 1 1 0 1 
19 Data dredging 0 1 1 1 1 1 1 1 1 1 
20 Appropriate statistical tests 0 1 1 1 1 0 1 1 1 1 
21 Fidelity to treatment 1 1 1 1 1 0 1 0 1 1 
22 Valid and reliable outcome measures 1 0 1 1 1 0 1 1 1 1 
23 Analysis adjusted to length of follow up 1 0  1 1 1 1 1 1 1 1 
24 Recruitment population equal for all groups 1 0 1 0 1 1 1 1 1 1 
25 Recruitment timing equal for all groups 0 0 1 1 1 0 1 1 0 0 
26 Adjustment for confounders 0 0 1 1 1 0 1 1 0 1 
27 Attrition accounted for 1 1 1 1 1 1 1 1 1 1 
28 Power 0 0 1 0 0 0 1 0 0 0 






1 Is the hypothesis/ aim/ objectives of the study clearly described 
2 Are the main outcomes to be measured clearly described in the introduction or methods section 
3 Are the characteristics of the clients included in the study clearly described 
4 Are the interventions/ treatments of interest clearly described 
5 Are the distributions of principal confounders in each group of clients to be compared (or within a single group) clearly described 
6 Are the main findings of the study clearly described 
7 Does the study provide estimates of the random variability in the data for the main outcomes 
8 Have all the important adverse events that may be a consequence of the intervention/ treatment been reported 
9 Have the characteristics of clients lost to follow-up been described 
10 Have actual probability values been reported (e.g. 0.035 rather than ,0.05) for the main outcomes except where the probability value is less than 0.01 
11 Have sufficient data been provided to enable calculation of outcomes such as pre–post ESs, estimates of reliable and clinically significant change 
12a Were the clients asked to participate in the study representative of the entire population from which they were recruited 
12b Were clients referred through usual clinic routes 
13 Were those clients who were prepared to participate representative of the entire population from which they were recruited 
14a Were client heterogeneous in personal characteristics 
14b Were clients heterogeneous in terms of presenting problems 
15a Were the staff, places, facilities where the patients were treated representative of the treatment the majority of patients receive 
15b Was the treatment conducted in a non-university setting 
15c Was implementation of treatment monitored  
16 Were therapists experienced, professionals with regular caseloads 
17 Were therapists free to use a wide variety of procedures in treatment and not just limited to one treatment procedure 
18 Were therapists trained immediately before the study and in the specific treatment being studied 
19 If any of the results of the study were based on ‘data dredging’ was this made clear  
20 Were the statistical tests used to assess the main outcomes appropriate 
21 Was the compliance with the intervention/ s/treatments reliable 
22 Were the main outcome measures used accurate (valid and reliable) 
23 Do the analyses adjust for different lengths of follow-up of patients in different treatment groups 
24 Were the clients in different intervention /treatment groups recruited from the same population 
25 Were the clients in different  intervention /treatment groups recruited over the same period of time 
26 Was there adequate adjustment for confounding in the analysis from which the main findings were drawn 
27 Were losses of clients to follow-up taken into account 
28 Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5% 




 Aims of studies 
All included studies aimed to assess the impact of cognitive rehabilitation on participants’ 
cognitive or functional abilities. Not all studies described their intervention as cognitive 
‘rehabilitation’; however, studies have been included where all or part of the intervention 
meets the definition of cognitive rehabilitation as described by Clare & Woods (2008).  
 Characteristics of cohort 
All 10 studies in this review recruited participants with a diagnosis of dementia. Nine studies 
stated that participants met criteria for a diagnosis of dementia according to widely used 
and well-validated criteria; either ICD-10 criteria (Kurz, Tho, Cramer, Egbert, Fro lich, Gertz, 
et al., 2012), DSM-IV criteria (Kessels & Olde Henskena, 2009; Neely et al., 2009), or NINCDS-
ADRA criteria (Clare, Wilson, Carter, Roth & Hodges, 2002; Clare et al., 2010; Hwang et al., 
2012; Kixmiller, 2002; Niu, Tan, Guan, Zhang & Wang, 2010). One study mentioned both 
NINCDS-ADRA and DSM-IV criteria (Matsuda, Shido, Hashikal, Shibuya, Kouno, Hara, & Saito, 
2010). Anderson et al., 2001, stated that participants met diagnostic criteria for dementia, 
but did not specify the criteria used. Eight studies specified the type of dementia diagnosed, 
with six studies including patients with a diagnosis of AD (according to NINCDS-ADRA or 
DSM-IV criteria; Clare et al., 2002; Hwang et al., 2012; Kessels, et al., 2009; Kixmiller, 2002; 
Matsuda et al., 2010; Niu et al., 2010). Two studies included participants with AD, VaD or 
mixed AD and VaD (Clare et al., 2010; Neely et al., 2009). Six studies specified the severity of 
dementia using supporting evidence from standardised measures such as MMSE, CDR or 
GDS (Global Deterioration Scale; Reisberg, Ferris, Leon, et al., 1982). Of these, only one 
included participants with severe dementia (MMSE <14; Kessels et al., 2009), whilst all other 
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studies included participants with ‘moderate’, ‘mild’ or ‘minimal’ dementia (MMSE 14-26; 
Anderson et al., 2002; Clare et al., 2002; Hwang et al., 2012; Kixmiller, 2002; Kurz et al., 
2012).  
 Sample size of groups 
The number of participants in the intervention group ranged from small N’s (e.g. Anderson 
et al., 2001; with N=3 per intervention group) to larger samples (e.g. Kurz et al., 2012; with 
N=100 in the intervention group). The total number of participants receiving cognitive 
rehabilitation was N=277, with N=236 receiving either a control condition (e.g. wait-list 
control) or alternative intervention (e.g. relaxation group, medical management, 
occupational therapy group). Whilst Clare et al. (2010) received the highest quality score, 
the sample size used was relatively small (N=21 in the intervention group).  
 Comparison group  
Studies varied in the treatment received by the comparison group. One study compared two 
rehabilitative techniques (Anderson et al., 2001). One study had a control condition, rather 
than a control group, meaning that participants acted as their own controls (Clare et al., 
2002). One study (Kessels et al., 2009) used a non-dementia group as a control; instead 
using a ‘somatic’ participant sample. However, this study included two intervention groups, 
one that received an errorless learning paradigm, and another that used trial and error 
learning, which effectively comprised a dementia control group, as they received no training 
in cognitive strategies to aid learning. The remaining eight studies had a dementia 
comparison group that received no intervention (e.g. wait-list control, standard medical 
management), or who participated in communication exercises, occupational therapy or 
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spent the equivalent amount of time completing questionnaires (Clare et al., 2010; Hwang 
et al., 2012; Kixmiller, 2002; Kurz et al., 2012; Matsuda et al., 2010; Neely et al., 2009; Niu et 
al., 2010). Kurz et al. (2012) reported significant demographic differences between groups at 
baseline, despite having the largest sample size.   
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Table 3. Summary of characteristics of studies and conclusions  
Study, 
Country 







baseline (s.d1)  
Allocation to 
group 
Groups and N 
per group 
























(List of 22 personal 
orientation questions) 
7 days and 8 
days 
The purpose of 
intervention was to train 
participants to recall 
personal orientation 
information using either 







Spaced retrieval technique. 
Group A: 
12 sessions each 
30 minutes 
duration, 4 per 




12 sessions each 
30 minutes 
duration, 4 per 
week for 3 
weeks.  
 
Improvement was found 
across all subjects, 
although no statistical 
analysis was performed. 
 
 
The spaced retrieval 
group learned target 
information quicker 
than the errorless 
learning group. 












according to  
NINCDS-ADRDA;  
Minimal: MMSE 
24+, Mild: MMSE 
18-23 







Yes – some participants 
taking 
acetylcholinesterase 
inhibitor, some not; one 
began during study, two 
discontinued prior to 
study (donepezil and 
rivastigmine) 





act as own 
controls.  
N= 12 10 free recalls of 12 
photographs (asked to 
name person in photo), 
given over 3 sessions.  
 
1,3, 6 and 12 
months 
Intervention: 
Purpose of intervention 
was to facilitate 
participants’ learning of 
photographs using 
mnemonic, spaced-
retrieval, vanishing cues.  
 
Participants act as their 
own controls by being 
trained on some items, and 





Six sessions of 
unknown length.  
Just over half of the 
participants showed 
clear benefit from the 
intervention.  
                                                     
1 S.D = Standard Deviation 
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N= 56, mixed 
Alzheimer disease 
and vascular 
dementia N = 13. 
MMSE 18+ 
Yes – stable dose for 4 
weeks prior to study. 
(N=46 were taking 
donepezil, N=18 were 
taking reminyl, and N=4 
were taking 
rivastigmine) 








Primary: COPM.  
Secondary: RBMT-II, 
Verbal fluency, TEA 
(map search, elevator 
counting, elevator 
counting with 




relatives stress scale, 
brain imaging (fMRI) 
6 months Intervention Group: 
Individualised intervention 
addressing personal goals. 
Supported by practical aids 
and strategies, techniques 
for learning new 
information using face-
name learning, practice in 
maintaining attention and 
concentration, techniques 
for stress management.  
 





No contact with researcher 
between initial assessment 




Eight sessions,  
held weekly, 




The Intervention group 
showed significant 
improvement in ratings 
of goal performance and 
satisfaction, with large 
effects sizes in 
comparison to other 
groups.  
 
At 6 month follow up 
Intervention Group 
subjectively rated their 
memory more positively 
than the Control Group.  
 
fMRI data showed 
increased activation 
during encoding and 
recognition of face-
naming task in 












Stage 4 on Korean 
GDS  
MCI Group: 




Petersen et al. 
(2001).  
 
On stable dose for 8 




65% Range 50-80 Unclear  AD Group: 
Intervention 
N= 6,  





Control N=5.  
SVLT, ROCF, Digit Span 
forwards/backwards, 





















visual imagery, errorless 
learning, finding key words 
of a story or news item, 
giving a title to a story or 









weekly,  each 50 
minutes 
duration.  
The AD intervention 
group showed 
significant improvement 
in global cognition and a 
trend towards a 
significant improvement 























Unclear  60% Severe 
dementia: 
Errorless = 83.6 
(8.1) 














Random  Severe 
dementia: Trial 















1-3 days Participants had to learn a 
procedural problem-
solving task; the Action 
Programme subtest of the 
BADS.  
Two task conditions: 
 
Trial & error condition: 
Standard instructions 
given. Cues only provided if 
participant unable to 
complete next step.  
 
Errorless learning 
condition: Cues are 
provided before 
participant completes 
sequence, so that no errors 







superior for the 
errorless learning group 
compared to the trial 
and error learning group 
across all dementia 
groupa. The benefit was 
largest after delay 










MMSE mean = 20 
Unclear  DK DK Unclear Intervention 








3, 4 and 7 
weeks 
Intervention Group: 
Used errorless learning and 
spaced-retrieval 
techniques to learn  one of 
two prospective memory 
tasks: 
 
Event -based task: The task 
was initiated by research 
assistant calling participant 
at home. This prompts a 
series of steps the 
participant has to take. 
 
Time-based task: 
Participants had to call the 
research assistant with 





twice weekly,  
each lasting 30-




performed well in the 
following 7 weeks post-
treatment .  







and tasks.  
 





10 criteria.  
MMSE mean >26 
.  


















DEMQOL, GDS, NPI, 
WMS Logical memory, 
TMT, verbal fluency 
(Regensburg word 
fluency test), MMSE 
(German version).   
 
Carer: Zarit Buren 
interview, BDI, 
 




intensive: 1 day.  
Followed by manualised 
intervention covering 4 
modules: 
Use of external memory 
aids; introduction of daily 
routines (rehabilitation 
strategies); day structuring; 





medical management. Not 
standardised across sites; 
could vary between OT, 
physiotherapy, carer 
counselling, carer support 





plus 12 weekly 1 
hour individual 
sessions. 
No significant group 
effect of intervention on 
the participants’ ability 
to perform activities of 
daily living. 
 
Significant effect of 
intervention on 
depressive symptoms in 
females in intervention 


















Yes – taking donepezil 












HDS-R - Intervention Group: 
Completed cognitive 
exercises and developed 
learning techniques 
including cued-recall and 
word completion exercises 
 
Control Group: 




7 sessions, each 
30 minutes in 
length.  




cognitive decline to a 
greater extent than 
donepezil alone.  
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Neely et al., 
2009,  
Sweden 




























Unclear.  Collaborative 
Intervention 




Group: N= 20 
 
Control Group:  
N= 20 




recall, random; recall of 
non-categorisable 
word;,recall of 
categorisable words.  
BDI, Zarit caregiver 
burden.  
 
- Collaborative Intervention 
Group: 
Intervention focused on 
two different learning 
strategies; spaced retrieval 
and hierarchical cueing. 
Aimed to learn how to set 
a table. Task 
difficulty/goals 
individualised based on 
name recall capacity. With 




As above, but without 
caregiver involvement to 
provide cues, this was 
instead provided by 
research assistant.  
 
Control Group:  











No group differences 
were found.  
 
Authors conclude that 
study shows that 
caregiver involvement is 
beneficial, that people 
with dementia can 
benefit from the 
caregiver gaining 
knowledge of cognitive 
rehabilitation 
interventions.  










Yes – stable dose for 3 




 80.56 (4.23)  
Control Group: 
79.13 (4.38) 
Random  Intervention 
Group: N=16 
Control Group:  
N=16 
MMSE, NPI - Intervention Group: 
Difficulty level varied for 
each patient.  
Reality orientation/ fluency 
task (category and letter), 
overlapping figure task, 
photo-story learning task 




communication exercise.  
20 sessions 
10 weeks, 2x 
session per week 
each 45 minutes 
long. 
Significant improvement 
on NPI, improvement in 
domains of apathy and 
depression. MMSE 
improvement in score 
compared to control 
group. Concluded that 
mild-mod AD on stable 






AFIB: Aachen functional item inventory; BADL: Bayer Activities of Daily living; BADS: Behavioural Assessment of the Dysexecutive Syndrome; BDI: Beck Depression Inventory; COPM: Canadian Occupational 
Performance Measure; DEMQOL: Quality of Life in Dementia; GDS: Geriatric Depression Scale; GDS-K: Geriatric Depression Scale – Korean version; GHQ-12: General Health Questionnaire; HADS: Hospital Anxiety and 
Depression Scale; HDS-R: Hasegawa Dementia Scale-Revised; ILS: Independent Living Scales; K-BNT: Korean version of the Boston Naming Test; MARS: Memory Awareness Rating Scale; MMSE: Mini-Mental State 
Examination; NPI: Neuropsychiatric Inventory; RMBT-II: Rivermead Behavioural Memory Test; ROCF: Rey-Osterrith Complex Figure Test; SVLT: Seoul Verbal Learning Test; TEA: Test of Everyday Attention; TMT: Trail 






 Anticholinesterase medication 
Of the included studies, four were unclear as to whether participants were taking any 
cholinesterase inhibitor (Anderson et al., 2001; Kessels et al., 2009; Kixmiller, 2001; Neely et 
al., 2009). Niu et al. (2010) included only participants that had been on a stable dose of 
donepezil for a minimum of eight weeks prior to the study, whilst Matsuda et al. (2010) 
included participants that were taking donepezil, but did not specify the length of time it 
had been prescribed. Similarly, Kurz et al. (2012) stated that participants were taking a 
cholinesterase inhibitor, but did not specify which medication, nor how long it had been 
prescribed. Hwang et al. (2012) stated that participants had been on a stable dose for a 
minimum of eight weeks prior to the study, but did not specify the medication. Finally, both 
Clare et al. (2002) and Clare et al. (2010) specified that participants had been taking a 
cholinesterase inhibitor for a minimum of four weeks, including donepezil, rivastigmine and 
reminyl. Clare et al. (2002) also specified that some participants discontinued medication 
during the study. Only Matsuda et al. (2010) and Clare et al. (2010) had a priori planned 
comparison between those who did and those who did not take medication.   
 
4.3.3 Cognitive rehabilitation intervention  
The interventions outlined in the included studies ranged in length from one session 
(Kessels et al., 2009) to 18 sessions (Hwang et al., 2012), with an average of 10.4 sessions. 
Session length ranged from 30-120 minutes duration. Of the 10 studies, six assessed the 




hierarchical cueing (Clare et al., 2002; Hwang et al., 2012; Kessels et al., 2009; Matsuda et 
al., 2010; Neely et al., 2009 and Niu et al., 2010). One study examined the impact of a 
memory aid (Kurz et al., 2012). Two studies examined the impact of memory aids and 
cognitive strategies (Clare et al., 2010; Kixmiller, 2002). One study compared two different 
strategies (Anderson et al., 2001; errorless learning Vs. spaced retrieval). Only one study 
actively involved caregivers in the intervention (Neely et al., 2009). Training delivery was 
unclear for two studies (Matsuda et al., 2010; Kessels et al., 2009). Niu et al. (2010) 
delivered their intervention in a group format. The remainder used individualised 
interventions; with rehabilitation taking place either at home (Clare et al., 2002; Clare et al., 
2010; Kixmiller, 2002; Neely et al., 2009), in clinic (Hwang et al., 2012; Kurz et al., 2012) or in 
care homes (Anderson et al., 2001).  Interpretation of results was confounded in four 
studies by the inclusion of additional interventions, such as cognitive stimulation strategies 
(reality orientation; Hwang et al., 2012; Niu et al. 2010), cognitive training (Matsuda et al., 
2010), and psychotherapeutic approaches (Kurz et al., 2012).  
 
4.3.4 Primary outcome measures  
 Cognition measures 
Seven studies included standardised measures as primary outcome indicators (Clare et al., 
2010; Hwang et al., 2012; Kessels et al. 2009; Kurz et al., 2012; Matsuda et al., 2010; Neely 
et al., 2009; Niu et al., 2010). There was no single measure used consistently across all 




(e.g in English; Clare et al., 2010, in German; Kurz et al., 2012; and Korean, Hwang et al., 
2012), meaning that their direct comparison was not possible.  
 The MMSE was used as a measure of global cognitive ability by Hwang et al. (2012; 
Korean version; Kang, 2006), Kurz et al. (2012; German version; Kessler, Markowitsch & 
Denzler, 1990) and Niu et al. (2010). In contrast, Matsuda et al. (2010) used the Hasegawa 
Dementia Scale-Revised (HDS-R; Kato, Shimogaki, Onodera et al., 1991), and Neely et al. 
(2009) assessed intelligence using the Wechsler Adult Intelligence Scale-Revised (WAIS-R; 
Wechsler, 1981). Standardised measures of memory ability were used by four studies. Clare 
et al. (2010) used the Rivermead Behavioural Memory Test (RBMT; Wilson, Cockburn & 
Baddeley, 1985), whilst Hwang et al. (2012) used the Digit Span subtest of the Wechsler 
Adult Intelligence Scale-Revised, the Rey Osterrith Complex Figure task (RCFT; Loring, Lee, & 
Meador, 1988) and the Seoul Verbal Learning Test (SVLT). Kurz et al. (2012) assessed 
memory performance using the Wechsler Memory Scale Logical Memory subtest (WMS; 
Wechsler, 1997), and Neely et al. (2009) assessed memory using the Digit Span subtest of 
the Wechsler Adult Intelligence Scale-Revised (WAIS-R).  
 Four studies assessed aspects of executive functioning (such as fluency, processing 
speed, naming ability, awareness, inhibition). Clare (2010) used the Test of Everyday 
Attention (map search, elevator counting, elevator counting with distraction subtest, TEA; 
Robertson, Ward, Ridgeway et al., 1994) and verbal fluency. Hwang et al. (2012) used the 
Stroop Test, animal fluency, phonemic fluency, calculation, the Korean version of the Boston 
Naming Test (Kim & Na, 1997), and the Self-Assessment of Cognition to assess executive 
functioning ability. Kessels et al. (2009) used performance on the Behavioural Assessment of 




their primary outcome measure. Kurz et al. (2012) used the Trail Making Test (TMT; Reitan, 
1958) and verbal fluency. Finally, Neely et al. (2009) assessed executive functioning using 
category fluency and the Swedish Synonym Test (SST; Dureman & Salde, 1959). Of these 
seven studies, only Matsuda et al. (2010) discussed the validity and reliability of the 
measure/s used to assess cognition. 
 In contrast, Anderson et al. (2001), Clare et al. (2002) and Kixmiller (2001) all used 
measures created specifically for their study as their primary outcome measure. Anderson 
et al. (2001) used an orientation measure consisting of 22 personal orientation questions, 
ranging from “What day is this?” to “What time do you go to lunch?”, with no information 
provided regarding it’s reliability and validity. Clare et al. (2002) used participants’ ability to 
recall correct face-name associations as their primary outcome measure. Again, there was 
no indication of the reliability and validity of this measure. Kixmiller (2001) used percentage 
recall of prospective memory tasks as their primary outcome, again without evidence of 
reliability and validity. Neely et al. (2009) used a combination of both standardised 
measures (as outlined above) plus four memory tasks (collaborative object recall, clustered; 
collaborative object recall, random; recall of non-categorisable word; recall of categorisable 
words) developed specifically for the study.  
 Functional measures 
Three studies included assessment of function as part of their primary outcome measure.  
For Clare et al. (2010) the Canadian Occupational Performance Measure (COPM; Law, 
Baptiste, Carswell et al., 2005) was used to assess personal goals and satisfaction, alongside 




Daily Living (BADL; Hindmarch, et al., 1998) to assess informant/caregiver views on patients’ 
capacity for self-care and self-management and the Aachen Functional Item Inventory (AFIB; 
Bocker, Eberle & Gauggel, 2007) to assess functional ability. Clare et al. (2002) used the 
Clifton Assessment Procedure for the Elderly (CAPE; Pattie & Gilleard, 1979) to examine 
cognitive and behavioural functioning. Both Clare et al. (2010) and Kurz et al. (2012) 
discussed the reliability and validity of their measures, with Clare et al. (2010) in particular, 
discussing the link between the study’s intervention goals and their outcome measures.  
 Additional measures 
Whilst the majority of studies focused on cognitive and functional change, additional 
changes in quality of life, mood and behavioural disturbance were assessed by six studies. 
Mood and satisfaction was assessed by Clare et al. (2010) using the Hospital Anxiety and 
Depression Scale (HADS; Snaith & Zigmund, 1994) and Quality of Life in Alzheimer disease 
(QoL-AD; Logsdon, Gibbons, McCurry et al., 1999.). Hwang also used the QoL-AD, Korean 
version as well as the Geriatric Depression Scale- Korean version (GSD-K; Bae & Cho, 2004), 
and a satisfaction questionnaire. Changes in mood (depressive symptoms) was assessed by 
Kurz et al. (2012) using the GDS, by Neeley et al. (2009), using the Beck Depression 
Inventory (BDI; Beck, Steer & Brown, 1996) and by Clare et al. (2002), using the HADS. 
Behavioural disturbance was measured by Kurz et al. (2012) and Niu et al. (2010) using the 
Neuropsychiatric Inventory (NPI; Cummings, 1997). None of these studies discussed the 




Table 4. Summary of primary outcomes measures, domain of measurement and intervention effect size 
Study Primary outcome measure Domain Pre-intervention between group effect size 
calculated using cohen’s d 
Post-intervention between group effect size  Follow up between group effect size 
Anderson et al., 2001 Non-standardised orientation 
measure 
Cognition: Attention and  
orientation 
- - - 
Clare et al., 2002 Free recall of words Cognition: Memory - - - 
Clare et al., 2010 COPM Goal performance and 
satisfaction 
ES= -0.011 (COPM Performance CR Vs. RT) 
ES= -0.022 (COPM Satisfaction CR Vs. NT)  
ES= 0.000 (COPM Satisfaction CR Vs. RT) 
ES= 1.175 (COPM Performance CR Vs. RT) 
ES= 0.865 (COPM Satisfaction CR Vs. NT)  




Hwang et al., 2012 Neuropsychological test battery 
and quality of life measure 
Cognition and quality of life ES= 0.674 (K-QoL)  
ES= 0.081 (K-MMSE) 
- ES= -0.85 (K-QoL)  
ES= 0.52 (K-MMSE)  




ES= 0.31(Severe dementia BADS)  
ES= 0.52(Mild dementia BADS)  
ES= 0.60 (Severe dementia BADS)  
ES= 1.61 (Mild dementia BADS)  
Kixmiller, 2002 
 
Adherence to completing event 
based or time-based task 
Cognition: prospective 
memory 
- - - 
Kurz et al., 2012 BADL Functional ability - - - 
Matsuda et al., 2010 HDS-R Cognition  ES= -0.192 (HDS-R) ES= 0.27 (HDS-R) - 
Neely et al., 2009 Memory tasks, Zarit, BDI Cognition; Memory, 
caregiver burden, mood.  
ES= 0.-0.023 (Categorisable words) 
ES= 0.200 (Non-categorisable words) 
ES= 0.88 (Categorisable words) 
ES= -0.05 (Non-categorisable words) 
- 
- 
Niu et al., 2010 MMSE, NPI Cognition, behavioural and 
psychiatric disturbances 
- - - 
BADL: Bayer Activities of Daily living; BADS: Behavioural Assessment of the Dysexecutive Syndrome; BDI: Beck Depression Inventory; COPM: Canadian Occupational Performance Measure; HDS-R: Hasegawa 





4.3.5 Power and effect size 
Only two studies reported a priori power calculations to determine sample sizes (Clare et al., 
2010; Kurz et al., 2012). Both Clare et al. (2010) and Kurz et al. (2012) assumed their planned 
analyses would be able to detect a large (0.8) effect size significant at the 5% level. Kurz et 
al. (2012) calculated their required sample size based upon their study having 80% power, 
whilst Clare et al’s. (2010) had 78% power to detect a large effect size. Similarly, only three 
studies provided details of effect sizes at the post-intervention or follow up phase (Clare et 
al., 2010; Kessels et al., 2009; Matsuda et al., 2009), however, some studies included 
sufficient data for this to be calculated using the formula for Cohen’s d: [(treatment mean – 
control mean)/ pooled standard deviation], see Table 4 for effect sizes (ES). Post-
intervention ES ranged from small (0.27) (Matsuda et al., 2010) to large (0.88) (Neely et al., 
2009) for performance on memory tasks. Post-intervention performance on measures of 
executive functioning showed a small ES (0.31) for those with severe dementia, whilst a 
medium ES (0.52) was found for those with mild dementia (Kessels et al., 2009). A large ES 
(ranging from 0.865-1.175) was found at post-intervention for a measure of occupational 
performance (Clare et al., 2010). At follow up, a medium ES (0.52) was found for a measure 
of global cognition (Hwang et al., 2012). Finally, at follow up a medium ES (0.60) was found 
for a measure of executive functioning for severe dementia and a large ES (1.61) for mild 
dementia (Kessels, 2009). Attrition was discussed by all studies, and where relevant, was 






4.3.6 Summary of main findings  
The main findings of each study will be considered in turn, alongside their main strengths 
and weaknesses: 
Anderson et al. (2002) recruited six participants with mild-moderate probable dementia, 
and compared two approaches (errorless learning and spaced retrieval) for learning 
personal orientation information. Each group (N=3) received 12 individual sessions of 
cognitive rehabilitation for 30 minutes over a duration of four weeks at their care home. All 
participants were tested on their recall of personal orientation information using an 
orientation measure consisting of 22 items, at pre-intervention, post-intervention and at 7 
days and 8 days follow up. Results were primarily descriptive, with no statistical analysis 
completed. Results showed improvement in recall across all subjects, with the spaced 
retrieval group learning target information quicker than the errorless learning group. The 
main strength of this study was the matching of the intervention to the outcome measure; 
it’s main weaknesses were the lack of statistical analysis, low N and short follow up.  
Clare et al. (2002) recruited 12 participants with minimal-mild probable AD. No 
control group was recruited; instead, participants completed an experimental condition and 
a control condition. Participants received six individual, home-based sessions of unknown 
length, during which they received training on numerous strategies (mnemonics, spaced-
retrieval and vanishing cues) to support learning for one set of photographs (experimental 
condition), whilst receiving no training for a second set of photographs (control condition). 
The primary outcome measure was explicit free recall of 10 photographs. Assessment was 




Results indicated a statistically significant effect of the intervention, whereby recall of 
trained items and untrained items was improved. This improvement was maintained at 6 
months, with scores remaining above baseline at 12 months. Although this study benefitted 
from matching the intervention to a relevant outcome measure and a substantial length of 
follow up, the sample size was small and it lacked a control group.  
Clare et al. (2010) recruited participants with AD and mixed dementia (AD and VaD), 
who were on a stable dose of anticholinesterase inhibitor. Participants were randomly 
allocated to a CR group (N=21), a relaxation group (RT; N=23) or a control group (NT; N=21). 
The CR group received eight individual, weekly, home-based, one-hour sessions of CR, which 
included techniques for facilitating learning, stress management, and memory aids, in order 
to address individual personalised goals. The RT group received an equivalent amount of 
input during which relaxation techniques were practiced, whilst the NT group received no 
input pre-post intervention. The primary outcome measure was the COPM, which measures 
goal performance and satisfaction. Assessment took place at the pre and post-intervention 
stage, and at a 6 month follow up. Results indicated a significant effect of group; the CR 
group performing significantly better on the COPM at follow up, with a large effect size. At 
the 6 month follow up, the CR group rated their memory as better than the RT or NT groups, 
and carers of the RT group rated their quality of life as better. fMRI data supported these 
findings by demonstrating increased activation during assessment on a face-naming task for 
the CR group. Increased cortical activation was found within several visual associative brain 
regions, particularly during encoding and recognition. Whilst the study reached statistical 




meeting a ‘two-point criterion’ (Clare et al., 2010), i.e. a two point change in overall score on 
the COPM. The authors accounted for this by noting that their intervention targeted only a 
small selection of personal goals, rather than all goals for rehabilitation. In common with the 
previous studies, Clare et al.’s sample size was relatively small, particularly for the fMRI 
group but their strong adherence to CR principles, the fMRI data, the calculation of ES and 
the long term follow up are significant strengths.   
Hwang et al. (2012) recruited four groups; an AD intervention group (N=6), AD 
control group (N=3), aMCI intervention group (N=6) and an aMCI control group (N=5). The 
intervention groups received 18 individual, clinic-based, weekly sessions of 50 minutes 
duration, which included aspects of cognitive stimulation (e.g. reality orientation), and 
aspects of cognitive rehabilitation (e.g. errorless learning). The control groups were 
allocated to a wait list. Pre-intervention, post-intervention and follow up (the intervention 
group had a 2 week and 3 month follow up, whilst the control group had a 3 month follow 
up) assessment was completed. Outcome measures included a neuropsychological 
assessment, plus a quality of life measure. Results indicated that the AD intervention group 
performed significantly better on measures of global cognition and executive functioning at 
post-intervention and follow up than the AD control group, although the AD group 
benefitted less than the aMCI group. Main strengths of this study include the long term 
follow up and the inclusion of a clear control group; weaknesses include the confounding of 
the CR intervention with a CS intervention, not matching the intervention to the outcome 




Kessels et al. (2009) compared learning techniques (trial and error learning and 
errorless learning) in patients with mild-moderate dementia (N=20) and severe dementia 
(N=20), as well as a control group without dementia (N=20). Participants were randomly 
allocated to either an errorless learning condition or a trial and error condition, creating six 
groups with N=10 per group. The primary outcome measure was performance on the Action 
Programme subtest of the Behavioural Assessment of the Dysexecutive Syndrome (BADS). 
The intervention consisted of one session, of unknown duration, with participants learning 
how to complete the Action Programme using either trial and error learning or errorless 
learning. Results demonstrated an effect of condition, with all groups performing better 
following errorless learning compared to trial and error learning. The benefit of condition 
was largest 1-3 days post-intervention. Strengths of this study include the specific, goal 
oriented nature of the intervention, with the outcome measure matched to the 
intervention, and an a priori ES calculation. Limitations include small follow up time and the 
briefness of the intervention. 
Kixmiller (2002) recruited seven participants with probable AD into a pilot 
programme for improving prospective memory performance. Participants were allocated to 
two groups; an intervention group (N=5) and a control group (N=2). The intervention group 
received six individual, home-based, sessions of CR, each lasting 30-120 minutes, during 
which participants used errorless learning and spaced retrieval techniques to learn one of 
two tasks; an event-based task, and a time-based task. The control group received no 
training, but spent time completing questionnaires and “tasks”. The primary outcome 




Performance was measured post-intervention and at follow up (3, 4 and 7 weeks). Results 
were descriptive as no statistical analysis was completed. This indicated that the 
intervention group performed ‘well’ compared to the control group at post-intervention and 
follow up. The main strength of this study is that the intervention was related to the 
outcome measure; limitations of this study include the small N, the lack of clarity around the 
intervention itself and the relatively unstandardised nature of the outcome measure. 
Kurz et al. (2012) evaluated a cognitive behavioural and cognitive rehabilitation 
intervention in 201 participants with mild dementia in a multicentre RCT. Participants were 
randomly allocated to either an intervention group (N=100) or a control group (N=101). The 
intervention was multicomponent and manualised, with an initial pre-study training day 
followed by 12 weekly, individual, clinic-based, one-hour individual sessions, conducted in 
various outpatient settings. The intervention included aspects of CR (e.g. external memory 
aids) as well as aspects of cognitive-behaviour therapy (e.g. day structuring, activity 
planning). The control group received site specific treatment as usual; which varied between 
medication only, carer counselling or occupational therapy input. The primary outcome 
measure was the Bayer Activities of Daily Living (BADL), and was assessed pre and post-
intervention, as well as at three and nine month follow up.  Results indicated no significant 
effect of CR on functional outcomes, patient or carer treatment satisfaction or patient or 
carer mood at post-intervention or follow up. Interestingly, the only significant finding was 
an intervention-related improvement in depressive symptoms in females at post-
intervention and follow up. The main strengths of this study include the large N and 




intervention with principles of CBT, and the lack of a goal-focused, intervention-related 
outcome measure. 
Matsuda et al. (2010) recruited 49 participants with AD all taking donepezil, 
allocated to either an intervention group (N=31) or a wait list control group (N=18). The 
intervention group received seven individual, hospital-based, 30 minute sessions comprising 
aspects of cognitive training (e.g. verbal fluency) and cognitive rehabilitation (e.g. cued-
recall and word completion exercises). The primary outcome was performance on the 
Hasegawa Dementia Scale-Revised (HDS-R). Results indicated a significant decrease in HDS-
R, indicating improved cognition. The authors concluded that donepezil plus the cognitive 
intervention slowed cognitive decline to a greater extent than donepezil alone. The main 
strengths of this study include the large sample size and the calculation of ES; main 
limitations include confounding of the intervention with aspects of CT, and the lack of an 
intervention-related outcome measure.  
Neely et al. (2009) examined the effectiveness of a cognitive intervention in 
participants with AD or VaD, and their partners, in an RCT. The intervention used two 
learning strategies (hierarchical cueing and spaced-retrieval) to learn a face-naming task, 
and complete a table setting activity, and was delivered in participants’ homes in eight 
weekly sessions. The intervention was delivered either individually (intervention group, 
N=10 couples) or collaboratively (with both patients and their partners, N=10 couples). The 
control group received no input (N=10 couples).  Primary outcome measures included four 
memory tasks, caregiver burden and depression, and were completed at pre and post-




indicating no effect of CR. The authors noted that there was anecdotal evidence to suggest 
that the collaborative intervention improved patients’ episodic memory more so than 
individual interventions. The main strengths of this study include the goal-oriented nature of 
the intervention; the main limitation was that the outcome measure was not related to the 
intervention goal, and there was no follow up.  
Niu et al. (2010) completed an RCT examining the effect of a cognitive intervention 
on cognition and neuropsychiatric symptoms in participants with probable AD, who had a 
stable dose of cholinesterase inhibitor. Participants were randomly assigned to either the 
intervention (N=16) or control group (N=16). The intervention used aspects of CS (e.g. 
reality orientation) and CR (e.g. errorless learning) and was delivered in group format over 
20 sessions, each lasting 45 minutes, occurring twice per week. The control group 
participated in ‘communication’ exercises. The primary outcome measures were MMSE and 
NPI, which were administered at pre and post-intervention. Results indicated that the 
cognitive intervention has a significant effect on cognition (MMSE scores), apathy and 
depression (NPI score). The authors argued that by their participation in communication 
exercises, the control group also control for the effect of social interaction and so the 
beneficial effects of the intervention on cognition were not thought to be mediated by 
social interaction. Additionally, as all groups were taking an acetlycholinesterase inhibitor, 
this could not account for any group differences. The main strength of this study was the 
length of the intervention; main limitations include the confounding of the CR intervention 
with aspects of CS, the lack of a goal-related intervention, the use of outcome measures 




4.3.7 Synthesis of results according to study dimensions 
 Consideration of quality of studies 
The ten studies included in this review varied in overall quality score from 10/32 (Kixmiller, 
2002) to 30/32 (Clare et al., 2010), with a mean average score of 25.2. Seven good quality 
studies were identified (scoring 20+ out of a possible 32 on the quality assessment tool). 
However, one of these studies confounded the intervention through poor fidelity to 
treatment (by including features of CS; Niu et al., 2010). This therefore leaves six studies of 
moderate to high quality. Of these, four found a positive effect of CR, whilst two found no 
evidence for the efficacy of CR.  
 Consideration of heterogeneity of intervention 
Synthesising results of this review is difficult due to the variation in the interventions that 
are considered ‘Cognitive Rehabilitation’. Such interventions are defined by Clare and 
Woods (2008) as consisting of either: 1) the use of strategies to facilitate learning by utilising 
relatively spared aspects of cognition, such as errorless learning and 2) the use of strategies 
to compensate for impairment, such as external aids.  
 Strategies to facilitate learning 
Examples of this approach include errorless learning, spaced retrieval and hierarchical 
cueing. Kurz et al. (2012) was the only study that did not include this type of approach at all; 
and interestingly was one of the only studies to find no effect of the intervention. Clare et 




intervention. Therefore, seven studies examined only cognitive strategies to facilitate 
learning, without the inclusion of external aids. Within the different types of facilitative 
strategies, errorless learning was used most often, although the majority of studies used 
more than one strategy. For example, Clare et al. (2002) included spaced-retrieval and 
mnemonics; Kixmiller (2002) used spaced-retrieval and errorless learning and Anderson et 
al. (2001) compared errorless learning to spaced retrieval. Both Hwang et al. (2012) and Niu 
et al. (2010) used errorless learning and reality orientation, the latter of which is classed as a 
cognitive stimulation approach rather than a CR approach. Whilst Hwang et al. (2012) found 
a large ES for their intervention, the individual effects of CR and CS cannot be separated and 
so few conclusions can be made. Results indicate a mixed picture: whilst Neeley et al. (2009) 
found no effect of such strategies, Clare et al. (2002) did find an effect. In addition, 
Anderson et al. (2001) found that spaced-retrieval was superior to errorless learning, and 
Kessels et al. (2009) found that errorless learning was superior to trial and error learning, 
with a small ES for severe dementia participants post-intervention and a medium ES for mild 
dementia patients post-intervention, increasing to a medium ES at follow-up for severe 
dementia, and a large ES at follow-up for mild dementia patients. Finally, Matsuda et al. 
(2012) found that cued-recall and word completion strategies were superior to no 
intervention, with a small ES. These results suggest an overall picture in favour of the use of 
facilitative strategies as part of CR; however, results are unclear as to which particular 






 External memory aids 
Two studies examined the efficacy of memory aids in combination with facilitative 
strategies; Clare et al. (2010) and Kixmiller (2002). In addition, Kurz et al. (2012) used 
external memory aids without using facilitative strategies, but used cognitive-behaviour 
therapy (CBT) strategies instead. Kurz et al. (2012) found no effect on cognitive or functional 
ability, however, their intervention cannot be considered purely CR in nature due to the 
additional features of CBT. Both Clare et al. (2010) and Kixmiller (2002) concluded that their 
interventions improved outcomes; based upon goal-related performance and prospective 
memory performance. Clare et al. (2010) in particular, found a large ES for their 
intervention. These findings suggest that external memory aids may be a useful feature of 
CR, however it is not possible to partial out the effects of each aspect of the CR intervention.  
 Consideration of appropriate outcome measures   
A methodological factor highly relevant to this review is the extent to which studies 
matched the primary outcome measure to the targeted area of learning i.e did the outcome 
measure capture any change in targeted ability? Four studies used measures that were 
developed specifically to assess the cognitive domain directly targeted by the intervention; 
Anderson et al. (2001), Clare et al. (2002), Kixmiller (2002) and Neeley et al. (2009). These 
studies all used non-standardised measures such as ability to complete a prospective 
memory task (Kixmiller, 2002) or recall of face-name associations (Clare et al., 2002). Whilst 
the unstandardised nature of these outcome measures is open to criticism; they do attempt 




measured outcome using MMSE and NPI (i.e. global cognition and behavioural disturbance) 
whereas the intervention was focused upon memory. A similar problem was encountered 
by Kurz et al. (2012) who measured overall goal satisfaction, whilst only targeting some 
goals with the intervention. In this instance it could be argued that the outcome measure 
was too ambitious, and attempted to measure overall change in functioning, rather than 
specific aspects of functioning. Similar criticism can be applied to Clare et al. (2010) who 
measured goal performance and satisfaction, but did not address all clinically relevant goals 
with the intervention. Given the prevalence of this methodological issue it is surprising that 
the majority of studies reported an effect of the intervention. This suggests that had the 
outcome measure been better aligned with the intervention, results may have been more 
conclusive. 
 Consideration of intervention consolidation 
Clare & Woods (2008) argue that studies investigating CR interventions should measure long 
term follow up. This is because maintenance of improved functioning is a crucial aim of CR, 
as is a successful transference of learning to real life settings. Three studies in this review 
did not measure long term follow up (Matsuda et al., 2012; Neely et al., 2009; Niu et al., 
2010). The remaining studies varied in the length of follow up from one day (Kessels et al., 
2009) to 12 months (Clare et al., 2002). Four studies found a benefit of the intervention at 
follow up; Clare et al. (2002), at six month and 12 month follow up; Clare et al. (2010) at six 
month follow up; Hwang et al. (2012) at three month follow up; and Kessels et al. (2009) at 




 Interestingly, whilst some of these results were not statistically significant, where 
results remained above baseline performance, this was seen as a reflection of a maintained 
benefit (e.g. Clare et al., 2002). This raises an interesting aspect of measurement; no 
significant change in performance over time (particularly for follow up of six or 12 months) 
may actually reflect a benefit of intervention for a dementia population, who would 
normally be expected to show significant decline in performance. It is therefore unfortunate 
that follow up ES was unable to be calculated for the majority of studies. For the two studies 
where this could be calculated (Hwang et al., 2012; Kessels et al., 2009), medium to large 
ES’s were found (0.52-1.61). In addition, all studies in this review can be criticised for placing 
little emphasis upon long terms gains, with only one study (Clare et al., 2002) attempting to 
measure the amount to which participants practised the strategies they had developed 
during the intervention. Future studies should attempt to measure this, and include this 
variable in their analysis, so as to assess the contribution of practice and consolidation of 
learning on long term outcome. Overall, there is limited evidence to suggest a long term 
benefit of CR. Future studies should attempt to measure long term gains more appropriately 
and consistently, whilst also taking account of any attempt by participants to consolidate 










4.4.1 Findings of current review 
This systematic review identified all original studies of CR for dementia using a highly 
rigorous search method. In addition to all RCTs completed on this topic, non-RCTs were 
included, in order to exhaustively review the literature and develop a clinically relevant 
summary of findings. It is perhaps surprising then, that only 10 studies were identified. 
Within these studies, there was significant heterogeneity in methodological quality and 
study design. Of the 10 included studies, four confounded their findings by including non-CR 
principles embedded into the intervention; both Niu et al. (2010) and Hwang et al. (2012) 
included aspects of both CR and CS (e.g. reality orientation), whilst Kurz (2012) included 
aspects of cognitive-behaviour therapy and Matsuda et al. (2010) included aspects of CT. Of 
these, only Kurz et al. (2012) reported no effect of the intervention on cognition or 
functional measures. Of the remaining six, one study (Neeley et al., 2009) found no effect of 
intervention. The remaining five studies found a positive effect of CR on cognition or 
functional ability, however these studies vary in their methodological quality. Overall, there 
is some evidence to support the efficacy of CR for dementia, however, more good quality 
studies are required in order to develop an evidence base of how such interventions should 
be delivered in order to gain maximum benefit to patients.  
  Identifying ways in which the current review adds to previous findings is difficult due 




seemingly provided evidence for all non-pharmacological interventions, including CR (e.g 
Olazaran et al., 2010), when this is examined more closely, there is in fact only evidence in 
relation to CT interventions, and only for cognitive outcomes. Little evidence has been 
gathered for CR interventions. For example, Clare and Woods (2008) and Bahar-Fuchs et al. 
(2013) attempted to conduct a meta-analysis for CR, but were unable to do so because of 
strict inclusion criteria meaning only one study of CR was identified. Bahar-Fuchs et al. 
(2013) acknowledge that limiting reviews to RCTs only may be problematic, as high-quality 
non-RCTs can have fewer threats to internal validity than some poorly conducted RCTs. The 
current review therefore attempts to address this problem and build upon the 
recommendations of past research.  
 This review supports previous research into the mechanisms underlying non-
pharmacological interventions. For example, Beaunieux et al. (2012) and Vanhalle et al. 
(1998) identified that learning can be facilitated in early dementia by drawing upon 
relatively spared abilities. The evidence from this review supports this hypothesis, as the 
majority of studies used strategies to facilitate learning, such as errorless learning or 
hierarchical cueing, which rely less on areas that are associated with early changes in AD 
(e.g. Hippocampal regions; Hodges, 2000). In addition, fMRI data from Clare et al. (2010) 
supported the hypothesis that participants receiving a CR intervention had increased neural 
activation in visual-associate brain regions during encoding and recognition. This suggests 
that CR may encourage patients to utilise spared abilities and neural pathways, and adapt 





4.4.2 Strengths of current review 
This review includes all studies that have compared CR to a control group, control condition 
or an alternative intervention, for patients with dementia. Previous reviews of CR have 
focused only on RCTs, meaning that few conclusions can be developed and little guidance 
can be offered to clinicians. This review therefore has significant implications for clinical 
practice. The ALOIS database and a past Cochrane review (Clare and Woods, 2008) were 
used to identify papers for this review. The ALOIS database is updated monthly and so an 
additional search of three major databases (MEDLINE, EMBASE, PSYCHINFO) was completed 
to ensure that no recently published papers had been missed. The current review also used 
a well-validated quality assessment tool that has been identified as suitable for use where 
RCTs and non-RCTs are included in systematic reviews (Deeks et al., 2003; Cahill et al., 
2010). An independent reviewer also rated papers, with 87.5% agreement (increasing to 
100% after discussion and re-checking of papers). Using an independently developed, 
widely-used tool, as well as a secondary reviewer, minimised any subjective bias in the 
rating of studies and ensured greater methodological quality of this review.  
 
4.4.3 Limitations of current review 
The current review was limited to articles published in English, and to those databases 
included by ALOIS. In addition, the search terms used were based upon those used for a 
previous Cochrane review of CR (Clare and Woods, 2008). It is therefore possible that these 




this review. In addition, the heterogeneity of studies means that synthesising and 
interpreting findings is difficult. An additional weakness of the current review was that 
authors were not contacted directly, and so there may be unpublished data held by authors 
that is relevant to this review. Publication bias may also have affected this review, meaning 
that studies that found little or no effect of CR were not identified. However, given that any 
addition to this limited literature would be clinically relevant (be it a positive or negative 
outcome for CR) it is likely that such a study would still be published. However, by not 
contacting authors directly, any publication bias may have been exacerbated.  
 
4.4.4 Implications for clinical practice 
The considerable amount of heterogeneity between studies in this review makes it difficult 
to develop comprehensive guidelines for clinicians, however the following points should be 
considered when developing a CR intervention for patients; 
• There is evidence to suggest that interventions should draw upon both types of CR 
strategies, i.e. strategies to facilitate learning plus memory aids; 
• It was not possible to draw any conclusions regarding the specific types of facilitative 
strategies that are most effective. However, errorless learning and spaced-retrieval 
were used most frequently by the studies in this review. Other strategies include 




• There was no evidence to suggest a negative effect of combining a cholinesterase 
inhibitor with CR. Indeed, Matsuda et al. (2012) found that combining these 
approaches was superior to medication alone, although their intervention did 
combine aspects of CR with CT; 
• Outcome measures should be matched to the intervention in order to maximise 
fidelity; 
• Post-intervention consolidation of the intervention should be considered; 
• The areas of functioning targeted by the intervention should be linked to patients’ 
goals and be relevant to everyday life; 
• Few patterns emerged regarding number of sessions, however, several studies 
commented that the number of sessions provided should be sufficient to address all 
relevant goals for the patient; 
• Several studies also commented that future interventions should focus on specific 
goals and apply specific CR strategies extensively to that goal, rather than trying to 
address multiple goals; 
• The majority of studies in this review used CR with mild-moderate AD, VaD or mixed 
dementia (AD and VaD). This review provides strongest evidence for the efficacy of 
CR for mild-moderate dementia, with the largest ES’s for this group. The ES’s for 
severe dementia were smaller, but still provides some evidence for its efficacy with 




4.5 Conclusions  
This review included RCTs and non-RCTs and so methodological quality varied greatly. Given 
that the evidence came from a limited number of trials, with methodological limitations, it is 
surprising to see that the majority of studies found an effect of the intervention on 
measures of cognition and functioning. This therefore builds upon findings of previous 
individual studies, and provides weight to the theoretical underpinnings of CR. Overall, this 
review has found promising evidence to support the efficacy of CR for mild-moderate 
dementia. Future research should focus on specific aspects of CR and match the outcome 
measure to the intervention more explicitly. Clinically, this review suggests that 
interventions should use strategies to facilitate learning in addition to memory aids in order 
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Measures that estimate premorbid ability should 1) capture current ability in controls and 2) 
be resistant to cognitive decline. 
Objectives 
To assess whether the Cognitive Reserve Index Questionnaire (CRIq) and the NART, meet 
these two criteria.  
Method 
N=20 older controls and N=13 patients with dementia were recruited and assessed using 
the NART, the CRIq and a measure of current ability (controls only).  
Results 
CRIq and NART over-estimated current ability in controls. NART was negatively affected by 
cognitive decline, whilst CRIq was not.  
Conclusions 
CRIq did not meet the first criteria, but did meet the second criteria. Better norms for UK 
populations are required.  
 





Diagnosing dementia requires clinicians to establish that a decline in cognitive functioning 
has taken place in comparison to previous ability or ‘premorbid ability’. Clinicians are often 
required to make this judgement after only a single assessment (Lezak, Howieson, Bigler & 
Tranel, 2012) and for the vast majority of patients premorbid ability has to be estimated as 
there is  no assessment of ability prior to the perceived  onset of decline to allow direct 
comparison. Accurately establishing a patients’ level of premorbid cognitive ability can 
therefore allow clinicians to be more confident in their diagnosis, rather than relying on a 
comparison with normative data. This is because whilst normative data can provide 
information regarding current ability in comparison to population norms, this tells you little 
about current ability in comparison to previous ability. This is particularly problematic if, for 
example, a patient performs in the ‘average’ range on standardised tests, but their 
premorbid ability is superior. This would mean that compared to their own baseline, their 
ability is impaired, but their performance may be considered unimpaired based on 
normative date. An additional problem is that normative data based on demographic 
information tends to err towards the average, meaning that few people are categorised 
within the extreme ranges of ability, leading to under-detection of impairment. 
Several techniques have been employed to estimate premorbid cognitive functioning 
including; demographic equations, ‘best performance’ indicators, and so-called ‘hold tests’. 
 Demographic equations estimate premorbid ability based on information such as 
education and occupational history (e.g. Barona, Chastain & Reynolds, 1984; Crawford & 




are based on large, standardised samples (e.g. Barona et al., 1984) and remove subjective 
interpretation by the clinician. This therefore means that performance and interpretation 
are unaffected by current ability. However, this method has been criticised for having range 
restriction at the extreme ends of ability (i.e. IQ <75 or >125), which may lead to over or 
underestimation of premorbid ability (Reynolds, 1997).  
 ‘Best performance’ indicators are used when a battery of tests has been completed 
with the patient. The clinician selects the test with the best performance as an indicator of 
premorbid ability. Reynolds (1997) argues that this approach is psychometrically flawed and 
is likely to lead to the over-estimation of premorbid ability. This is because, even in normal, 
standardised populations there is large variability in performance across tests, and so this 
technique fails to consider psychometric issues regarding regression to the mean.  
 Hold tests are used to measure abilities that are thought to be relatively resistant to 
cognitive decline. The most prominent and widely measured ability is word reading ability 
(e.g. NART; National Adult Reading Test, Nelson, 1982; WTAR; Wechsler Test of Adult 
Reading, Wechsler, 2001; and CCRT; Cambridge Contextual Reading Test, Beardsall, 1998).  
Word reading ability has long been hypothesised to remain intact in the presence of 
dementia, particularly in Alzheimer’s disease (AD) (e.g Barona et al., 1984; Yuspeh & 
Vandenploeg, 2000). This method has been critiqued in terms of its theoretical 
underpinning. The hypothesis that a single measure of ability can accurately predict global 
premorbid ability has been criticised by researchers due to the significant variation in 
abilities across different domains that is found in normal populations (Lezak et al., 2012; 




  In an attempt to marry two techniques, demographic equations have also been 
combined with hold tests in order to predict premorbid functioning (e.g. Oklahoma 
Premorbid Intelligence Estimation; OPIE; Krull, Scott & Sherer, 1995; Crawford, Cochrane, 
Besson, Parker & Stewart, 1990). These have been found to predict 73% of variance; an 
increase on 66% for hold tests alone in normal populations (Crawford, Stewart, Parker et al., 
1989). However, when tested in a clinical population, these formulas do not significantly 
increase the percentage of variance accounted for above hold tests alone (Bright, Jaldow & 
Kopelman, 2002). 
 Reviews and studies comparing different methods of premorbid estimation tend to 
recommend the use of demographic equations above the use of hold tests and best 
performance methods (Taylor, 1999; Schretlen, Buffington, Meyer & Pearlson, 2005; Griffin, 
Mindt, Rankin, Ritchie & Scott, 2002; Lezak et al., 2012; Reynolds, 1997). Despite this, hold 
tests - the NART in particular - are still routinely used in clinical practice and in research, and 
it is routinely considered the ‘gold standard’ in premorbid assessment.  
O’Carroll, Mofoot, Ebmeier, & Goodwin (1992) recommend that any measure of 
premorbid functioning should fulfil three criteria. It should 1) be highly correlated with 
current ability when tested in a healthy population; 2) be resistant to cognitive decline, i.e 
performance should not be affected by the presence of dementia; and 3) have high inter-
rater reliability.  
 The NART has been widely researched with regard to the first two criteria. For 
example, Dykiert and Deary (In Press) retrospectively validated the NART on the first criteria 




healthy aging population correlated highly (r=.66-68) with childhood ability (measured more 
than 70 years previously). This bypassed a common methodological problem for studies by 
having a comparative measure of ability before the onset of age-related cognitive decline. 
However, some studies have examined this further and identified that NART correlates 
more highly with some aspects of functioning than others. For example, Schretlen et al. 
(2005) found that whilst NART was significantly correlated with current verbal and full-scale 
IQ (Intelligence Quotient) it was less strongly correlated with other cognitive domains such 
as visual memory. This may be problematic when diagnosing dementia, as cognitive 
screening measures (e.g. MMSE; Mini-Mental State Examination, Folstein; Folstein & 
McHugh, 1975; ACE-R; Addenbrookes Cognitive Examination – R; Mioshi, Dawson, Mitchell, 
Arnold, & Hodges, 2006) tend to tap into current global cognitive ability (e.g thinking 
abilities such as memory and processing speed) rather than current IQ (intellectual 
performance). This means that clinicians may be attempting to establish deterioration in 
function by comparing current cognitive ability to premorbid IQ, which, whilst related, are 
not the same thing. This may lead to over or under-estimation of impairment.  
 With regard to O’Carroll et al’s., (1992) second criteria (resistance to cognitive 
decline), the NART has had mixed results. For example Sharpe and O’Carroll (1991) found 
that performance on the NART was relatively unimpaired in dementia patients, and McGurn 
et al. (2004) found that NART performance was stable over time, even in individuals who 
went on to develop dementia. In contrast, O’Carroll et al. (1995) found that the NART 
underestimated premorbid ability in patients with dementia, particularly in those who were 




was poor at estimating premorbid ability in patients with AD who scored within the mild-
moderate range of impairment on the MMSE.  
 These findings suggest that the NART may not be as robust as commonly thought, 
particularly when considered in terms of O’Carroll et al’s. (1992) recommended criteria for 
measures of premorbid ability. One further problem with tests of word-reading ability, and 
with the NART in particular, has also been identified; it’s poor reliability amongst patients 
with language disturbance. Given that the NART is a word-reading task, it would be logical 
to expect that performance would be affected in patients for whom language disturbance is 
present e.g progressive aphasia, semantic dementia or variants of AD (Taylor, 1999; Lezak et 
al., 2012). This has been shown to be the case for patients with Korsakoff’s syndrome 
(O’Carroll et al., 1992).  It is therefore likely to be unsuitable for use in all dementia 
populations.  
An alternative measure of premorbid ability 
The concept of Cognitive Reserve was developed to account for individual differences in the 
impact of neuropathology on cognitive impairment; why some individuals cope better with 
the same level of pathology than others (e.g. Stern, 2009). For example, Katzman et al. 
(1988) found that some individuals had pathological changes associated with AD (identified 
post-mortem) but without any cognitive impairment. They accounted for this by the 
individuals’ higher brain weight, indicative of larger brains and greater ‘brain reserve’. 
Cognitive reserve expands on this and considers the importance of other potentially 
protective factors affecting neural plasticity such as engagement in intellectually stimulating 




account when diagnosing dementia (Stern, 2009). For example, for individuals with high 
cognitive reserve but with performance on cognitive tests within the normal or low average 
range, this may be associated with large pathological changes and so should be interpreted 
cautiously.  
 Measuring the amount of cognitive reserve an individual has accumulated 
throughout their life may therefore be relevant to the estimation of premorbid ability. 
Nucci, Mapelli & Mondini (2011) attempted to do this by developing the CRIq (Cognitive 
Reserve Index Questionnaire; Nucci, Mapelli & Mondini, 2011). This is a self or other report 
questionnaire that combines demographic information regarding lifelong 1) Education 2) 
Working activity and 3) Leisure time in an attempt to quantify the amount of cognitive 
reserve an individual has accumulated over their life. In its current form, the CRIq calculates 
this based on the amount of education and training completed throughout an individuals’ 
lifetime, up to the present day. The Working Activity and Leisure Time components are 
calculated based upon engagement in these activities as an adult (age 18-present). Nucci et 
al. (2011) argue that the three most important and well-researched areas of CR are related 
to 1) education and training, 2) the degree of intellectual stimulation and personal 
responsibility that is/was required occupationally, and 3) participation in cognitively 
stimulating activities. They therefore included these three aspects of cognitive reserve in 
their questionnaire. In order to rule out any effects of age, three linear models were 
developed, transposed and standardised (with a mean of 100, s.d3 15) so that individuals of 
different ages could be compared. In a validation study of the CRIq, these three components 
                                                     




of cognitive reserve were found to correlate only moderately with each other (ranging from 
r=.30 to .44; Nucci et al., 2011), but highly with overall score (r=.72 to .78) highlighting their 
individual contribution to the overall CRIq score. In addition, performance on the CRIq was 
found to correlate only moderately with IQ (r=.45), as measured by the WAIS-R Vocabulary 
(Italian version of the Wechsler Adult Intelligence Scalre - Revised; Orsini & Laicardi, 1997) 
and the TIB (Test di Intelligenza Breve; Colombo, Sartori & Stima, 2002) which is a reading 
test similar to the NART. The authors (Nucci et al., 2011) therefore argue that CR and IQ are 
two different constructs; with measures such as NART and WAIS reflecting “intellectual 
performance” (Nucci et al., 2011, pg 14), and the CRIq reflecting “the potential cognitive 
capability acquired throughout life” (Nucci et al., 2011, pg 14).  
 Whilst the NART has been found to correlate highly with premorbid verbal IQ, CRIq 
appears to have the potential to capture alternative aspects of premorbid global cognitive 
functioning. If this is the case, this may provide clinicians with a tool that: 
• Does not rely on word reading ability. This may be particularly useful in patients with 
language disturbance;  
• Takes into account aspects of global cognitive functioning (particularly premorbid 
non-verbal ability) rather than only premorbid verbal ability; 
• Can be completed by a caregiver or someone who knows that individual well, 
eliminating the need to administer a test directly with the patient. This may have 




neuropsychological tests for the patient, and 2) performance is likely to be 
unaffected by the severity of dementia; 
• Can be used as a complimentary measure to NART, by capturing non-verbal 
premorbid ability as well as verbal premorbid ability. This may provide a more global, 
comprehensive assessment of premorbid functioning if used together; 
• Is not affected by the presence of dementia: If the CRIq was completed based on 
demographic information up to the point of symptom onset, this would provide 
further resistance to cognitive decline. If the CRIq were to be based on information 
that pre-dated the onset of dementia, this would ensure that performance was not 
affected by dementia. However, this would be an amendment to the current 
administration of the CRIq.  
 
In summary, estimating premorbid ability is a crucial part of diagnosing dementia. 
Numerous methods for this have been proposed, however, the NART remains the most 
commonly used. Several methodological limitations of the NART have been identified; 
reliance on a single ability to represent global ability (Reynolds, 1997), lack of resistance to 
cognitive decline (O’Carroll et al., 1995; McFarlane et al., 2006); poor correlation with non-
verbal abilities (Schretlen et al., 2005); and poor reliability in patients with language 
disturbance (Taylor, 1999; Lezak et al., 2012). Cognitive Reserve (CR) is an alternative 




CR that has been accrued by an individual, this could be compared to current performance 
to estimate whether any change in cognitive ability has occurred.  
5.1.1 Study aims and research questions  
This pilot study aims to evaluate how a new measure of CR, the CRIq, is feasible as a 
measure of premorbid functioning by evaluating it against two of O’Carroll et al’s. (1992) 
criteria. An additional aim is to assess how CRIq performance compares to performance on 
the NART. The following research questions will be addressed: 
1) Does CRIq capture current non-verbal ability in a healthy population?  
This will be examined by investigating how CRIq performance relates to performance 
on a measure of current non-verbal ability (WAIS-IV PRI; Wechsler Adult Intelligence 
Scale – Fourth Edition, Perceptual Reasoning Index, Wechsler, 2008) in a healthy 
control group; 
2) Is performance on the CRIq affected by cognitive decline? 
This will be examined by investigating whether performance on the CRIq differs 
between a patient group and a control group, whilst controlling for potential 
confounders such as education and mood (scores on a depression scale); 
3) Is performance on CRIq related to performance on the NART?  
As the NART is so well researched and is considered the ‘gold-standard’ measure of 
premorbid functioning, the two measures will be compared in order to examine 






This study was quantitative, with both within-subjects and between-subject design 
elements. Favourable ethical opinion was provided by the local National Health Service 
Research Ethics Committee (South East Scotland Research Ethics Committee 2; see 
Appendices B1, B2, C1 and C2). Power analysis was completed in relation to each research 
question. All power calculations were based upon parameters recommended by Cohen 
(1992), namely that power for any study should be 0.8 with a standard α level of 0.05: 
1) Does CRIq capture current non-verbal ability in a healthy population?  
Power calculation for this research question was considered based upon the available 
evidence for the existence of a relationship between performance on the CRIq and non-
verbal ability (WAIS-IV PRI). There is little direct evidence available from studies examining 
the CRIq, as the one known study to date (Nucci et al., 2011) only examined the relationship 
between CRIq performance and verbal ability, finding a moderate correlation (r = 0.42--
0.45). Not surprisingly, the strongest association was found between CRI Education and 
verbal ability (r = .44 and r = .43, as measured by the TIB and the Vocabulary subtest of the 
Italian version of the WAIS). As the CRIq is heavily based upon education, other studies 
examining the link between education and non-verbal ability provide some evidence for an 
association. For example, Williams (1992) found that race, gender, education and 
occupation accounted for 21% variance in global memory performance. However, it is 




that was able to partial out the individual effect of education found a small effect on non-
verbal ability (Hilsabeck et al., 2009, found r = .21 between education and performance on 
‘Anagram Solutions’). In contrast, numerous studies consider education to be a vital part of 
understanding or estimating intelligence and cognitive ability (e.g. Crawford & Allen, 1997). 
Given this variation in findings of previous studies, there appears to be little rationale for 
assuming a particularly small or large effect size, and so a medium effect size was assumed. 
Based on these parameters a sample size of N=64 for the control group was required for 
performance on two measures to be compared.  
2) Is performance on the CRIq affected by cognitive decline? 
As with the previous research question there was little rationale upon which to base an 
assumption of effect size given that CRIq has not previously been used with a clinical group. 
However, in this instance the power calculation is made in an attempt to establish that 
there is no effect of cognitive decline on CRIq performance. Using a default medium effect 
size, a sample size of N= 64 per group was required in order to indicate an 80% probability 
that there was not a medium effect of cognitive decline on CRIq performance.   
3) Is performance on CRIq related to performance on the NART?  
As with the previous two research questions, the effect size calculation was based upon 
previous studies examining the link between performance on the NART and performance on 
the CRIq. Nucci et al (2011) found that CRIq was moderately correlated (r = -.45) with TIB 
errors (an Italian version of the NART). Given that CRIq is heavily weighted upon education, 




have found a large effect size. For example, Taylor (1999) found r = .61 between years of 
education and NART estimated IQ in patients with established dementia. These findings 
provide support for assuming a large effect size. Based on these parameters a sample size of 
N=28 per group was required in order to detect a significant correlation between the two 
measures.  
Based upon the above parameters, and using the most conservative estimate of effect size, 
a sample size of N = 64 per group was required in order to address the research questions. 
However, difficulty with recruitment meant that this was not achieved, resulting in N=13 in 
the patient group and N=20 in the control group.  
5.2.2 Participants 
Patient group 
The patient group comprised of 13 individuals with dementia. Eligibility criteria for the 
patient group were that participants a) had a diagnosis of dementia given by a Consultant 
Psychiatrist, further specified as either AD (N= 10) or mixed AD and vascular dementia (N= 
3), b) were aged over 60 years, c) the diagnosis was given within the past two months to 
four years (mean time since diagnosis 17.92 months, s.d 15.68), d) symptom onset was at 
least one year prior to testing (mean 54.00 months, s.d 43.17), and e) scored below the 
clinical cut off for AD or mixed dementia (< or equal to 17/30) on the MOCA (mean 13.25, 
s.d 5.43). Exclusion criteria comprised the following; a) a diagnosis of dementia other than 
AD or mixed dementia, b) presence of any other neurodegenerative condition (e.g. 




or substance misuse, e) inability to provide written and verbal consent, as defined by 
referring clinician (e.g Psychiatrist), f) below 60 years of age, and g) did not speak English as 
a first language. Medication status was variable; one participant was not taking any 
medication for dementia, whilst N=12 were on a stable dose of anticholinesterase inhibitor 
including donepezil (N=7), memantine (N=3) and glantamine (N=2). All participants gave 
verbal and written informed consent.  
With regard to demographic characteristics of this group, the mean age of the 
patient group was 82.77 (s.d 4.76), mean years of education was 11.62 (s.d 3.59) and the 
male: female ratio was 6:7. All were retired, and N=12 were right handed. GAI (Geriatric 
Anxiety Inventory; Pachana et al., 2007) and GDS-15 (Geriatric Depression Scale-15; Sheikh 
& Yesavage, 1986) scores were all within normal ranges (GAI mean 1.69, s.d 2.90; GDS mean 
2.38, s.d 2.33).  
Control group 
The control group comprised of N=20 healthy older adults. Eligibility for control participants 
were a) absence of cognitive impairment, evidenced by group mean performance (26.75, s.d 
2.17) within the ‘normal’ range on the MOCA (26 or above/30), and all individuals 
performing over the cut off point for MCI (<21/30), in line with established norms for the 
MOCA (Nasreddine et al., 2005) b) aged 60 or above, and c) spoke English as their first 
language. Exclusion criteria comprised the following; a) presence of any neurodegenerative 
condition (e.g. Parkinson’s disease), b) current or previous psychiatric illness, c) current or 
previous alcohol or substance misuse, and d) previous brain injury e.g. stroke, tumour, 




With regard to the demographic characteristics of the control group, mean age was 
70.20 years (s.d 5.93), mean years of education were 13.15 (s.d. 3.62), the male: female 
ratio was 3:17, all were right handed, and all were retired. GAI and GDS scores were all 
within normal ranges (mean GAI 1.55, s.d 2.31, and mean GDS 1.55, s.d. 1.90).  
 
5.2.3 Materials 
Assessments were conducted by an appropriately trained clinician, who was aware of the 
research aims. Participants completed a battery including the following tests: 
Tests of premorbid ability 
The National Adult Reading Test (NART; Nelson, 1982) was used with all participants to 
estimate premorbid cognitive functioning based on word reading ability, and has been 
validated against the Wechsler Adult Intelligence Scale – Revised (WAIS-R; Wechsler, 1981) . 
Participants are required to read aloud 50 irregular words. It is quick to administer and 
frequently used with an older adult population (e.g Schretlen et al., 2005). The NART has 
been established as a reliable and valid measure of premorbid intelligence in older adult 
populations, as discussed previously (e.g. Sharpe & O’Carroll, 1991).  
 The Cognitive Reserve Index Questionnaire (CRIq; Nucci et al., 2011) was used with 
all participants to estimate premorbid ability based on self or carer-reported education, 
working activity and leisure activity. The CRIq aims to quantify the amount of cognitive 




functioning. It has recently been standardised in a sample of 558 individuals aged of 18-102 
(Nucci et al., 2011), but has yet to be used with a clinical sample or an English speaking 
sample. It has recently been translated into English by the authors. 
Mood measures 
The Geriatric Depression Scale- Short (GDS-15) was used with all participants to measure 
symptoms of low mood and depression. It was specifically developed for, and validated in, 
the older adult population (Sheikh & Yesavage, 1986). The GDS-15 has also been found to 
have good specificity and sensitivity in a meta-analysis of 42 studies (Wancata et al., 2006). 
This indicates that it can be reliably used as a screening measure for depression in later life. 
The Geriatric Anxiety Inventory (GAI; Pachana et al., 2007), was used to measure anxiety. It 
is reported to have good psychometric properties, with excellent inter-rater reliability, and 
was designed for use with older adults.  
Cognitive screening measure 
The Montreal Cognitive Assessment (MOCA; Nasreddine et al., 2005) was used with all 
participants as a brief cognitive screening tool. It has been shown to be more sensitive than 
MMSE in detecting mild cognitive impairment, AD and Vascular dementia in an elderly 
population, using a cut-off point of <21 for MCI and <17 for Vascular Dementia (Freitas, 






Measure of current intellectual ability   
The control group completed the three subtests comprising the Perceptual Reasoning Index 
(PRI) of the WAIS-IV. This was used to assess current non-verbal ability. The PRI is calculated 
based on performance on Block Design, Matrix Reasoning and Visual Puzzles. The WAIS-IV is 
a well validated measure of current ability, frequently used for this purpose in an older adult 
population (e.g Baxendale, 2011). Only the control group completed this measure as only 
they were required to complete an assessment of current intellectual functioning (non-
verbal ability) in order to address research question 1). Completing this measure with the 
patient group would have increased administration time to over 90 minutes and was likely 
to result in unnecessary fatigue.  
 
5.2.4 Procedures 
Recruitment of patient group 
Patients with dementia were recruited through several routes; through the Scottish 
Dementia Clinical Research Network (SDCRN) and through local NHS Older Adult Memory 
services (this includes Memory Clinics and Community Mental Health Services, who provide 
a Community Psychiatric Nursing (CPN) service for patients with dementia). The SDCRN aims 
to “improve the quantity and quality of dementia research in Scotland” 
(http://www.sdcrn.org.uk/about-us/what-we-do) and has a participant register of 
individuals with a diagnosis of dementia and their carers who are interested in participating 




Prospective members are screened by an SDCRN clinician, who assesses cognitive 
ability and capacity to consent to participate in research. Researchers can apply for their 
study to be ‘adopted’ by the SDCRN, thus granting them access to an agreed number of 
participants meeting inclusion criteria. The SDCRN database was searched for individuals 
meeting the inclusion criteria, including ability to provide written informed consent. A total 
of 46 SDCRN patients were identified and invited to participate, with four responses. Upon 
checking of inclusion criteria, two were removed from the study, leaving two participants 
recruited through the SDCRN. 
NHS clinicians (including Consultant Psychiatrists, Community Psychiatric Nurses and Clinical 
Neuropsychologists) identified potential patients on their caseload that met inclusion 
criteria, and whom they believed would be able to provide informed written consent to 
participate in the study (N=46). These patients were invited to participate in the study, of 
which 12 expressed an interested. Upon further checking of the inclusion criteria, one 
patient was excluded, leaving 11 recruited from NHS clinics. In total, 88 patients were 
identified, all of which were invited to participate, resulting in N=13 taking part. Uptake 
from the initial screening of potential participants was therefore 14.77%. 
Recruitment of control group 
Control participants were recruited through the SDCRN carer’s register and through 
a local community group. A total of N=40 SDCRN carers were identified as meeting inclusion 
criteria and were invited to participate in the study, with four responding to the invitation 























Invited to participate 
 
SDCRN patients: N= 46 
NHS Memory Clinics/CMHT: N=42 
CONTROL GROUP 
Invited to participate 
 
SDCRN carers: N= 40 
Community group: N= Approximately 100 
(Chief investigator attended a community 




SDCRN patients: N= 2 
NHS Memory Clinics/CMHT: N=11 
 
 
Unsuitable for study 
 
SDCRN patients unsuitable for study: N=2 (Reason: N= 1 
diagnosis not AD or mixed; N=1 broke hip before 
appointment and unable to participate) 
NHS patients unsuitable for study: N=1 (Reason: 




SDCRN carers: N= 4 
Community group members: N= 16 
 
Unsuitable for study 
 
Community group members: N= 3 (Reason: N=2 
Unable to contact; N=1 ongoing depressive illness) 
 
Interested in participating 
 
SDCRN patients: N= 4 
NHS Memory Clinics/CMHT: N=12 
 
Interested in participating 
 
SDCRN carers: N= 4 
Community group members: N= 
19 
Total for patient group 
 
N = 13 
Total for control 
group 
 




researcher attending a monthly meeting, at which were approximately 100 members. N=19 
members responded to this invitation, with three excluded due to not meeting inclusion 
criteria. A total of N=16 community group members therefore participated. This recruitment 
pathway is outlined in Fig 1. This means that at least N=140 individuals were invited to 
participate, with N=20 taking part, yielding an approximate uptake of 14.29%. 
Assessment procedure 
Participants were assessed either in a hospital clinic or in their own homes (where 
appropriate). Participants in the patient group gave written informed consent and received 
an assessment lasting approximately one hour (ranging from 45 minutes to two hours). The 
assessment consisted of; GDS, GAI, NART, CRIq, MOCA. Participants in the control group 
gave written informed consent and received an assessment lasting approximately 90-
miuntes (ranging from one hour to 2.5 hours). The assessment was as per the patient group, 
with the addition of three Perceptual Reasoning subtests from the WAIS-IV. 
 
5.2.5 Analysis 
Descriptive statistics were used to define each group. Parametric tests were used as even 
though there was relatively low N, the data was still able to meet the assumptions of 
parametric data (e.g normal distribution, homogeneity of variance). Group differences for 
demographic variables (i.e. age, education) were examined using multiple independent t-




1. Does CRIq capture current non-verbal ability in healthy adults?  
This question was addressed using multiple paired-samples t-tests and correlational 
analysis to examine mean differences in CRIq and NART predicted premorbid ability 
scores and obtained a) current non-verbal ability (WAIS-IV PRI) and b) current global 
cognitive ability scores (MOCA) for the control group.  
2. Is CRIq performance affected by cognitive decline?  
This research question was examined using ANCOVA (Analysis of Covariance) by 
comparing mean score on CRIq and NART between groups, with any demographic 
variables that were significantly different between groups added as covariates in order 
to control for their effect on CRIq and NART performance.  
3. Does performance on CRIq relate to performance on NART?  
This was addressed by using paired t-tests and correlations to compare mean scores on 
NART and CRIq for each group.   
 
5.3 Results 
Data integrity and distribution 
There was no missing data for any of the 20 control group participants. One participant in 
the patient group was unable to complete the MOCA due to fatigue, and so this was coded 




using the Shapiro-Wilk Test at p>0.05 (as recommended by Field, 2005, for samples sizes < 
50). This indicated that the assumption of normality was not violated. Homogeneity of 
variance was examined for all statistical tests using Levene’s test for equality of variances, 
for which the majority of results were p > 0.05, and so equal variances were assumed. 
Whenever p < 0.05, equal variances were not assumed, and so corrected results are 
reported instead.  
Data analysis 
Descriptive statistics were used to define each group and Independent Samples T-tests were 
used to identify any differences between group means (control group Vs. patient group) for 
demographic variables and MOCA performance. This is summarised in Table 1 and shows 
that the control group were significantly younger (control: 70.20, s.d 5.92 Vs. patient: 82.77, 
s.d 4.76) (t= 6.409, df = 31, p = .000) than the patient group. Results also show that the 
control group performed significantly better on the MOCA than the patient group (control: 
26.75, s.d 2.17 Vs. patient: 13.25, s.d 5.43) (t = -8.227, df = 13.147, p = .000), confirming that 
the patient group were cognitively impaired. The control group’s mean performance on the 







Table 1. Descriptive statistics: Group mean performance across demographic variables, with 




Variable Control group 






t df p 
Age (years) 70.20 (5.92) 82.77 (4.76) 6.41 31 .000** 
Years of Education 13.15 (3.61) 11.62 (3.59) -1.19 31 .242ns 
Age at retirement 60.40 (4.62) 62.77 (8.55) 1.03 31 .309ns 
GAI score 1.55 (2.30) 1.69 (2.90) .16 31 .877ns 
GDS score 1.55 (1.90) 2.38 (2.32) 1.13 31 .269ns 
MOCA score 26.75 (2.17) 13.25 (5.43) -8.23 13.147 .000** 
WAIS-IV PRI^ 101.80 (11.33) - - - - 
Notes: No Missing data. GAI = Geriatric Anxiety Inventory; GDS = Geriatric Depression Scale; 
MOCA = Montreal Cognitive Assessment; WAIS-IV PRI = Wechsler Adult Intelligence Scale, 
Perceptual Reasoning Index.  Ns = Not significant *p<0.05, **p<0.01 ^this test (WAIS-IV PRI) 





5.3.1 Research question 1: Does CRIq capture current non-verbal ability in healthy controls? 
a) Does CRIq capture current non-verbal intellectual functioning in healthy controls? (WAIS-
IV PRI) 
This research question was addressed by examining whether predicted ability according to 
CRIq subscores and NART estimated FSIQ was significantly different from actual 
performance on WAIS-IV PRI for the control group. NART estimated FSIQ was included so 
that CRIq and NART results could be compared throughout the analyses. As both of these 
measures are reported as equivalent IQ scores, mean performance could be directly 
compared with obtained WAIS-IV PRI IQ scores. Multiple paired-samples t-tests were 
conducted between WAIS-IV PRI score and NART estimated FSIQ, CRIq Total score, plus CRIq 
subscores; CRIq Education, CRIq Working Activity and CRIq Leisure Activity.  
 Pearson’s correlation between these variables was also examined. Table 2 shows 
that, for the control group, WAIS-IV PRI mean score was significantly different from mean 
score on NART estimated FSIQ (t = 6.26, df = 19, p = .000, two tailed), CRIq Total score (t = 
7.73, df = 19, p = .000), CRIq Education (t = -6.28, df = 19, p = .000), and CRIq Leisure Activity 
(t = -8.66, df = 19, p = .000). Only CRIq Working Activity and WAIS-IV PRI were not 
significantly different (t = -1.92, df = 19, p = .070, ns). This shows that CRIq Total, CRIq 
Education, CRIq Leisure Activity and NART estimated FSIQ over-estimated performance in 
comparison to obtained scores on WAIS-IV PRI. Correlational analysis was also completed 
and showed a significant correlation between CRIq Total and WAIS-IV PRI (r = .52, p = .018) 
between CRIq Education and WAIS-IV PRI (r = .59, p = .018) and between NART and WAIS-IV 




Table 2. Research question 1: Paired t-tests and correlations for performance on CRIq, NART 
and WAIS-IV PRI for the control group 
  Vs. WAIS-IV PRI M = 101.80 (11.33) 
 t P df r 
CRIq Total M = 125.70 (15.81) 7.73 =.000* 19 .52* 
CRIq Education M = 117.35 (12.99) -6.28 =.000* 19 .59* 
CRIq Working Activity M = 108.35 (15.81) -1.92 =.070ns 19 .41ns 
CRIq Leisure activity M = 132.70 (15.16) -8.66 =.000* 19 .30ns 
NART estimated FSIQ M^ = 114.95 (8.82) 6.26 = .000* 19 .59* 
Notes: CRIq = Cognitive Reserve Index Questionnaire; WAIS-IV PRI = Wechsler Adult 
Intelligence Scale, Perceptual Reasoning Index; NART = National Adult Reading Test. Ns = 




b) Does CRIq capture current global functioning in healthy controls? (MOCA) 
This research question was addressed by examining the correlation between MOCA and 
CRIq subscores, NART estimated FSIQ and WAIS-IV PRI for the control group. Results 
indicated that none of these measures were significantly correlated with MOCA 





5.3.2 Research question 2: Is CRIq performance affected by cognitive decline?  
In order to examine whether performance on CRIq was affected by cognitive decline, mean 
CRIq predicted premorbid ability was compared between groups. This was examined using 
 
Table 3. Research question 1: Correlations for performance on CRIq, NART and MOCA for the 
control group 
 MOCA M = 101.80 (11.33) 
 r 
CRIq Total M = 125.70 (15.81) .18 ns 
CRIq Education M = 117.35 (12.99) -.004ns 
CRIq Working Activity M = 108.35 (15.81) .31 ns 
CRIq Leisure activity M = 132.70 (15.16) .11ns 
NART estimated FSIQ M^= 114.95 (8.82) .04ns 
WAIS-IV PRI M = 101.80 (11.33) .03ns 
Notes: CRIq = Cognitive Reserve Index Questionnaire; MOCA = Montreal Cognitive 
Assessment; NART = National Adult Reading Test; WAIS-IV PRI = Wechsler Adult 
Intelligence Scale, Perceptual Reasoning Index. Ns = Not significant, ^ NART estimated 
FSIQ is based upon norms for WAIS-R.  
 
ANCOVA with CRIq and NART estimated FSIQ performance as the dependent variables and 




found to differ significantly in terms of age this variable was added as a covariate in order to 
control for its possible confounding effects. In addition, years of education and GDS (mood) 
score were added as covariates in order to control for their effect on performance on CRIq 
and NART estimated FSIQ. These variables were added despite the lack of group difference 
in scores, as they are both important variables to consider when assessing premorbid ability. 
Results showed that after controlling for age, education and GDS score there was a 
significant effect of Group on NART performance (F (2, 28) = 6.120, p = .020) , partial η2= 
.179, but not for CRIq Total score (F(2, 28) = 0.143, p = .708), partial η2= .005, see Table 4. 
This showed that after controlling for differences in age, education level, and mood (GDS 
score), CRIq performance was not affected by cognitive decline (with a weak ES of group), 
whereas NART performance was affected by cognitive decline (with a modest ES of group).  
 
Table 4. Performance on NART and CRIq by each group and ANCOVA result after controlling 
for age, education, and mood (depression).  
Variable Control group 
mean and s.d 
(N= 20) 
Patient group 
means and s.d 
(N= 8) 
F df p η
2
 









5.3.3. Research question 3: Does performance on CRIq relate to performance on NART? 
In order to understand whether CRIq performance was related to NART estimated FSIQ 
performance, i.e. if they predict a similar pattern of premorbid ability, multiple paired t-
tests and correlations were used to compare mean score on NART estimated FSIQ and CRIq 
Total and CRIq subtests for each group.   
Control group 
Results for the control group indicate that NART predicted premorbid ability was 
significantly lower than predicted premorbid ability according to CRIq Total (mean 114.95, 
s.d 8.82 Vs. mean 125.70, s.d 15.81) (t = -3.79, df = 19, p = .001) and CRIq Leisure Activity 
(mean 114.95, s.d 8.82 Vs. mean 132.70, s.d 15.16)(t = -4.92, df = 19, p = .026). However, 
NART predicted premorbid ability was significantly higher than predicted premorbid CRIq 
Working Activity (mean 114.95, s.d 8.82 Vs. mean 108.35, s.d 15.81) (t = 2.41, df = 19, p = 
.000). Correlational analysis showed that there were significant correlations between NART 
estimated FSIQ and CRIq Total (r = .60, p = .005), between NART estimated FSIQ and CRIq 
Education (r = .68, p = .001) and between NART estimated FSIQ and CRIq Working Activity (r 
= .64, p = .003).  
Notes: No Missing data. NART = National Adult Reading Test; CRIq = Cognitive Reserve Index 
Questionnaire; Ns = Not significant, *p<0.05, **p<0.01, ^ NART estimated FSIQ is based 




Table 5. Research question 3: The relationship between NART performance and CRIq 
performance for the control group 
  Vs. NART estimated FSIQ M = 
114.95 (8.82) 
 t df p r 
CRIq Total M = 125.70 (15.81) -3.79 19 .001** .60* 
CRIq Education M = 117.35 (12.99) -1.12 19 .276ns .68** 
CRIq Working Activity M = 108.35 (15.81) 2.41 19 .026* .64** 
CRIq Leisure activity M = 132.70 (15.16) -4.92 19 .000** .18ns 
Notes: CRIq = Cognitive Reserve Index Questionnaire; NART = National Adult Reading Test.  
Ns = Not significant  * significant at p<0.05, ** significant at p<0.01 
 
Patient group 
Results for the patient group indicate that performance on NART estimated FSIQ was 
significantly lower than performance on CRIq Total (mean 101.15, s.d 11.92 Vs. mean 
120.77, s.d 18.06) (t = -3.810, df = 12, p = .001), CRIq Education (mean 101.15, s.d 11.92 Vs. 
mean 116.62, s.d 13.63) (t = -4.209, df = 12, p = .002), and CRIq Leisure (mean 101.15, s.d 
11.92 VS. mean 124.00, s.d 23.26) (t= -3.567, df = 12, p = .004). Correlational analyses 
indicated that there were no significant correlations between NART performance and CRIq 





Table 6. Research question 3: The relationship between NART performance and CRIq 
performance for the patient group 
 Vs. NART estimated FSIQ M =101.15 (11.92) 
 t df p r 
CRIq Total M = 120.77 (18.06) -3.81 12 .002** .29ns 
CRIq Education M = 116.62 (13.63) -4.21 12 .001** .47ns 
CRIq Working Activity M = 106.23 (15.72) -.90 12 .387ns -.07ns 
CRIq Leisure activity M = 124.00 (18.06) -3.57 12 .004** .27ns 
Notes: CRIq = Cognitive Reserve Index Questionnaire; NART = National Adult Reading Test.  
Ns = Not significant  * significant at p<0.05, ** significant at p<0.01 
 
 
 5.4 Discussion 
 
The diagnosis of dementia requires clear evidence that a decline in cognitive functioning has 
taken place in comparison to premorbid ability (Lezak et al., 2012). Accurately establishing 
the level of premorbid ability can therefore enable more reliable diagnosis of dementia. As 
previously discussed, three main approaches to establishing premorbid ability have been 
developed; demographic equations (e.g. Barona, Chastain & Reynolds, 1984; Crawford & 
Allan, 1997), best performance indicators, and hold tests (e.g. NART, WTAR, CCRT). The 




commonly, the NART (e.g Starr & Lonie, 2007). This is despite numerous reviews concluding 
that demographic equations are the most valid and reliable method (Taylor, 1999; 
Schretlen, 2005; Buffington et al., 2005; Griffin et al., 2002; Lezak et al., 2012; Reynolds, 
1997).  O’Carroll et al. (1991) highlighted three criteria against which any measure of 
premorbid ability should be assessed; they should 1) be able to capture current ability in 
controls in order to establish validity, 2) be resistant to cognitive decline, and 3) have high 
inter-rater reliability. This current study sought to examine whether a measure originally 
developed to quantify cognitive reserve, the Cognitive Reserve Index Questionnaire (CRIq) 
can feasibly function as a measure of premorbid ability. As the CRIq had not been used in a 
UK sample or with a clinical population, this pilot study attempted to examine whether it 
meets the first two of O’Carroll et al’s. (1991) criteria, in order to establish proof of concept.  
 O’Carroll et al’s. (1991) first criteria focuses on the importance of premorbid 
measures proving their validity by accurately assessing current functioning in healthy 
controls. Results showed that CRIq had a large positive correlation with current non-verbal 
intelligence (WAIS-IV PRI) (r= .52 to .59), however, it significantly over-estimated ability 
compared to WAIS-IV performance. CRIq’s overestimation of current non-verbal intelligence 
could be explained by the CRIq being normed on an Italian population, who may have 
different cultural norms to the Scottish population used in this study. Indeed, in the 
validation study of the CRIq, Nucci et al. (2011) found that the majority of older participants 
had only five years of education, whereas this study found that the control group had an 
average of 13.15 (s.d. 3.62) years of education, whilst the patient group had 11.62 (s.d 3.59). 




explain why the control group were predicted to be significantly more able than they 
actually were.  Previous studies have also indicated that the CRIq is highly related to current 
ability in a healthy population (Nucci et al., 2011). It is not surprising therefore, that CRIq 
Education was highly related to WAIS-IV PRI as numerous studies have found intelligence 
and education to be highly related (e.g. Deary and Dykiert, In Press). However, the CRIq 
significantly over-estimated ability when compared to actual ability, which does not 
replicate Nucci et al’s. (2011) finding. The CRIq is difficult to compare directly to other 
measures of premorbid ability, as it was not designed for this purpose, but instead attempts 
to capture lifelong cognitive reserve. However, the content of the measure (which is a 
composite of three subscores regarding lifelong education, working activity and leisure 
activity) is similar to the demographic equation technique. These tend to combine 
information regarding education and occupational history to predict premorbid ability (e.g 
Barona et al., 1984, and Crawford & Allan., 1997). Previous studies examining the accuracy 
of demographic equations have shown that they can over estimate premorbid ability (e.g. 
Reynolds, 1997). The current finding is therefore in line with previous studies that have 
identified a similar problem with the use of demographic equations. However, this study is 
unable to establish whether the CRIq would be preferable to other equation techniques for 
estimating premorbid ability, due in part to the small sample size precluding the use of 
regression to analyse the individual capability of each measure to predict current 
functioning. Results also suggest that CRIq would require further adjustment (e.g. to be 
adapted using UK norms) before this type of comparison could be made. This would allow 




significant contribution to the estimation of premorbid ability, over and above other 
methods.  
 A crucial finding of this study was that CRIq performance was not affected by the 
presence of dementia. This has not been addressed by any other study previously. Indeed, 
the original validation study of the CRIq (Nucci et al., 2011) did not include a clinical group, 
preventing direct comparison. In comparison with other demographic equations that predict 
premorbid ability, the CRIq is less reliant on current ability and so a) removes subjective 
interpretation of results and b) is less likely to be affected by cognitive decline (Reynolds, 
1997). The finding that NART was affected by the presence of dementia supports previous 
research recommending the use of demographic equations over the use of hold tests for 
this population (e.g Taylor, 1999; Schretlen et al., 2005; Griffin et al., 2002; Lezak et al., 
2012; Reynolds, 1997). However, the question of whether the CRIq was affected by 
cognitive decline could be overcome if the measure was completed based upon 
demographic information before the onset of dementia. This would mean that the CRIq was 
based upon information that pre-dated the onset of cognitive decline and so addresses 
O’Carroll’s second criteria.  In order to fully address this question, a longitudinal study would 
need to be conducted in order to establish that CRIq is resistant to cognitive decline over a 
period of time, rather than using a cross-sectional design.  
 An important finding of this study was that NART and CRIq performance were 
related for the control group, but not for the patient group. This finding is similar to Nucci et 
al. (2011) who found a moderate positive correlation between an Italian version of the 




and the CRIq in the patient group is in line with past research that has shown that hold tests 
and demographic equations capture different aspects of premorbid ability. For example, 
Crawford et al. (1989) found that hold tests alone accounted for 66% variance in premorbid 
ability in normal populations, but that this increased to 73% when demographic equations 
were combined with hold test performance. This suggests that demographic equations tap 
into related, but separate aspects of premorbid ability to that of hold tests. This was 
hypothesised by Nucci et al. (2011) in their validation of the CRIq, and is supported by the 
results of this study.  
 The finding that NART performance and CRIq performance were unrelated for the 
dementia group can also be accounted for by NART being weak at resisting the effects of 
cognitive decline (e.g O’Carroll et al., 1995; McFarlane et al., 2006). These findings can be 
explained by the NART being a verbal IQ ‘performance’ measure and so relies on word-
reading ability being relatively spared in patients with dementia. This may be an unrealistic 
expectation given that dementia is characterised by degenerative cognitive impairment. The 
CRIq is less dependent on current performance and instead captures indicators of lifelong 
non-verbal ability as well as protective factors such as participation in intellectually 
demanding activities. It therefore appears that performance on NART and CRIq are related, 
but measure different characteristics and produce different estimates of premorbid ability 
in a patient group.  
The NART as a measure of premorbid ability 
This study has used the NART as an exemplar of a measure of premorbid ability. In terms of 




correlated with performance on WAIS-IV PRI (r= .59), but not correlated with performance 
on the MOCA (r= .04) in healthy controls. This supports previous findings by Schretlen 
(2005) who found that NART was highly related to current intellectual ability, and Dykiert 
and Deary (In Press), who found that NART correlated with intellectual ability in healthy 
older adults r= .66 to .68. It also supports previous findings by Schretlen (2005) who found 
that NART was less related to other aspects of cognition e.g executive functioning, memory. 
The NART was found to be negatively affected by the presence of dementia. This supports 
previous research suggesting that the NART may be weak at resisting the effects of cognitive 
decline (e.g. O’Carroll et al., 1995; McFarlane et al., 2006).  
 
5.4.1 Study limitations  
This study replicated aspects of the original CRIq validation study (Nucci et al., 2011) by 
including a measure of current ability (WAIS-IV PRI) as well as a measure of word reading 
ability (NART), and an additional cognitive screening tool (MOCA). Whilst the MOCA is a well 
validated cognitive screening tool for use in clinical populations, our results appear to show 
ceiling affects within the control group. This lack of variance in scores allows little scope to 
test for correlations between NART and CRIq score and global cognitive ability (i.e. MOCA 
score), as opposed to nonverbal ability (which was measured by WAIS-IV). A more in-depth 
screening measure such as the ACE-R may have overcome this problem; however, the ACE-R 
was unable to be used at the time of data collection due to issues regarding copyright. 
Whilst the MOCA remains a valid screening tool for cognitive impairment, and was a useful 




allow for further investigation into the question of whether the CRIq captures global 
cognitive ability or only non-verbal ability. It may have been helpful to measure other 
aspects of cognition in the control group in order to compare premorbid verbal Vs. non-
verbal ability more explicitly (e.g. non-verbal memory, executive functioning). This may have 
been able to better address how CRIq compares to NART at capturing specific domains of 
functioning in the control group, and provide better validation of the utility of the CRIq for 
specific clinical presentations. For example, measuring verbal ability using a well validated 
measure such as the Verbal Comprehension Index from the WAIS-IV may have allowed 
comparison between premorbid verbal Vs. non-verbal ability.  
 This study used a cross-sectional design to examine whether CRIq performance 
differed between a healthy control group and a cognitively impaired group. Whilst this is a 
common method by which premorbid measures are validated and tested (e.g. Duff, Chelune 
& Dennett, 2011; Schretlen et al., 2005), it is a less robust method compared to other 
techniques. A longitudinal study examining participants that either go on to develop 
dementia, or for whom their cognitive impairment worsens, would allow the CRIq to be fully 
evaluated against this criteria. In addition, the lack of matching between the control group 
and the clinical group may have exacerbated this design limitation.  
 Uptake for the control group and patient group from the initial stage of recruitment 
was 14.77% and 14.29% respectively. This is difficult to compare to previous research as 
many studies only report the final N recruited per group, not the number that were 
approached (e.g. Griffin et al., 2002; McFarlane et al., 2006; Hilsabeck & Sutker, 2009). 




adult population, using similar statistical methods to analyse their data (e.g Law & O’Carroll, 
1998, who had an AD group with N=21; Hilsabeck & Sutker, 2009, who had N=20 in their AD 
group and N=27 in their control group, and Lough et al., 2006, who had N=13 in their control 
group and N=18 in their fronto-temporal dementia group). The older adult population is 
notoriously difficult to recruit, and there are numerous challenges when trying to engage 
this population in research (for a discussion of these issues see Knechel, 2013). 
Nevertheless, this study was under-powered and so the results should be interpreted with 
caution. This is also likely to limit the generalisability of the results.   
 Several avenues of recruitment were pursued, including local community groups, 
NHS clinics and charitable organisations that support research into dementia. The control 
group was recruited through the Scottish Dementia Clinical Research Network (SDCRN) and 
a local community group. One reason for the low N was that the SDCRN were limited in the 
number of members they could provide details of, due to the high demand on the network 
for participants. In addition, the local community group were limited in how many times 
they could remind their members about the study, so as not to exert undue pressure to 
participate. The patient group were recruited through the SDCRN and NHS Lothian Older 
Adult services (e.g. memory clinics, CMHT’s). It is unknown how many cases were 
considered at the initial stage of recruitment by clinicians, as they were only asked to 
identify those whom they believed met inclusion criteria. It is likely that had inclusion 
criteria been less stringent i.e had the study accepted individuals with co-morbidities, or 
variants of dementia other than AD and mixed dementia, more participants would have 




 There are limitations to using an established database for research including; 
potential research fatigue, practice effects, and the possibility that those who register for 
research databases are not representative of the population as a whole. Recruiting from 
local community groups faces similar problems; they may not be a representative sample, 
and given their participation in the community group, they may not represent normal trends 
for participation in leisure activities. This is an important factor to consider as the majority 
of control group participants were recruited from the community group (16/20) and so this 
may have affected the control group’s overall performance on the CRIq Leisure Activity 
score as well as the CRIq Total score. This therefore limits the generalisability of the study 
findings. However, this is a problem common for research into dementia (Knechel, 2013) 
and many studies do not identify how their control sample was recruited (e.g Lowe & 
Rogers, 2011) or instead use carers as controls (e.g McFarlane et al., 2006).  
 A final limitation of the study relates to the use of the NART as opposed to other 
‘hold’ measures of premorbid functioning such as the WTAR or TOPF. Whilst the control 
group’s current ability was assessed using the WAIS-IV, the NART is validated against the 
WAIS-R, possibly accounting for the NART’s overestimation of FSIQ. This is because of 
factors such as the “Flynn Effect”; the purported increase in worldwide ability seen since IQ 
tests were first introduced in the 1930s. This means that were someone to complete both 
the WAIS-R and the WAIS-IV today, they would be likely to achieve a higher score on the 
WAIS-R than the WAIS-IV. This may explain why there were differences between obtained 
WAIS-IV PRI performance and predicted FSIQ based on NART. However, this limitation is less 




5.4.2 Future research 
This study provides limited evidence to suggest that the CRIq may be a helpful tool to 
estimate premorbid ability for patients with dementia. Whilst it was under-powered, it 
demonstrates the importance of conducting pilot studies to examine the feasibility of 
research hypotheses. It also highlights the importance of funding for studies to enable 
recruitment of a large sample, allowing for the use of more sophisticated analyses including 
multiple regression. This would allow for a greater understanding of the CRIq’s contribution 
to the assessment of premorbid ability, independent to other measures such as the NART or 
other demographic equations. Other measures of ability (e.g. different domains of 
cognition) could be used as a dependent variable, and examined in order to see whether 
CRIq has better predictive ability than the NART for cognitive domains other than verbal IQ. 
Further scope for future studies relates to the study design; the cross sectional nature of 
this study allowed for limited assessment of the CRIq’s ability to resist cognitive decline over 
time. Future studies should consider a longitudinal design that evaluates change in cognition 
over time, allowing for a more robust examination of the CRIq’s resistance to cognitive 
decline. In addition, better matching of control and clinical group participants would reduce 
any confounding effects of demographic variation on groups (e.g. age and education).  
  Performance on neuropsychological measures has been shown to be negatively 
affected by effort and fatigue in older adults with dementia (Bortnik, Horner, & Bachman, 
2013).  Because the CRIq can be completed by a carer, it is less performance-based and so 




upon performance (e.g. NART, WTAR). Future studies could examine this further and assess 
how effort or fatigue affects performance on the CRIq compared to other measures.  
  Future studies could examine patients’ experience of completing the CRIq in 
comparison to traditional neuropsychological measures. With national guidelines taking a 
person-centred approach to patient care (e.g NICE Clinical Guidelines CG42, 2006), patients’ 
acceptability of assessment measures is an important consideration. Structured approaches 
to assessing patients’ acceptability of procedures for the assessment of dementia have been 
undertaken (e.g Parikh et al., 2013). It is possible that completing the CRIq may be perceived 
by patients and clinicians as person-centred as it asks patients about their life experience. 
However, it may be less preferable for some patients as it takes longer to complete than 
measures such as NART. As mentioned previously, fatigue and effort may influence this 
experience (Bortnik et al., 2013). This could be examined in further detail to ensure that all 
aspects of dementia care; from assessment to post-diagnostic support, is focused on the 
individual and takes account of patients’ needs and preferences.  
Finally, the CRIq appears to over-estimate current ability in healthy controls. This is 
highly likely to be a reflection of the norms used for the calculation of the CRIq Total score 
and subscores, given that these were based on a population with far fewer years of 
education. Therefore, more appropriate norms should be developed for the UK population. 
Other assessments of premorbid ability have been widely re-normed for specific 
populations. For example, the NART has been validated in numerous languages e.g Swedish, 
(Rolstad et al., 2008), French (Mackinnon & Mulligan, 2005), as well as in different English-




5.4.3 Clinical implications  
Establishing whether deterioration has taken place in comparison to premorbid ability is 
often a key aim of neuropsychological assessment (Lezak et al., 2012). Tests of reading 
ability such as the NART and WTAR are the predominant methods by which premorbid 
ability is estimated in clinical practice. Such tests should be able to capture current ability 
when measured in controls, but also be resistant to the effects of cognitive decline so that 
they can reliably allow the detection of change when dementia is present (O’Carroll et al., 
1991).  There has been considerable evidence to suggest that traditional hold tests such as 
the NART are able to capture current verbal ability in healthy populations (e.g Dykiert & 
Deary, 2013), but struggle to remain valid when tested in patients with dementia (e.g 
Schretlen, 2005; McFarlane et al., 2006). This study supports these findings and so adds 
further weight to the argument that measures such as NART may not be a valid and reliable 
method by which to measure premorbid ability in individuals with established dementia 
(performing below the cut off point for dementia on MOCA; Freitas et al., 2012). This study 
found that CRIq significantly over-estimated current ability in controls and so was unable to 
meet O’Carroll et al’s. (1991) first criteria. The finding that it was then resistant to cognitive 
decline is therefore redundant unless appropriate norms are developed for specific 
populations so that the CRIq is reliable and valid at capturing current ability. However, once 
this is completed, the CRIq may have clinical utility in the following areas:  
 The CRiq may be helpful to use to alongside the NART in order to gain a more 
complete picture of premorbid ability. Whilst both measures were highly related to each 




different aspects of premorbid ability. Again, this will be more definitive once the CRIq has 
developed norms for a UK population, and studies with larger samples have demonstrated 
the variance accounted for by each approach. 
 One population where CRIq may have particular clinical utility is with patients with 
language disturbance. The main diagnostic category relevant for this is the frontal 
dementias, particularly the primary progressive aphasias, which includes semantic 
dementia, progressive nonfluent aphasia (Mesulam, 2003), and logopenic aphasia (Gorno-
Tempini et al., 2008). These dementias are characterised by word comprehension deficits, 
impaired articulation, and impaired speech repetition (Mesulam, 2003) and so such patients 
would clearly struggle to complete word reading tests such as the NART. Similarly, NART 
performance has been shown to be impaired in patients with Korsakoff’s syndrome, who 
can present with poor comprehension and confabulation (O’Carroll et al., 1992). These 
presentations are all rarer types of dementia, however, language disturbance can also be 
found in AD, which constitutes roughly 60% of all dementias (NICE CG42, 2006). For these 
patients, inclusion of the CRIq in their assessment may allow for a more reliable assessment 
of their premorbid ability.  
 Complex assessment for dementia is often undertaken by Clinical Psychologists who 
are appropriately trained to administer, score and interpret neuropsychological measures. 
Administration of the CRIq is designed to be completed by an informant, carer or by the 
patient themselves, and so would not require complex training of clinicians in order for it to 




2011) means that this can be scored and interpreted easily and without the use of 
comparison to specific norms, as scores are converted to an age-adjust IQ equivalent.  
 
5.5 Conclusions  
This study demonstrated that the CRIq over-estimates premorbid ability in healthy controls 
and so would be likely to over-estimate impairment if used in its current form within a 
clinical setting. The development of norms appropriate for a UK population may overcome 
this problem, however, in its current form, the CRIq cannot be considered a valid and 
reliable measure of premorbid ability as it does not meet O’Carroll et al’s. (1991) first 
criteria. Once this has been overcome, the CRIq has potential for use with populations 
where language disturbance is a feature of the clinical presentation. The study also provided 
further evidence against the clinical utility of the NART, by demonstrating that performance 
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Appendix A2: Quality assessment checklist (from Cahill et al., 2010).  






1  Is the hypothesis/ 
aim/objectives of the 
study clearly described 
  
2 Are the main outcomes to be 
measured clearly described in 
the introduction or methods 
section 
If the main outcomes are first mentioned in the 
results section, the question should be 
answered No 
 
3 Are the characteristics of the 
clients included in the study 
clearly described 
Inclusion and/or exclusion criteria should be given. Emphasis on 
inclusion and exclusion criteria, other characteristics are 
age/gender/morbidity 
 
4 Are the interventions/ 
treatments of interest clearly 
described? 
Treatments and placebo (where relevant) that are to be 
compared should be clearly described  
 
5 Are the distributions of 
principal confounders in each 
group of clients to 
be compared (or within a single 
group) clearly described? 
A list of principal confounders is provided. Morbidity, co-
morbidity, age, gender, previous history. Good quality will 
include adjustment regression or matching 
 
 




Simple outcome data (including denominators and numerators) 
should be reported for all major findings so that the reader can 
check the major analyses and conclusions. This question does 
not cover statistical tests which are considered below 
 
7 Does the study provide 
estimates of the random 
variability in the data for the 
main outcomes? 
In non normally distributed data the inter-quartile range of 
results should be reported. In normally distributed data the 
standard error, standard deviation, or confidence intervals 
should be reported. 
If the distribution of the data is not described, it must be 
assumed that the estimates used were appropriate and the 
question should be answered yes 
 
8 Have all the important adverse 
events that 
may be a consequence of the 
intervention/ treatment been 
reported? 
This should be answered yes if the study demonstrates that 
there was a comprehensive attempt to measure adverse events 
(A list of adverse events is provided). E.g. early discontinuation of 
therapy 
 
9 Have the characteristics of 
clients lost to follow-up been 
described? 
This should be answered yes where there were no losses to 
follow-up or where losses to follow-up were so small that 





 answered No where a study does not report the number of 
patients lost to follow-up. Follow up= post -therapy, or loss from 
study at baseline 
10 Have actual probability values 
been reported (e.g. 0.035 
rather than ,0.05) 
for the main outcomes except 
where the probability value is 
less than 0.01 
  
11 Have sufficient data been 
provided to enable calculation 
of outcomes such as pre–post 
ESs, estimates of reliable and 
clinically significant change 
If data are provided to enable calculation of any one of these 
outcomes score the question yes 
External validity/clinical representativeness 
 
External validity/clinical representativeness 
12a (a) Were the clients asked to 
participate in the study 
representative of the entire 




12b  (b) Were clients referred 
through usual 
clinic routes 
The study must identify the source population for clients and 
describe how the patients were selected. Clients would be 
representative if they comprised the entire source population, 
an unselected sample of consecutive clients, or a random 
sample. Random sampling is only feasible where a list of all 
members of the relevant population exists. Where a study does 
not report the proportion of the source population from which 
the patients are derived the question should be answered as 
unable to determine 
 
13 Were those clients who were 
prepared to participate 
representative of the entire 
population from which they 
were recruited? 
The proportion of those asked who agreed should be stated. 
Validation that the sample was representative would included 
demonstrating that the distribution of the main confounding 
factors was the same in the study sample and the source 
population 
 




14b  (b)Were clients heterogeneous 
in terms of presenting problems 
  
15a (a) Were the staff, places, 
facilities where the patients 
were treated representative of 
the treatment the majority of 
patients receive? 
For the question to be answered yes the study should 
demonstrate that the intervention was representative of that in 
use in the source population 
 
15b (b) Was the treatment 
conducted in a non 
university setting 
 
The question should be answered no if, for example, the 
intervention was undertaken in a specialist centre 
unrepresentative of the hospitals most of the source population 
would attend 
 







16 Were therapists experienced, 
professionals with regular 
caseloads 
  
17 Were therapists free to use a 
wide variety 
of procedures in treatment and 
not just 
limited to one treatment 
procedure 
  
18 (R)Were therapists trained 
immediately 
before the study and in the 
specific treatment being 
studied 
  
Internal reliability of measurement and treatment 
19 If any of the results 
of the study were based 
on ‘data dredging’ was this 
made clear 
Any analysis that had not been planned at the outset of the 
study should be clearly indicated. If no retrospective unplanned 
subgroup analysis were reported, then answer yes 
 
20 Were the statistical tests used 
to assess the main outcomes 
appropriate 
The statistical techniques used must be appropriate to the data. 
For example, non parametric methods should be used for small 
sample sizes. Where little statistical analysis has been 
undertaken, but where 
there is no evidence of bias, the question should be answered 
yes. If the distribution of the data (normal or not) is not 
described it must be assumed that the estimates used were 
appropriate and the question should be answered yes  
 
21 Was the compliance with the 
intervention/ s/treatments 
reliable? 
Where there was non compliance with the allocated the 
question should be answered no 
 
22 Were the main outcome 
measures 
used accurate (valid and 
reliable) 
For studies where the outcome measures are clearly described, 
the question should be answered yes. For studies which refer to 
other work or that demonstrates the outcome measures are 
accurate, the question should be answered yes 
 
23 Do the analyses adjust for 
different lengths of follow-up of 
patients in different treatment 
groups? 
Where no comparison group score 0. Where lengths of follow-up 
the same score 1 
 
Internal reliability of confounding variables 
24 Were the clients in different 
intervention /treatment groups 
recruited from the same 
population 
For example, clients for all comparison groups should be selected 
from the same source population. The question should be 
answered unable le to determine where there is no information 
concerning the source of patients included in the study. Where 
no comparison group score 0 
 
25 Were the clients in different  
Intervention /treatment groups 
For a study which does not specify the time period over which 





recruited over the same period 
of time? 
to determine. Where no comparison group score 0 
26 Was there adequate 
adjustment for 
confounding in the analysis 
from which 
the main findings were drawn 
This question should be answered no if the main conclusions of 
the study were based on analyses of treatment rather than 
intention to treat; the distribution of known confounders was 
not described; 
or the distribution of confounders differed between the 
treatment groups but was not taken into account in the analyses. 
If the effect of the main confounders was not investigated or 
confounding was 
demonstrated but no adjustment was made in the final analyses, 
the question should be answered no 
 
27 Were losses of clients to follow-
up taken 
into account? 
If the numbers of clients lost to follow-up are not reported, the 
question should be answered as unable to determine. If the 
proportion of lost to follow-up was too small to affect the main 
findings, the question should be answered yes  
 
28 Did the study have sufficient 
power to 
detect a clinically important 
effect where the probability 
value for a difference being due 
to chance is less than 5% 
Sample sizes have been calculated to detect a difference of x and 
y%. Has power analysis been performed  
Size of smallest intervention group 
A <N1 = 0  
B N1–N2 =1 
C N3–N4 =2 
D N5–N6 =3 
E N7–N8 =4 













Appendix A3: Final study selection and reason for exclusion from systematic review from stage 8 of 
main search and stage 1 from Clare & Woods, (2008) rejected studies based on being non-RCTs. 
Study Name Reason for Exclusion  
Agguire 2013 Describes cognitive stimulation 
Andersen 2012 Describes cognitive stimulation 
Arkin 1997 No access to paper 
Bernhardt 2002 In German  
Brinkman 1982 Intervention as adjunct to pharmacotherapy  
Brodaty 1989 Describes cognitive training 
Buettner 2011 Describes cognitive stimulation 
Eckroth-Bucher 2009 Describes aspects of cognitive stimulation and cognitive training 
Ermi-Fuenfsch 2002 In German 
Gaitan 2013 Describes cognitive training 
Galante 2007 Describes cognitive training 
Graessel 2011 Describes cognitive stimulation 
Kwok 2013 Participant criteria not met (participants had diagnosis of MCI not dementia) 
Lam 2010 Describes functional enhancement programme, not cognitive rehabilitation 
Onor 2007 Describes cognitive stimulation 
Panza 1996  Describes aspects of cognitive stimulation and cognitive training 
Park 2009 Describes cognitive stimulation 
Schrieber 1999 Describes cognitive training 
Schwenk 2010 Intervention not aimed at cognitive change 
Smith 2009  Participant criteria not met (participants are healthy not dementia) 
Tarraga 2006 Describes cognitive stimulation 
Yanguas 2006 Limited details to determine if cognitive rehabilitation 




Appendix A4: Author guidelines for systematic review. Guidelines for Neuropsychological 
Rehabilitation – An International Journal  
Taken from:  
http://www.tandfonline.com/action/authorSubmission?journalCode=pnrh20&page=instructions#.Uff3
1G2Alfs  
Neuropsychological Rehabilitation considers all manuscripts on the strict condition that they have 
been submitted only to Neuropsychological Rehabilitation , that they have not been published 
already, nor are they under consideration for publication or in press elsewhere. Authors who fail to 
adhere to this condition will be charged with all costs which Neuropsychological Rehabilitation incurs 
and their papers will not be published. 
Contributions to Neuropsychological Rehabilitation must report original research and will be 
subjected to review by referees at the discretion of the Editorial Office. 
This journal is compliant with the Research Councils UK OA policy. Please see the licence options and 
embargo periods here .  
  
Please note that Neuropsychological Rehabilitation uses CrossCheck™ software to screen papers for 
unoriginal material. By submitting your paper to Neuropsychological Rehabilitation you are agreeing 




1. General guidelines 
• Papers are accepted only in English. British English spelling and punctuation is preferred/Any 
consistent spelling style may be used. Please use double quotation marks, except where “a 
quotation is ‘within’ a quotation”. 
• There is no word limit for manuscripts submitted to this journal. Authors should include a 
word count with their manuscript. 
• Manuscripts should be compiled in the following order: title page; abstract; keywords; main 
text; acknowledgments; appendixes (as appropriate); references; table(s) with caption(s) (on 
individual pages); figure caption(s) (as a list). 
• Abstracts of150-200 words are required for all papers submitted. Avoid abbreviations, 
diagrams, and references to the text in the abstract. 




• Search engine optimization (SEO) is a means of making your article more visible to anyone 
who might be looking for it. Please consult our guidance here . 
•  All the authors of a paper should include their full names, affiliations, postal addresses, 
telephone numbers and email addresses on the cover page of the manuscript. One author 
should be identified as the corresponding author. The affiliations of all named co-authors 
should be the affiliation where the research was conducted. If any of the named co-authors 
moves affiliation during the peer review process, the new affiliation can be given as a 
footnote. Please note that no changes to affiliation can be made after the article is accepted. 
Please note that the email address of the corresponding author will normally be displayed in 
the article PDF (depending on the journal style) and the online article. 
• Biographical notes on contributors are not required for this journal. 
• For all manuscripts non-discriminatory language is mandatory. Sexist or racist terms should 
not be used. 
• Authors must adhere to SI units . Units are not italicised. 
• When using a word which is or is asserted to be a proprietary term or trade mark, authors 
must use the symbol ® or TM. 
• Authors should supply a shortened version of the title suitable for the running head, not 
exceeding 50 character spaces. Section headings should be concise and should not contain 
numbering. 
• Acknowledgements should be gathered into a brief statement at the end of the text. All 
sources of financial sponsorship are to be acknowledged, including the names of private and 
public sector sponsors. This includes government grants, corporate funding, trade 
associations and contracts. 
• Tables should be kept to the minimum. Each table should be typed double spaced on a 
separate page, giving the heading, e.g., "Table 2", in Arabic numerals, followed by the 
legend, followed by the table. Make sure that appropriate units are given. Instructions for 
placing the table should be given in parentheses in the text, e.g., "(Table 2 about here)". 
•  Results of statistical tests should be given in the following form: 
"... results showed an effect of group, F (2, 21) = 13.74, MSE = 451.98, p < .001, but there was no 
effect of repeated trials, F (5, 105) = 1.44, MSE = 17.70, and no interaction, F (10, 105) = 1.34, MSE = 
17.70." 
Other tests should be reported in a similar manner to the above example of an F -ratio. For a fuller 
explanation of statistical presentation, see the APA Publication Manual (6th ed.). 
• Abbreviations that are specific to a particular manuscript or to a very specific area of 
research should be avoided, and authors will be asked to spell out in full any such 
abbreviations throughout the text. Standard abbreviations such as RT for reaction time, SOA 
for stimulus onset asynchrony or other standard abbreviations that will be readily 
understood by readers of the journal are acceptable. Experimental conditions should be 
named in full, except in tables and figures. 
2. Style guidelines 
• Description of the Journal’s reference style 






•  It is in the author's interest to provide the highest quality figure format possible. Please be 
sure that all imported scanned material is scanned at the appropriate resolution: 1200 dpi 
for line art, 600 dpi for grayscale and 300 dpi for colour. 
• Figures must be saved separate to text. Please do not embed figures in the paper file. 
• Files should be saved as one of the following formats: TIFF (tagged image file format), 
PostScript or EPS (encapsulated PostScript), and should contain all the necessary font 
information and the source file of the application (e.g. CorelDraw/Mac, CorelDraw/PC). 
• All figures must be numbered in the order in which they appear in the paper (e.g. Figure 1, 
Figure 2). In multi-part figures, each part should be labelled (e.g. Figure 1(a), Figure 1(b)). 
• Figure captions must be saved separately, as part of the file containing the complete text of 
the paper, and numbered correspondingly. 
• The filename for a graphic should be descriptive of the graphic, e.g. Figure1, Figure2a. 
4. Publication charges 
Submission fee 
There is no submission fee for Neuropsychological Rehabilitation . 
Page charges 
There are no page charges for Neuropsychological Rehabilitation . 
Colour charges 
Authors should restrict their use of colour to situations where it is necessary on scientific, and not 
merely cosmetic, grounds. Colour figures will be reproduced in colour in the online edition of the 
journal free of charge. If it is necessary for the figures to be reproduced in colour in the print version, 
a charge will apply. Charges for colour pages are £250 per figure ($395 US Dollars; $385 Australian 
Dollars; 315 Euros). If you wish to have more than 4 colour figures, figures 5 and above will be 
charged at £50 per figure ($80 US Dollars; $75 Australian Dollars; 63 Euros). Waivers may apply for 
some papers – please consult pnrh-peerreview@tandf.co.uk regarding waivers. 
Depending on your location, these charges may be subject to Value Added Tax . 
5. Reproduction of copyright material 
As an author, you are required to secure permission to reproduce any proprietary text, illustration, 
table, or other material, including data, audio, video, film stills, and screenshots, and any 
supplemental material you propose to submit. This applies to direct reproduction as well as 




from a copyrighted source). The reproduction of short extracts of text, excluding poetry and song 
lyrics, for the purposes of criticism may be possible without formal permission on the basis that the 
quotation is reproduced accurately and full attribution is given. For further information and FAQs, 
please see http://journalauthors.tandf.co.uk/permissions/usingThirdPartyMaterial.asp 
6. Supplemental online material 
Authors are welcome to submit animations, movie files, sound files or any additional information for 
online publication.  
• Information about supplemental online material 
  
Manuscript submission 
All submissions should be made online at the Neuropsychological Rehabilitation ScholarOne 
Manuscripts site .  New users should first create an account. Once logged on to the site, submissions 
should be made via the Author Centre. Online user guides and access to a helpdesk are available on 
this website. 
Manuscripts may be submitted in any standard format, including Word, EndNote and PDF. These 
files will be automatically converted into a PDF file for the review process. LaTeX files should be 
converted to PDF prior to submission because ScholarOne Manuscripts is not able to convert LaTeX 
files into PDFs directly. 
•   Click here for Information regarding anonymous peer review 
   
Copyright and authors’ rights 
It is a condition of publication that all contributing authors grant to Taylor & Francis the necessary 
rights to the copyright in all articles submitted to the Journal. Authors are required to sign an Article 
Publishing Agreement to facilitate this. This will ensure the widest dissemination and protection 
against copyright infringement of articles. The “article” is defined as comprising the final, definitive, 
and citable Version of Scholarly Record, and includes: ( a ) the accepted manuscript in its final and 
revised form, including the text, abstract, and all accompanying tables, illustrations, data; and ( b ) 
any supplemental material. Copyright policy is explained in detail at 
http://journalauthors.tandf.co.uk/permissions/reusingOwnWork.asp . 




As an author, you will receive free access to your article on Taylor & Francis Online. You will be given 
access to the My authored works section of Taylor & Francis Online, which shows you all your 
published articles. You can easily view, read, and download your published articles from there. In 
addition, if someone has cited your article, you will be able to see this information. We are 
committed to promoting and increasing the visibility of your article and have provided guidance on 
how you can help . Also within My authored works , author eprints allow you as an author to quickly 
and easily give anyone free access to the electronic version of your article so that your friends and 
contacts can read and download your published article for free. This applies to all authors (not just 
the corresponding author). 
Reprints and journal copies 
Corresponding authors can receive a complimentary copy of the issue containing their article. Article 
reprints can be ordered through Rightslink® when you receive your proofs. If you have any queries 
about reprints, please contact the Taylor & Francis Author Services team at reprints@tandf.co.uk . 
To order extra copies of the issue containing your article, please contact our Customer Services team 
at Adhoc@tandf.co.uk . 
Open access 
Taylor & Francis Open Select provides authors or their research sponsors and funders with the 
option of paying a publishing fee and thereby making an article permanently available for free online 
access – open access – immediately on publication to anyone, anywhere, at any time. This option is 
made available once an article has been accepted in peer review.  
Full details of our Open Access programme 
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Study Protocol: Can a questionnaire measuring Cogni tive Reserve provide an 
alternative way of estimating premorbid functioning  in individuals with dementia? A 
Pilot study.  
 
A crucial part of diagnosing dementia requires clinicians to estimate an individuals’ level of 
ability before the onset of cognitive decline, or their ‘premorbid ability’. Traditional measures 
of estimating premorbid functioning (e.g NART; National Adult Reading Test; Nelson, 1982) 
rely on assessing word reading ability, an ability that is said to be relatively resistant to 
cognitive decline. However, there are numerous clinical conditions where word reading 
ability is impaired (e.g semantic dementia) and so these measures may not reliably predict 
premorbid functioning in all cases. In addition, premorbid verbal ability may not be wholly 
reflective of global premorbid cognitive ability e.g it may not reflect an individuals’ executive 
functioning or visuo-spatial functioning. This pilot study aims to assess whether a newly 
developed questionnaire that is said to measure Cognitive Reserve, the CRIq (Cognitive 
Reserve Index Questionnaire, Nucci et al, 2011) can function as a measure of premorbid 
non-verbal ability. As the CRIq has never been used in this way before, the study will 
attempt to achieve proof of concept, in order that a larger study can be completed at a later 
date.  
 
In order to achieve this, several factors will be considered. Any measure of premorbid 
functioning should fulfil the following criteria: 
1) High correlation with intelligence (when tested in a healthy population); 
2) Be resistant to cognitive decline (e.g dementia); 
3) Have high inter-rater reliability.  
 
The CRIq will be evaluated against the first two criteria to examine how well it captures non-
verbal premorbid functioning. It’s resistance to decline will also be compared to traditional 
‘gold standard’ measures of premorbid functioning such as the NART. If the CRIq is found to 
accurately capture premorbid functioning this may provide clinicians with a tool that: 
• Does not rely on word reading ability. This may be particularly useful when language 
is impaired (e.g in specific forms of dementia such as Semantic Dementia or in 
patients with Aphasia).  
• Takes into account aspects of global cognitive functioning (non-verbal premorbid 
ability) and the ability of the brain to withstand pathology; 




• Can be completed by a caregiver or someone who knows that individual well, 
eliminating the need to administer a test directly with the patient; 
• Can be used as a complimentary measure to NART, by capturing non-verbal 
premorbid ability rather than verbal premorbid ability. This may provide a more 
global, comprehensive assessment of premorbid functioning if used together.   
 
Aims 
This pilot study will evaluate how CRIq functions as a measure of premorbid functioning, and 
how it compares to traditional measures such as NART. As the CRIq has only been 
investigated with an Italian speaking population, an additional aim of this study is to utilise 
the CRiQ with an English speaking sample. 
Research Questions  
4) How well does CRIq correlate with a measure of current non-verbal intelligence in a 
healthy population? Does it capture current ability?  
5) Is performance on the CRIq affected by cognitive decline (dementia)? Is there any 
difference in performance on the CRIq between groups? 
6) Is performance on CRIq related to performance on other hold tests such as NART? 
 
Hypothesis 
The null hypothesis for this study is that the CRiQ will not:  capture premorbid non-verbal 
ability, be resistant to decline, and will not compare well to other hold tests.  
The alternative hypothesis is that the CRiQ will : capture premorbid non-verbal ability, be 
resistant to decline, and will compare well to other hold tests.  
 
Method of investigation 
Participants 
Two groups will be recruited into the study, 1) a clinical sample of individuals that have 
experienced cognitive decline (dementia), and 2) a control sample of healthy older adults. 
There will be 26 participants recruited per group. Inclusion and exclusion criteria are outlined 
below: 
 
Please note that in all correspondence Group 1 refe rs to the Dementia Group and 







Inclusion criteria for dementia group 
(Group 1) 
 Inclusion crite ria for control groups                   
(Group 2) 
 
• Diagnosis of dementia (either AD or 
mixed ) within last 2-5 years 
• Able to provide informed consent 
• Are over the age of 60; 
• Do not have any problems with 
anxiety, low mood or have any 
diagnosed mental health problem, as 
defined by clinical cut off on 
screening measures; 
• Are a native English speaker, and do 
not speak any other language 
fluently; 
• Can read and write in English; 
• Do not have any significant health 
problem (e.g heart disease); 
• Have not had any kind of brain injury 
e.g stroke, brain injury, tumour; 
• Can self travel to St John’s Hospital, 
Livingston or to the Royal Edinburgh 
Hospital, Edinburgh.  
 
• Are over the age of 60; 
• Do not have any problems with 
anxiety, low mood or have any 
diagnosed mental health problem, as 
defined by clinical cut off on 
screening measures; 
• Are a native English speaker, and do 
not speak any other language 
fluently; 
• Can read and write in English; 
• Do not have any significant health 
problem (e.g heart disease); 
• Do not have any problem with your 
cognitive ability (thinking skills such 
as memory); 
• Have not had any kind of brain injury 
e.g stroke, brain injury, tumour; 
• Can self travel to St John’s Hospital, 





Exclusion criteria for dementia group  
(Group 1)  
 
• Aged under 60 
• Unable to provide informed consent 
• Pre-existing cognitive impairment e.g 
Learning Disability, acquired brain 
injury, stroke.  
• Sensory impairment e.g blind or deaf  
• Current or history of substance 
misuse, life limiting illness 





Exclusion criteria for control group  
(Group 2)  
 
• Aged under 60 
• Unable to provide informed consent 
• Acquired brain injury e.g Stroke, 
traumatic brain injury 
• Sensory impairment e.g blind or deaf  
• Cognitive impairment evidenced by 
performance below clinical cut off for 
dementia on screening measures 
(<21 on MOCA).  
• Current or history of substance 
misuse, life limiting illness 





This study is a quantitative, within subjects design, with participants assigned to either the 
dementia group or the control group. All participants will complete the CRIq, GAI, GDS-15, 
NART, MOCA and demographic questionnaire. The control group will complete the 
Perceptual Reasoning Subtests from the WAIS-IV (Wechsler Adult Intelligence Scale- Fourth 
Edition).  
Measures 
The following measures will be used in this study: 
National Adult Reading Test (Nelson, 1982) 
The NART is a commonly used tool that provides an estimate of premorbid cognitive 
functioning based on word reading ability. Participants are required to read aloud 50 irregular 
words. It is quick to administer and frequently used with an older adult population (e.g 
Schretlen et al, 2005). NART is routinely used in clinical practice, and has been shown to 
have high correlation with premorbid intelligence and hold over time (Crawford et al, 2001). 
Similarly, NART performance has been shown to be stable over time, even in individuals 
who go on to develop dementia (McGurn et al, 2004).  
Cognitive Reserve Index Questionnaire (CRIq, Nucci et al, 2011).  
The CRiQ is a self report questionnaire that aims to quantify the amount of cognitive reserve 
accumulated throughout an individual’s lifetime. It focuses on three areas of cognitive 
reserve: education, working activity and leisure activities. It has recently been standardised 
in a sample of 558 individuals aged of 18-102, but has yet to be used with a clinical sample 
or an English speaking sample. It has recently been translated into English by the authors. 
Geriatric Depression Scale- Short  (GDS-15, Poon, 1987) 
This questionnaire is a self-report questionnaire used to detect the presence of low mood 
and depression and was specifically developed for, and validated in, the older adults 
population (Sheikh, 1986). The GDS-15 has also been found to have good specificity and 
sensitivity in a meta-analysis of 42 papers (Wancata et al, 2006). This indicates that it can be 
reliably used as a screening measure for depression in later life.  
Geriatric Anxiety Inventory (GAI: Pachana et al, 2007) 
This is a 20 item self-report questionnaire used to measure anxiety in older people. It is 
reported to have good psychometric properties, with excellent inter-rater reliability (Pachana 
et al, 2007).  
Montreal Cognitive Assessment (MOCA; Nasreddine et al, 2005) 
The MOCA has been recently developed as a brief cognitive screening tool. It takes 10 
minutes to complete, with participants achieving a score out of 30. The test includes aspects 




Many studies typically use the MMSE (Folstein, 1975) or ACE-R (Mioshi et al, 2005), (which 
contains the MMSE embedded into it), as a cognitive screen. However with recent issues 
regarding copyright of the MMSE, both of these screening tools are no longer being used by 
NHS Lothian Psychology. The MOCA is copyright free, and has recently been validated as 
being more sensitive than MMSE in detecting mild cognitive impairment, Alzheimer’s 
disease and Vascular dementia in an elderly population, using a cut-off point of <21 for MCI 
and <17 for Alzheimer’s disease (Freitas et al, 2011a), and Vascular Dementia (Freitas et al, 
2011b).  
Perceptual Reasoning Subtests from the WAIS-IV (Wechsler Adult Intelligence Scale- Fourth 
Edition, Wechsler, 2008) 
Three subtests from the WAIS-IV will be used to assess non-verbal ability in the control 
group; the Block Design, Matrix Reasoning and Visual Puzzles, which comprise the 
Perceptual Reasoning Index. The WAIS-IV is a well validated measure of current ability, 
frequently used for this purpose in an older adult population (e.g Baxendale, 2011).  
Demographic Questionnaire (devised by Chief Investigator)  
This questionnaire will be used with both groups to ensure that the participant meets the 
inclusion criteria. This will also gather details of non-dementia participants’ GP details in the 
event that they can be contacted if the researcher becomes aware of any previously 
unknown psychological or physical health problem/s. 
Recruitment: 
Control group 
Healthy controls will be invited to participate from the West Lothian 50+ network and from 
the Scottish Dementia Clinical Research Network (SDCRN) carer participant pool. Members 
of the West Lothian 50 + network will be provided with the Participant Information Sheet 
(PIS) by the network and invited to participate. The SDCRN will identify carer participant pool 
members that meet the inclusion criteria, and will pass on those contact details to the Chief 
Investigator. They will then be posted a copy of the PIS and invited to participate. All 
participants will be invited to complete a tear off slip and post it to the Chief Investigator in 
they are interested in participating in the study. They will also be able to contact the Chief 




The dementia group will be recruited from NHS Lothian Memory Clinics and from the 
SDCRN. Individuals with dementia that are registered with the SDCRN and who meet the 
inclusion/exclusion criteria will be identified by the SDCRN. Their contact details will be 
passed on to the Chief Investigator who will then be posted a copy of the PIS and invited to 




Investigator in they are interested in participating in the study. They will also be able to 
contact the Chief Investigator by telephone to ask questions and/or state their interest in 
participating in the study. Individuals recruited from NHS Lothian Memory Clinics will be 
initially identified by clinical staff (Nursing, Psychiatry, Clinical Psychology) as meeting the 
inclusion criteria. Clinical staff will provide patients with the PIS to patients, complete a tear 
off slip and post it to the Chief Investigator in they are interested in participating in the study. 
They will also be able to contact the Chief Investigator by telephone to ask questions and/or 
state their interest in participating in the study.  
Procedure 
After participants have expressed an interest in participating in the study (by tear off slip or 
by phone), they will be contacted by phone, email or by post (whichever is preferred by the 
participant) to arrange an appointment. Control Group participants will be sent the self-report 
questionnaires to complete before the appointment. All appointments will take place within 
NHS Lothian Premises at the Royal Edinburgh Hospital or St John’s Hospital, Livingston. 
Appointments will last approximately 1 hour and comprise of the following procedure (see 
Fig.1): 
• Clarification of meeting inclusion criteria (5 minutes); 
• Read and sign consent form (5 minutes); 
• Complete demographic questionnaire (Dementia Group) (5 minutes); 
 
Check completion of self-report questionnaires (Control Group) or complete during 
appointment (Dementia Group) (15 minutes):  
• Geriatric Depression Scale- 15  (GDS-15; Poon, 1987), Geriatric Anxiety Inventory 
(GAI; Pachana et al, 2007) and the Cognitive Reserve Questionnaire (CRIq; Nucci, 
Mapelli & Mondini, 2011); 
Complete cognitive screening assessment (10 minutes): 
• MOCA (Nasreddine et al, 2005) (10 mins) 
 
Assessment of reading ability and intelligence: 
• Control group:  Administer WAIS-IV Perceptual Reasoning Subtest (Wechsler, 
2008) max 30 mins)  
• Administer National Adult Reading Test – Revised (NART-R; Nelson, 1982) (10 
mins) 































Dementia Group  
Can opt into having a 
reminder text/call before 
appointment. 
All groups:  Provided with 
PIS 
All groups:  Arrange appointment by phone, email or post 
Control Group:  
Complete following assessments: 
• NART 
• WAIS-IV subtests x3 
All gr oups:  Participant expresses interest by completing tear off slip or 
telephoning Chief Investigator. Check inclusion/exclusion criteria. 
Control Group  
Sent out questionnaires to complete 






All groups:  Attend appointment at either: 
• St John’s Hospital 
• Royal Edinburgh Hospital 
Dementia Group:  
Complete following assessments: 
• NART 
• CRIq 
All groups:  
• Check inclusion/exclusion criteria 
• Check ability to consent 
• Read and sign consent form 
All groups:  
• Debrief/ answer questions 
Control Group:  
Complete screening measures and 
score questionnaires: 
• MOCA 
Control Group:  
Complete screening measures: 





ALL Groups : Score screening measures: 
If any participant scores above clinical cut off on GDS or GAI, or if control participants 
score above 21 on MOCA, they will be removed from the study. 
Participants will be informed of this, and provided with the relevant resource information 




Fig 1: Summary of Procedure 
 
All participants will be invited to take a break, reschedule the assessment or terminate 
participation if they become fatigued or distressed during the assessment. If participants 
become upset during the assessment, appropriate action will be taken. If participants are 
concerned about their memory after completing the assessment they will be advised to 
contact their GP. If participants would like to know about resources and support services for 
low mood, anxiety or dementia, they will be provided with an information sheet (see 
‘Resource Information Sheet 1’ and ‘Resource Information Sheet 2’’).  
Statistical analysis 
Correlational analysis will be used initially to assess the relationship between performance 
on all measures. Analysis of Variance (ANOVA) allows comparison between the ratio of 
systematic error variance to unsystematic error variance (Field, 2005) and will be used to 
compare any statistically significant differences in performance on all measures between the 
two groups. For example, a 2-way ANOVA can be used to identify any statistically significant 
differences in performance on CRIq and MOCA between the control group and the dementia 
group.  
Dissemination 
The findings of the study will be written up as a Doctoral Thesis in part fulfilment of the 
Doctorate in Clinical Psychology. A more concise write up of the project will be prepared for 
publication in a peer reviewed journal. A brief write up of the study will be freely available to 
participants, and for publication in the West Lothian 50+ network newsletter (and any other 
charities/organisations that may become involved). Poster Presentations summarising the 
research will also be given at relevant CPD events including the annual NHS Lothian 




Appendix B4: Participant Information Sheet – Dementia group 
                                                                                                                    
Understanding changes in thinking ability in later life 
Participant Information Sheet  
What is the study about?  
This study is examining the relationship between different questionnaires and psychological 
evaluations, routinely used in the assessment of memory problems.  
 
Why have I been asked to take part?  
SDCRN Members: 
This study has been approved by the Scottish Dementia Clinical Research Network 
(SDCRN). You have been invited to take part as you are registered with the SDCRN 
participant database, and have indicated that you may be interested in participating in 
research approved by the network. The SDCRN has identified that you may meet the criteria 
to be part of the study (included below) and so has passed on your name and address to the 
Chief Investigator. We are therefore contacting you to invite you to take part in the study. If 
you decide not to take part, this will not affect any future research you may be invited to 
participate in.   
Through NHS Lothian Memory Clinics:  
You have been invited to take part as your clinician (e.g Doctor, Nurse, Psychologist) thinks 
that you may be interested in taking part in the study. 
 
What will I be asked to do?  
The study requires participants to meet with the Chief Investigator (Jo Phillips), on one 
occasion  for approximately one hour . We will meet either at the Royal Edinburgh Hospital, 
Edinburgh, or at St John’s Hospital, Livingston, whichever is more suitable for you. We will 
meet at a date and time convenient for you. Please note that unfortunately we are unable to 
reimburse your travel expenses.  
At this meeting, you will have the opportunity to discuss the study and ask any questions you 





agree to take part in the study. We will also inform your GP (General Practitioner) that you 
are taking part in the study.  
We will then complete a series of tasks including: 
• A word reading task; 
• Questionnaires regarding your mood and your occupational and educational history.  
 
If at any point during the assessment you no longer wish to participate, you can withdraw 
from the study.  
 
Do I have to take part in the study?  
No. Your participation is entirely voluntary. If you decide to take part, you will be given this 
information sheet to keep and will be asked to sign a consent form. 
Taking part in the study will not affect the care you receive from any NHS service now or in 
the future. 
At any point during this study, if you no longer wish to participate, you can withdraw from the 
study without giving a reason why. 
 
What are the possible benefits of taking part?  
There will be no immediate benefits for participants taking part in the study. The study may, 
however, inform how the NHS assesses memory problems in the future.  
 
What are the possible disadvantages or risks of tak ing part?  
You may find completing the tasks tiring, or upsetting if you find them difficult. If this is the 
case we may need to take a break or reschedule a later meeting to complete the 
assessment. If you become upset we may need to let your GP or keyworker know. We can 
also provide you with information about other agencies or resources to access if you are 
worried about your mood.  
 
Will my taking part in the study be kept confidenti al?  
The study is confidential. The only people allowed to see the data are myself, my 
supervisors, and anyone appointed by the Sponsor to check the study is being carried out 




We will inform your General Practitioner (GP) that you are taking part in this study. We will 
not inform your GP of any details about your performance on the assessment, unless you 
report any difficulties with your mood. 
If you tell me anything that makes me think that you, or others around you, are at risk of 
harm, I would need to inform your GP and discuss with you how to address this. 
The information I gather from you will be kept for 3 years after the research has been 
completed, in accordance with NHS Research Ethic’s Guidelines.  
 
Will I find out the results of the study?  
If you wish to know the results of the study we can provide you with a written summary. The 
study will be completed in August 2013.  
 
What will happen to the results of the study?  
The information I collect will be written up as a Doctoral Thesis as part of my Clinical 
Psychology training course. I may also publish some of the data as a piece of research in a 
scientific journal. Any information collected will be kept anonymous and only myself and my 
supervisors will be able to identify the participants involved.  
 
Who is organising the research and why?  
I am conducting this study as part of my Doctorate in Clinical Psychology. It will be written up 
as my Doctoral Thesis.  
 
Who has reviewed the study?  
The study proposal has been reviewed by the University of Edinburgh Doctorate in Clinical 
Psychology course and my supervisors (Dr. Ken Laidlaw and Dr Sandy McAfee). Ethical 
approval has also been granted by South East Scotland Research Ethics Committee.  
 
What to do now?  
If you would like to know more about the study or are interesting in participating, please 
complete the tear off slip and send it to: 
Jo Phillips 
Trainee Clinical Psychologist 





St John’s Hospital 
 
If you do not wish to participate in the study you do not have to do anything. Thank you for 
reading this Participant Information Sheet.  
I would like to speak to an independent advisor reg arding the study  
If you would like to speak to someone else about the study please contact: 
Dr Emily Newman 
0Health Psychology Lecturer 
School of Health in Social Science 
Old Medical School 
University of Edinburgh 
Edinburgh EH8 9AG 


















Fig 1. Flow chart explaining participation process. 
I would like further information or 
would like to discuss how I can 
participate in the study 
Contact Jo Phillips or complete tear 
off slip and send to above address.  
 
You can contact Jo Phillips by phone 
to discuss the study (Tel No) 
Arrange a time/date to meet to 
complete the assessments. Your GP 
will be informed of your participation 
I would like to participate in the study 
I do not wish to take part in the 
study. Please inform Jo 
Phillips that you no longer 
wish to take part. You do not 
have to provide any reason.  
Attend appointment 
I do not wish to take part in 
the study 
If do not wish to take part in 
the study, you do not have to 
do anything. Thank you for 
reading the Participant 




Thank you for taking the time to read this informat ion sheet 
Jo Phillips, Trainee Clinical Psychologist 
If you would like to participate in the study, or w ould like further information, please 
complete the tear off slip below and send it to: 
 
Jo Phillips 
Trainee Clinical Psychologist 
Older Adults Clinical Psychology 
Psychology Department 








Tear off slip here 









I would like further information regarding the above study   
   
I would like to participate in the above study   
   
My preferred location for an appointment is: 
 
  
St John’s Hospital, Livingston   
   
Royal Edinburgh Hospital, Edinburgh   
   
Please contact me via  telephone  / email  / post (delete as appropriate)   











                                                                                                                                                                                         
Measuring lifelong ability and cognitive change  
 
Participant Information Sheet  
 
What is the study about?  
This study is examining the relationship between different questionnaires and psychological 
evaluations, routinely used in the assessment of memory problems.  
 
Why have I been invited to take part?  
SDCRN Members: 
This study has been approved by the Scottish Dementia Clinical Research Network 
(SDCRN). You have been invited to take part as you are registered with the SDCRN Carer’s 
database, and have indicated that you may be interested in participating in research 
approved by the network. The SDCRN has identified that you may meet the criteria to be 
part of this study (included below) and so has passed on your name and address to the 
Chief Investigator. We are therefore contacting you to invite you to take part in the study. If 
you decide not to take part, this will not affect any future research you may be invited to 
participate in.   
West Lothian 50+ Network Members: 
You have been given this Participant Information Sheet as you are a member of the West 
Lothian 50 + Network. The Network has agreed to distribute this information sheet so that 
members can contact the Chief Investigator if they are interested in participating in, or 
finding out more, about the study.  
 
How do I know if I can take part?  
You are invited to take part in the study if you: 
• Are over the age of 60; 
• Do not have any problems with anxiety, low mood or have any diagnosed mental 
health problem; 
• Are a native English speaker, and do not speak any other language fluently; 
• Can read and write in English; 
• Do not have any significant health problem (e.g heart disease); 
• Do not have any problem with your cognitive ability (thinking skills such as memory); 




• Have not had any kind of brain injury e.g stroke, brain injury, tumour; 
• Can self travel to St John’s Hospital, Livingston or to the Royal Edinburgh Hospital, 
Edinburgh.  
 
What will I be asked to do?  
The study requires participants to meet with the Chief Investigator (Jo Phillips), on one 
occasion  for approximately an hour and a half . We will meet either at the Royal Edinburgh 
Hospital, Edinburgh, or at St John’s Hospital, Livingston, whichever is more suitable for you. 
We will meet at a date and time convenient for you. Please note that unfortunately we are 
unable to reimburse your travel expenses. Before the meeting I will send you some 
questionnaires to complete at home before the appointment.  
At this meeting, you will have the opportunity to discuss the study and ask any questions you 
may have. If you still wish to participate, I will ask you to sign a consent form stating that you 
agree to take part in the study. We will also inform your GP (General Practitioner) that you 
are taking part in the study.  
We will then complete a series of tasks including: 
• A word reading task; 
• A memory task; 
If at any point during the assessment you no longer wish to participate, you can withdraw 
from the study.  
 
Do I have to take part in the study?  
No. Your participation is entirely voluntary. If you decide to take part, you will be given this 
information sheet to keep and will be asked to sign a consent form. 
Taking part in the study will not affect the care you receive from any NHS service now or in 
the future. 
At any point during this study, if you no longer wish to participate, you can withdraw from the 
study without giving a reason why. 
 
What are the possible benefits of taking part?  
There will be no immediate benefits for participants taking part in the study. The study may, 
however, inform how the NHS assesses memory problems in the future. 
 
What are the possible disadvantages or risks of tak ing part?  
You may find completing the tasks tiring, or upsetting if you find them difficult. If this is the 
case we may need to take a break or reschedule a later meeting to complete the 
assessment. If you become upset we may need to let your GP know. We can also provide 
you with information about other agencies or resources to access if you are worried about 
your memory or mood.  
 
Will my taking part in the study be kept confidenti al?  
The study is confidential. The only people allowed to see the data are myself, my 
supervisors, and anyone appointed by the Sponsor to check the study is being carried out 




We will inform your General Practitioner (GP) that you are taking part in this study. We will 
not inform your GP of any details about your performance on the assessment, unless: 
• You report any difficulties with your mood; 
• Your performance suggests that you may have be having significant problems with 
your memory.  
If you tell me anything that makes me think that you, or others around you, are at risk of 
harm, I would need to inform your GP and discuss with you how to address this. 
The information I gather from you will be kept for 3 years after the research has been 
completed, in accordance with NHS Research Ethic’s Guidelines.  
 
Will I find out the results of the study?  
If you wish to know the results of the study we can provide you with a written summary. The 
study will be completed in August 2013.  
 
What will happen to the results of the study?  
The information I collect will be written up as a Doctoral Thesis as part of my Clinical 
Psychology training course. I may also publish some of the data as a piece of research in a 
scientific journal. Any information collected will be kept anonymous and only myself and my 
supervisors will be able to identify the participants involved.  
 
Who is organising the research and why?  
I am conducting this study as part of my Doctorate in Clinical Psychology. It will be written up 
as my Doctoral Thesis.  
 
Who has reviewed the study?  
The study proposal has been reviewed by the University of Edinburgh Doctorate in Clinical 
Psychology course and my supervisors (Dr. Ken Laidlaw and Dr Sandy McAfee). Ethical 
approval has also been granted by South East Scotland Research Ethics Committee 2 
(REC2).  
 
What to do now?  
If you would like to know more about the study or are interesting in participating, please 
complete the tear off slip and send it to: 
 
Jo Phillips 
Trainee Clinical Psychologist 
Older Adults Clinical Psychology 
Psychology Department 





If you do not wish to participate in the study you do not have to do anything. Thank you for 
























Fig 1. Flow chart explaining participation process. 
 
I would like to speak to an independent advisor reg arding the study  
 
If you would like to speak to someone else about the study please contact: 
Dr Emily Newman 
Health Psychology Lecturer 
School of Health in Social Science 
Old Medical School 
University of Edinburgh 
I would like further information or 
would like to discuss how I can 
participate in the study 
Contact Jo Phillips or complete tear 
off slip and send to above address.  
 
You can contact Jo Phillips to 
discuss the study j.phillips8@nhs.net 
Arrange a time/date to meet to 
complete the assessments. Your GP 
will be informed of your participation 
I would like to participate in the study 
I do not wish to take part in the 
study. Please inform Jo 
Phillips that you no longer 
wish to take part. You do not 
have to provide any reason.  
Attend appointment 
You will be sent a series of 
questionnaires to complete and bring 
with you to the appointment 
I do not wish to take part in 
the study 
If do not wish to take part in 
the study, you do not have to 
do anything. Thank you for 
reading the Participant 




Edinburgh EH8 9AG 
0131 651 3945 
 
Thank you for taking the time to read this informat ion sheet 
Jo Phillips, Trainee Clinical Psychologist 
If you would like to participate in the study, or w ould like further information, please 
complete the tear off slip below and send it to: 
Jo Phillips 
Trainee Clinical Psychologist 
Older Adults Clinical Psychology 
Psychology Department 





Or contact: j.phillips8@nhs.net or 01506 523614 
 
Tear off slip here 
 








I would like further information regarding the above study   
   
I would like to participate in the above study   
   
My preferred location for an appointment is: 
 
  
St John’s Hospital, Livingston   
   
Royal Edinburgh Hospital, Edinburgh   
   
Please contact me via  telephone  / email  / post (delete as appropriate)   











                                                                                                                    
 
Group 1: Invitation letter for SDCRN members 
 
Measuring lifelong ability and cognitive change  
 
Dear SDCRN member, 
 
My name is Jo Phillips and I am training to be a Clinical Psychologist at the University of 
Edinburgh and work for NHS Lothian. As part of my training I am carrying out a study 
investigating the relationship between different psychological tests.  
 
I am writing to invite you to participate in the study. You are being provided with a Participant 
information Sheet as you are a member of the SDCRN (Scottish Dementia Clinical Research 
Network) Research Interest Register.  
 
The following information will tell you why the study is being carried out and what would be 
involved if you decide to take part.  
 
Please read the following information carefully, and feel free to show it to family and friends. 
It is important that you are aware that you are not obliged to participate in the study and can 
decide not to take part at any time.  
 
Thank you for taking the time to read this, and please feel free to ask any questions you 






Trainee Clinical Psychologist 
The University of Edinburgh/NHS Lothian 
 






                                                                                                                                                                                                                           
 
Group 1: Invitation letter for NHS patients 
 
Measuring lifelong ability and cognitive change  
 
 
Dear Sir/ Madam, 
 
My name is Jo Phillips and I am training to be a Clinical Psychologist at the University of 
Edinburgh and work for NHS Lothian. As part of my training I am carrying out a study 
investigating the relationship between different psychological tests.  
 
I am writing to you to invite you to participate in the study. You are being provided with a 
Participant information Sheet as you have indicated that you would like to hear more about 
the study. 
 
The following information will tell you why the study is being carried out and what would be 
involved if you decide to take part.  
 
Please read the following information carefully, and feel free to show it to family and friends. 
It is important that you are aware that you are not obliged to participate in the study and can 
decide not to take part at any time.  
 
Thank you for taking the time to read this, and please feel free to ask any questions you 







Trainee Clinical Psychologist 





                                                                                                                    
 
Group 2: Invitation letter for SDCRN members 
 
Measuring lifelong ability and cognitive change  
 
Dear SDCRN member, 
 
My name is Jo Phillips and I am training to be a Clinical Psychologist at the University of 
Edinburgh and work for NHS Lothian. As part of my training I am carrying out a study 
investigating the relationship between different psychological tests.  
 
I am writing to invite you to participate in the study. You are being provided with a Participant 
information Sheet as you are a member of the SDCRN (Scottish Dementia Clinical Research 
Network) Research Interest Register.  
 
The following information will tell you why the study is being carried out and what would be 
involved if you decide to take part.  
 
Please read the following information carefully, and feel free to show it to family and friends.  
It is important that you are aware that you are not obliged to participate in the study and can 
decide not to take part at any time.  
 
Thank you for taking the time to read this, and please feel free to ask any questions you 







Trainee Clinical Psychologist 
The University of Edinburgh/NHS Lothian 







                                                                                                                    
 
Group 2: Invitation letter for West Lothian 50+ members 
 
Measuring lifelong ability and cognitive change 
 
Dear West Lothian 50+ member, 
 
My name is Jo Phillips and I am training to be a Clinical Psychologist at the University of 
Edinburgh and work for NHS Lothian. As part of my training I am carrying out a study 
investigating the relationship between different psychological tests.  
 
I am writing to invite you to participate in the study. You are being provided with a Participant 
information Sheet as you are a member of the West Lothian 50+ Network. The network has 
kindly agreed to give out this information to its members so that interested members can 
participate in scientific research.    
 
The following information will tell you why the study is being carried out and what would be 
involved if you decide to take part.  
 
Please read the following information carefully, and feel free to show it to family and friends. 
It is important that you are aware that you are not obliged to participate in the study and can 
decide not to take part at any time.  
 
Thank you for taking the time to read this, and please feel free to ask any questions you 







Trainee Clinical Psychologist 


















RE: Name, Address of patient, D.O.B 
 
I am writing to inform you that …………..……………… has agreed to participate in my 
research study. The study is investigating the way in which premorbid functioning (the level 
of ability before the onset of illness) is estimated in patients with Dementia.  
 
The study is being conducted in part fulfilment of the Doctorate in Clinical Psychology at the 
University of Edinburgh. It has been granted ethical approval by East of Scotland Research 
Ethics Committee (approval granted on dd/mm/yy).  
 
……………… (name of pt) has been approached as they are volunteers for the Scottish 
Dementia Clinical Research Network (SDCRN) or have indicated to a clinician (Psychiatrist, 
Nurse or Psychologist) that they would be interested in participating in the study. They will 
be part of a clinical group of individuals with a diagnosis of dementia given in the past 2-5 
years.  
 
The research will require participants to complete a series of mood and neuropsychological 
measures, and will last up to one hour. Participants will be offered breaks throughout in 
order to minimise fatigue.  
 
I will not routinely inform GP’s of their patients’ performance in the study, unless any 
concerns are raised regarding; 
• Low mood or anxiety 
• Risk of harm to self or others. 
 
In these instances you will be informed of any concerns that have been raised. If you would 





Trainee Clinical Psychologist 
NHS Lothian/ The University of Edinburgh 
Psychology Department  
Livingston EH54 6PP 










RE: Name, Address of patient, D.O.B 
 
I am writing to inform you that …………..……………… has agreed to participate in my 
research study. The study is investigating the way in which premorbid functioning (the level 
of ability before the onset of illness) is estimated in patients with Dementia.  
 
The study is being conducted in part fulfilment of the Doctorate in Clinical Psychology at the 
University of Edinburgh. It has been granted ethical approval by East of Scotland Research 
Ethics Committee (approval granted on dd/mm/yy).  
 
……………… (name of pt) has been approached as they are volunteers for the Scottish 
Dementia Clinical Research Network (SDCRN)/ Members of the West Lothian 50+ network/ 
and have indicated that they would be interested in participating in the study. They will be 
part of a healthy control group.    
 
The research will require participants to complete a series of mood and neuropsychological 
measures, and will last up to one hour. Participants will be offered breaks throughout in 
order to minimise fatigue.  
 
I will not routinely inform GP’s of their patients’ performance in the study, unless any 
concerns are raised regarding; 
• Low mood or anxiety 
• Cognitive ability (e.g with memory) 
• Risk of harm to self or others. 
 
In these instances you will be informed of any concerns that have been raised. If you would 






Trainee Clinical Psychologist 
Psychology Department  
Livingston EH54 6PP 





                                                                                                                    
Understanding changes in thinking ability in later life  
 
 
Participant consent form 
          Please initial box  
 
I have read through, or someone has read to me, the Participant Information   
Sheet [date and version]  
  




I am aware that my participation is voluntary and I can stop at any time, without   
having to give a reason why  
  
I know that my involvement with the study will not affect the care I receive from   
any service, now, or in the future (whether or not you decide to participate)  
  
I understand that my General Practitioner (GP) will be informed that I am taking   
part in the study  
  
I understand that my GP will be informed if, through my participation in the study, 
there are any concerns raised, regarding: 
 
 
• Low mood or anxiety  
  
• My own, or someone else’s safety  
  
I understand that all information given by me in this study will remain confidential  
  
I would like to receive a written summary of the key findings  
  
I understand that relevant sections of my medical notes, and data collected during 
the study, may be looked at by the study researchers and individuals from the 
Sponsor, regulatory authorities or from the NHS organisation, where it is relevant  
to my taking part in this research. I give permission for these individuals to have  
 
access to my records  










                                           
                                          
 


































                                                                                                                    
Measuring lifelong ability and cognitive change  
 
Participant consent form 
          Please initial box  
 
I have read through, or someone has read to me, the Participant Information   
Sheet [date and version]  
 




I am aware that my participation is voluntary and I can stop at any time, without   
having to give a reason why  
  
I know that my involvement with the study will not affect the care I receive from   
any service, now, or in the future (whether or not you decide to participate)  
  
I understand that my General Practitioner (GP) will be informed that I am taking   
part in the study  
  
I understand that my GP will be informed if, through my participation in the study, 
there are any concerns raised, regarding: 
 
 
• Low mood or anxiety  
  
• My own, or someone else’s safety  
  
• My cognitive ability (e.g memory)  
  
I understand that all information given by me in this study will remain confidential  
  
I would like to receive a written summary of the key findings  
  
I understand that relevant sections of my medical notes, and data collected during 
the study, may be looked at by the study researchers and individuals from the 
Sponsor, regulatory authorities or from the NHS organisation, where it is relevant  
to my taking part in this research. I give permission for these individuals to have  
 
access to my records  
 








                                                                                                              
 
               
                            
                                          
 

































                                                                                                                                                       
          
 
Participant code  
Gender  
Date of Birth  Age  
Handedness  Years of education  
Wearing glasses if needed?                                                                                                 






Age at retirement  Marital status  
Medical History 
Dementia Diagnosis type  Date of diagnosis  
Date on onset of symptoms  Diagnosed by (professional)  
Medication for dementia?  
Other physical health conditions  
Other medications  
Currently being seen by any 
medical professional? 
 




History of brain injury (e.g TBI, 
tumor, stroke, TIA) 
 
Smoker/ Alcohol  
Mental Health History 
Any history of mental health 
difficulty (diagnosis, treatment 
received) 
 
Currently experiencing mental 
health difficulty? 
 
Additional Information  
 
  
Does participant meet inclusion 
criteria?  





























Journal of Clinical and Experimental Neuropsychology considers all manuscripts on the strict 
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Study Protocol: Can a questionnaire measuring Cogni tive Reserve provide an 
alternative way of estimating premorbid functioning  in individuals with dementia? A 
Pilot study.  
 
A crucial part of diagnosing dementia requires clinicians to estimate an individuals’ level of 
ability before the onset of cognitive decline, or their ‘premorbid ability’. Traditional measures 
of estimating premorbid functioning (e.g NART; National Adult Reading Test; Nelson, 1982) 
rely on assessing word reading ability, an ability that is said to be relatively resistant to 
cognitive decline. However, there are numerous clinical conditions where word reading 
ability is impaired (e.g semantic dementia) and so these measures may not reliably predict 
premorbid functioning in all cases. In addition, premorbid verbal ability may not be wholly 
reflective of global premorbid cognitive ability e.g it may not reflect an individuals’ executive 
functioning or visuo-spatial functioning. This pilot study aims to assess whether a newly 
developed questionnaire that is said to measure Cognitive Reserve, the CRIq (Cognitive 
Reserve Index Questionnaire, Nucci et al, 2011) can function as a measure of premorbid 
non-verbal ability. As the CRIq has never been used in this way before, the study will 
attempt to achieve proof of concept, in order that a larger study can be completed at a later 
date.  
 
In order to achieve this, several factors will be considered. Any measure of premorbid 
functioning should fulfil the following criteria: 
1. High correlation with intelligence (when tested in a healthy population); 
2. Be resistant to cognitive decline (e.g dementia); 
3. Have high inter-rater reliability.  
 
The CRIq will be evaluated against the first two criteria to examine how well it captures non-
verbal premorbid functioning. It’s resistance to decline will also be compared to traditional 
‘gold standard’ measures of premorbid functioning such as the NART. If the CRIq is found to 
accurately capture premorbid functioning this may provide clinicians with a tool that: 
• Does not rely on word reading ability. This may be particularly useful when language 
is impaired (e.g in specific forms of dementia such as Semantic Dementia or in 
patients with Aphasia).  
• Takes into account aspects of global cognitive functioning (non-verbal premorbid 
ability) and the ability of the brain to withstand pathology; 
• Can be completed by a caregiver or someone who knows that individual well, 
eliminating the need to administer a test directly with the patient; 
• Can be used as a complimentary measure to NART, by capturing non-verbal 
premorbid ability rather than verbal premorbid ability. This may provide a more 
global, comprehensive assessment of premorbid functioning if used together.   
 
 







This pilot study will evaluate how the CRIq functions as a measure of premorbid ability, and 
how it compares to traditional measures such as NART. As the CRIq has only been 
investigated with an Italian speaking population, an additional aim of this study is to utilise 
the CRIq with an English speaking sample. 
 
Research Questions  
1) How well does CRIq correlate with a measure of current non-verbal 
intelligence in a healthy population? Does it capture current ability?  
2) Is performance on the CRIq affected by cognitive decline (dementia)? Is there 
any difference in performance on the CRIq between groups? 




The null hypothesis for this study is that the CRIq will not:  capture premorbid non-verbal 
ability, be resistant to decline, and will not compare well to other hold tests.  
The alternative hypothesis is that the CRIq will : capture premorbid non-verbal ability, be 
resistant to decline, and will compare well to other hold tests.  
 
Method of investigation 
Participants 
Two groups will be recruited into the study, 1) a clinical sample of individuals that have 
experienced cognitive decline (dementia), and 2) a control sample of healthy older adults. 
There will be 26 participants recruited per group. Inclusion and exclusion criteria are outlined 
below: 
 
Please note that in all correspondence Group 1 refe rs to the Dementia Group and 
Group 2 refers to the Control Group. 
 
Inclusion criteria for dementia group 
(Group 1) 
 Inclusion criteria for control groups                   
(Group 2) 
 
• Diagnosis of dementia (either AD or 
mixed ) within last 2-5 years 
• Able to provide informed consent 
• Are over the age of 60; 
• Do not have any problems with 
anxiety, low mood or have any 
diagnosed mental health problem, as 
defined by clinical cut off on 
screening measures; 
• Are a native English speaker, and do 
not speak any other language 
fluently; 
• Can read and write in English; 
• Do not have any significant health 
• Are over the age of 60; 
• Do not have any problems with 
anxiety, low mood or have any 
diagnosed mental health problem, as 
defined by clinical cut off on 
screening measures; 
• Are a native English speaker, and do 
not speak any other language 
fluently; 
• Can read and write in English; 
• Do not have any significant health 
problem (e.g heart disease); 
• Do not have any problem with your 




problem (e.g heart disease); 
• Have not had any kind of brain injury 




• Have not had any kind of brain injury 
e.g stroke, brain injury, tumour; 
Exclusion criteria for dementia group  
(Group 1)  
 
• Aged under 60 
• Unable to provide informed consent 
• Pre-existing cognitive impairment e.g 
Learning Disability, acquired brain 
injury, stroke.  
• Sensory impairment e.g blind or deaf  
• Current or history of substance 
misuse, life limiting illness 
• Cardiovascular illness  
 
Exclusion criteria for control group  
(Group 2)  
 
• Aged under 60 
• Unable to provide informed consent 
• Acquired brain injury e.g Stroke, 
traumatic brain injury 
• Sensory impairment e.g blind or deaf  
• Cognitive impairment evidenced by 
performance below clinical cut off for 
dementia on screening measures 
(<21 on MOCA).  
• Current or history of substance 
misuse, life limiting illness 
• Cardiovascular illness  
 
Design 
This study is a quantitative, within subjects design, with participants assigned to either the 
dementia group or the control group. All participants will complete the CRIq, GAI, GDS-15, 
NART, MOCA and demographic questionnaire. The control group will complete the 





The following measures will be used in this study: 
 
National Adult Reading Test (Nelson, 1982) 
The NART is a commonly used tool that provides an estimate of premorbid cognitive 
functioning based on word reading ability. Participants are required to read aloud 50 irregular 
words. It is quick to administer and frequently used with an older adult population (e.g 
Schretlen et al, 2005). NART is routinely used in clinical practice, and has been shown to 
have high correlation with premorbid intelligence and hold over time (Crawford et al, 2001). 
Similarly, NART performance has been shown to be stable over time, even in individuals 
who go on to develop dementia (McGurn et al, 2004).  
 
Cognitive Reserve Index Questionnaire (CRIq, Nucci et al, 2011).  
The CRIq is a self report questionnaire that aims to quantify the amount of cognitive reserve 
accumulated throughout an individual’s lifetime. It focuses on three areas of cognitive 
reserve: education, working activity and leisure activities. It has recently been standardised 
in a sample of 558 individuals aged of 18-102, but has yet to be used with a clinical sample 





Geriatric Depression Scale- Short  (GDS-15, Poon, 1987) 
This questionnaire is a self-report questionnaire used to detect the presence of low mood 
and depression and was specifically developed for, and validated in, the older adults 
population (Sheikh, 1986). The GDS-15 has also been found to have good specificity and 
sensitivity in a meta-analysis of 42 papers (Wancata et al, 2006). This indicates that it can be 
reliably used as a screening measure for depression in later life.  
 
Geriatric Anxiety Inventory (GAI: Pachana et al, 2007) 
This is a 20 item self-report questionnaire used to measure anxiety in older people. It is 
reported to have good psychometric properties, with excellent inter-rater reliability (Pachana 
et al, 2007).  
 
Montreal Cognitive Assessment (MOCA; Nasreddine et al, 2005) 
The MOCA has been recently developed as a brief cognitive screening tool. It takes 10 
minutes to complete, with participants achieving a score out of 30. The test includes aspects 
of language, attention, orientation, memory, naming and visuospatial/executive functioning. 
Many studies typically use the MMSE (Folstein, 1975) or ACE-R (Mioshi et al, 2005), (which 
contains the MMSE embedded into it), as a cognitive screen. However with recent issues 
regarding copyright of the MMSE, both of these screening tools are no longer being used by 
NHS Lothian Psychology. The MOCA is copyright free, and has recently been validated as 
being more sensitive than MMSE in detecting mild cognitive impairment, Alzheimer’s 
disease and Vascular dementia in an elderly population, using a cut-off point of <21 for MCI 
and <17 for Alzheimer’s disease (Freitas et al, 2011a), and Vascular Dementia (Freitas et al, 
2011b).  
 
Perceptual Reasoning Subtests from the WAIS-IV (Wechsler Adult Intelligence Scale- Fourth 
Edition, Wechsler, 2008) 
Three subtests from the WAIS-IV will be used to assess non-verbal ability in the control 
group; the Block Design, Matrix Reasoning and Visual Puzzles, which comprise the 
Perceptual Reasoning Index. The WAIS-IV is a well validated measure of current ability, 
frequently used for this purpose in an older adult population (e.g Baxendale, 2011).  
 
Demographic Questionnaire (devised by Chief Investigator)  
This questionnaire will be used with both groups to ensure that the participant meets the 
inclusion criteria. This will also gather details of non-dementia participants’ GP details in the 
event that they can be contacted if the researcher becomes aware of any previously 





Healthy controls will be invited to participate from the West Lothian 50+ network and from 
the Scottish Dementia Clinical Research Network (SDCRN) carer participant pool. Members 




(PIS) by the network and invited to participate. The SDCRN will identify carer participant pool 
members that meet the inclusion criteria, and will pass on those contact details to the Chief 
Investigator. They will then be posted a copy of the PIS and invited to participate. All 
participants will be invited to complete a tear off slip and post it to the Chief Investigator in 
they are interested in participating in the study. They will also be able to contact the Chief 




The dementia group will be recruited from NHS Lothian Memory Clinics, from the SDCRN, 
and from the Scottish Dementia Working Group. Individuals with dementia that are 
registered with the SDCRN and who meet the inclusion/exclusion criteria will be identified by 
the SDCRN. Their contact details will be passed on to the Chief Investigator who will then 
post a copy of the PIS and invite them to participate. All participants will be invited to 
complete a tear off slip and post it to the Chief Investigator if they are interested in 
participating in the study. They will also be able to contact the Chief Investigator by 
telephone to ask questions and/or state their interest in participating in the study. Individuals 
recruited from NHS Lothian Memory Clinics will be initially identified by clinical staff (Nursing, 
Psychiatry, Clinical Psychology) as meeting the inclusion criteria. Clinical staff will provide 
patients with the PIS to patients. Patients will complete a tear off slip and post it to the Chief 
Investigator in they are interested in participating in the study. They will also be able to 
contact the Chief Investigator by telephone to ask questions and/or state their interest in 
participating in the study. Finally, they can ask their clinician to pass on their contact details 
to the Chief Investigator, who will then contact the patient. Individuals from the SDWG will be 
initially identified by SDWG co-ordinators as meeting the inclusion criteria. The SDWG co-
ordinators will provide members with the PIS. Members can express their interest in 
participating in the study, or to find out more information by either; completing a tear off slip 
and posting it to the Chief Investigator; by contacting the Chief Investigator via telephone or 
email; or by informing the SDWG co-ordinators that they consent to the Chief Investigator 
contacting them by phone, email or post (whichever they prefer). In this last instance, the 
SDWG co-ordinators will then pass on the member’s contact details to the Chief Investigator, 
who will then contact the interested SDWG member.    
 
Procedure 
After participants have expressed an interest in participating in the study, they will be 
contacted by phone, email or by post (whichever is preferred by the participant) to arrange 
an appointment. Control Group participants will be sent the self-report questionnaires to 
complete before the appointment. Participants can choose where appointments take place; 
either within NHS Lothian Premises at the Royal Edinburgh Hospital or St John’s Hospital, 
Livingston, or in their own homes (only if this is assessed as safe). Members of the SDWG 
will also have the option of conducting the appointment at Alzheimer Scotland premises.  
 
Home visits will only be offered as an option to those participants who are known to the 
intermediary (e.g NHS clinician, SDCRN recruiter, SDWG co-ordinator), and where the 




conducted in accordance with the NHS Lothian Lone Working Policy in order to minimise 
any risk of harm.   
 
Appointments will last approximately 1 hour and comprise of the following procedure (see 
Fig.1): 
 
• Clarification of meeting inclusion criteria (5 minutes); 
• Read and sign consent form (5 minutes); 
• Complete demographic questionnaire (Dementia Group) (5 minutes); 
Check completion of self-report questionnaires (Control Group) or complete during 
appointment (Dementia Group) (15 minutes):  
 
• Geriatric Depression Scale- 15  (GDS-15; Poon, 1987), Geriatric Anxiety Inventory 
(GAI; Pachana et al, 2007) and the Cognitive Reserve Questionnaire (CRIq; Nucci, 
Mapelli & Mondini, 2011); 
Complete cognitive screening assessment (10 minutes): 
• MOCA (Nasreddine et al, 2005) (10 mins) 
Assessment of reading ability and intelligence: 
 
• Control group only:  Administer WAIS-IV Perceptual Reasoning Subtest (Wechsler, 
2008) max 30 mins)  
• Administer National Adult Reading Test – Revised (NART-R; Nelson, 1982) (10 
mins) 






























Dementia Group  
Can opt into having a 
reminder text/call before 
appointment. 
All groups:  Provided with PIS 
All groups:  Arrange appointment by phone, email or post 
All groups:  Participant expresses interest by completing tear off slip or telephoning 
Chief Investigator or by informing SDWG co-ordinator or clinician that they consent 
to the Chief Investigator contacting them. Check inclusion/exclusion criteria. 
Control Group  
 Sent out questionnaires to complete 






All groups:  Attend appointment at either: 
St John’s Hospital or Royal Edinburgh Hospital 
• Alzheimer Scotland premises (SDWG members only) 
• Chief Investigator to conduct home visit (only if assessed as safe to do so) 
All groups:  
• Check inclusion/exclusion criteria 
• Check ability to consent 






































Fig 1: Summary of Procedure 
 
 
All participants will be invited to take a break, reschedule the assessment or terminate 
participation if they become fatigued or distressed during the assessment. If participants 
become upset during the assessment, appropriate action will be taken. If participants are 
concerned about their memory after completing the assessment they will be advised to 
contact their GP. If participants would like to know about resources and support services for 
low mood, anxiety or dementia, they will be provided with an information sheet (see 
‘Resource Information Sheet 1’ and ‘Resource Information Sheet 2’’).  
 
Statistical analysis 
Correlational analysis will be used initially to assess the relationship between performance 
on all measures. Analysis of Variance (ANOVA) allows comparison between the ratio of 
systematic error variance to unsystematic error variance (Field, 2005) and will be used to 
compare any statistically significant differences in performance on all measures between the 
two groups. For example, a 2-way ANOVA can be used to identify any statistically significant 
Control Group:  
Complete following assessments: 
• NART 
• WAIS-IV subtests x3 
• CRIq 
Dementia Group:  




All groups:  
• Debrief/ answer questions 
Control Group:  
Complete screening measures 
and score questionnaires: 
• MOCA 
Control Group:  
Complete screening measures: 




ALL Groups : Score screening measures: 
If any participant scores above clinical cut off on GDS or GAI, or if control 
participants score above 21 on MOCA, they will be removed from the study. 
Participants will be informed of this, and provided with the relevant resource 








The findings of the study will be written up as a Doctoral Thesis in part fulfilment of the 
Doctorate in Clinical Psychology. A more concise write up of the project will be prepared for 
publication in a peer reviewed journal. A brief write up of the study will be freely available to 
participants, and for publication in the West Lothian 50+ network newsletter (and any other 
charities/organisations that may become involved). Poster Presentations summarising the 
research will also be given at relevant CPD events including the annual NHS Lothian 









Measuring lifelong ability and cognitive change  
 
Participant Information Sheet  
 
What is the study about?  
 
This study is examining the relationship between different questionnaires and psychological 
evaluations, routinely used in the assessment of memory problems.  
 
Why have I been asked to take part?  
 
SDCRN Members: 
This study has been approved by the Scottish Dementia Clinical Research Network 
(SDCRN). You have been invited to take part as you are registered with the SDCRN 
participant database, and have indicated that you may be interested in participating in 
research approved by the network. The SDCRN has identified that you may meet the criteria 
to be part of the study (included below) and so has passed on your name and address to the 
Chief Investigator. We are therefore contacting you to invite you to take part in the study. If 
you decide not to take part, this will not affect any future research you may be invited to 
participate in.   
 
Through NHS Lothian Memory Clinics:  
You have been invited to take part as your clinician (e.g Doctor, Nurse, Psychologist) thinks 
that you may be interested in taking part in the study. 
 
Through the Scottish Dementia Working Group (SDWG) and Alzheimer Scotland: 
This study has been granted ‘research access’ by Alzheimer Scotland. You have been 
invited to take part as the SDWG co-ordinators think that you may be interested in taking 
part in the study.  
 
What will I be asked to do?  
 
The study requires participants to meet with the Chief Investigator (Jo Phillips), on one 
occasion  for approximately one hour . We will meet either at the Royal Edinburgh Hospital, 
Edinburgh, at St John’s Hospital, Livingston, or at an Alzheimer Scotland premises in 
Lothian, whichever is more suitable for you. In some exceptional circumstances, we may be 
Appendix C4: Revised Participant Information Sheet – Dementia Group for study amendment May 




able to visit you at home. We will meet at a date and time convenient for you. Please note 
that unfortunately we are unable to reimburse your travel expenses.  
 
At this meeting, you will have the opportunity to discuss the study and ask any questions you 
may have. If you still wish to participate, I will ask you to sign a consent form stating that you 
agree to take part in the study. We will also inform your GP (General Practitioner) that you 
are taking part in the study.  
 
We will then complete a series of tasks including: 
• A word reading task; 
• Questionnaires regarding your mood and your occupational and educational history.  
 
If at any point during the assessment you no longer wish to participate, you can withdraw 
from the study.  
 
Do I have to take part in the study?  
 
No. Your participation is entirely voluntary. If you decide to take part, you will be given this 
information sheet to keep and will be asked to sign a consent form. 
 
Taking part in the study will not affect the care you receive from any NHS service now or in 
the future. 
 
At any point during this study, if you no longer wish to participate, you can withdraw from the 
study without giving a reason why. 
 
What are the possible benefits of taking part?  
 
There will be no immediate benefits for participants taking part in the study. The study may, 
however, inform how the NHS assesses memory problems in the future.  
 
What are the possible disadvantages or risks of tak ing part?  
 
You may find completing the tasks tiring, or upsetting if you find them difficult. If this is the 
case we may need to take a break or reschedule a later meeting to complete the 
assessment. If you become upset we may need to let your GP or keyworker know. We can 
also provide you with information about other agencies or resources to access if you are 
worried about your mood.  
 
Will my taking part in the study be kept confidenti al?  
The study is confidential. The only people allowed to see the data are myself, my 
supervisors, and anyone appointed by the Sponsor to check the study is being carried out 





We will inform your General Practitioner (GP) that you are taking part in this study. We will 
not inform your GP of any details about your performance on the assessment, unless you 
report any difficulties with your mood. 
 
If you tell me anything that makes me think that you, or others around you, are at risk of 
harm, I would need to inform your GP and discuss with you how to address this. 
 
The information I gather from you will be kept for 3 years after the research has been 
completed, in accordance with NHS Research Ethic’s Guidelines.  
 
Will I find out the results of the study?  
 
If you wish to know the results of the study we can provide you with a written summary. The 
study will be completed in August 2013.  
 
What will happen to the results of the study?  
 
The information I collect will be written up as a Doctoral Thesis as part of my Clinical 
Psychology training course. I may also publish some of the data as a piece of research in a 
scientific journal. Any information collected will be kept anonymous and only myself and my 
supervisors will be able to identify the participants involved.  
 
Who is organising the research and why?  
 
I am conducting this study as part of my Doctorate in Clinical Psychology. It will be written up 
as my Doctoral Thesis.  
 
Who has reviewed the study?  
 
The study proposal has been reviewed by the University of Edinburgh Doctorate in Clinical 
Psychology course and my supervisors (Dr. Ken Laidlaw and Dr Sandy McAfee). Ethical 
approval has also been granted by South East Scotland Research Ethics Committee.  
 
What to do now?  
 
If you would like to know more about the study or are interesting in participating, please 
complete the tear off slip and send it to: 
 
Jo Phillips 
Trainee Clinical Psychologist 
Psychology Department 
St John’s Hospital 
Livingston 





If you do not wish to participate in the study you do not have to do anything. Thank you for 
reading this Participant Information Sheet.  
 
I would like to speak to someone else regarding the  study  
 
If you would like to speak to someone else about the study please contact: 
 
Dr Emily Newman 
Health Psychology Lecturer 
School of Health in Social Science 
Old Medical School 
University of Edinburgh  
Edinburgh  EH8 9AG 
































I would like further information or 
would like to discuss how I can 
participate in the study 
Contact Jo Phillips or complete tear 
off slip and send to above address.  
 
You can contact Jo Phillips by phone 
to discuss the study (Tel No) 
Arrange a time/date to meet to 
complete the assessments. Your GP 
will be informed of your participation 
I would like to participate in the study 
I do not wish to take part in the 
study. Please inform Jo 
Phillips that you no longer 
wish to take part. You do not 
have to provide any reason.  Attend appointment 
I do not wish to take part in 
the study 
If do not wish to take part in 
the study, you do not have to 
do anything. Thank you for 
reading the Participant 




Fig 1. Flow chart explaining participation process. 
 
Thank you for taking the time to read this informat ion sheet 
 
Jo Phillips, Trainee Clinical Psychologist 
If you would like to participate in the study, or w ould like further information, please 
complete the tear off slip below and send it to: 
 
Jo Phillips 
Trainee Clinical Psychologist 
Psychology Department 




Tear off slip here 









I would like further information regarding the above study   
   
I would like to participate in the above study   
   
My preferred location for an appointment is: (tick as many as apply to you): 
 
St John’s Hospital, Livingston   
   
Royal Edinburgh Hospital, Edinburgh   
   
Alzheimer Scotland premises in Edinburgh & Lothian (SDWG only)   
 
In my own home (only in exceptional circumstances)   
   
 
Please contact me via  telephone  / email  / post ( delete as appropriate)  
 













                                                                                              
Measuring lifelong ability and cognitive change  
 
Participant Information Sheet  
 
What is the study about?  
 
This study is examining the relationship between different questionnaires and psychological 
evaluations, routinely used in the assessment of memory problems.  
 
Why have I been invited to take part?  
 
SDCRN Members: 
This study has been approved by the Scottish Dementia Clinical Research Network 
(SDCRN). You have been invited to take part as you are registered with the SDCRN Carer’s 
database, and have indicated that you may be interested in participating in research 
approved by the network. The SDCRN has identified that you may meet the criteria to be 
part of this study (included below) and so has passed on your name and address to the 
Chief Investigator. We are therefore contacting you to invite you to take part in the study. If 
you decide not to take part, this will not affect any future research you may be invited to 
participate in.   
 
West Lothian 50+ Network Members: 
You have been given this Participant Information Sheet as you are a member of the West 
Lothian 50 + Network. The Network has agreed to distribute this information sheet so that 
members can contact the Chief Investigator if they are interested in participating in, or 
finding out more, about the study.  
 
How do I know if I can take part?  
 
You are invited to take part in the study if you: 
• Are over the age of 60; 
• Do not have any problems with anxiety, low mood or have any diagnosed mental 
health problem; 
• Are a native English speaker, and do not speak any other language fluently; 
• Can read and write in English; 
• Do not have any significant health problem (e.g heart disease); 
• Do not have any problem with your cognitive ability (thinking skills such as memory); 
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What will I be asked to do?  
The study requires participants to meet with the Chief Investigator (Jo Phillips), on one 
occasion  for approximately an hour and a half . We will meet either at the Royal Edinburgh 
Hospital, Edinburgh, or at St John’s Hospital, Livingston, whichever is more suitable for you. 
In some exceptional circumstances, we may be able to visit you at home. We will meet at a 
date and time convenient for you. Please note that unfortunately we are unable to reimburse 
your travel expenses. Before the meeting I will send you some questionnaires to complete at 
home before the appointment.  
 
At this meeting, you will have the opportunity to discuss the study and ask any questions you 
may have. If you still wish to participate, I will ask you to sign a consent form stating that you 
agree to take part in the study. We will also inform your GP (General Practitioner) that you 
are taking part in the study.  
 
We will then complete a series of tasks including: 
• A word reading task; 
• A memory task; 
 
If at any point during the assessment you no longer wish to participate, you can withdraw 
from the study.  
 
Do I have to take part in the study?  
No. Your participation is entirely voluntary. If you decide to take part, you will be given this 
information sheet to keep and will be asked to sign a consent form. 
 
Taking part in the study will not affect the care you receive from any NHS service now or in 
the future. At any point during this study, if you no longer wish to participate, you can 
withdraw from the study without giving a reason why. 
 
What are the possible benefits of taking part?  
There will be no immediate benefits for participants taking part in the study. The study may, 
however, inform how the NHS assesses memory problems in the future. 
 
What are the possible disadvantages or risks of tak ing part?  
You may find completing the tasks tiring, or upsetting if you find them difficult. If this is the 
case we may need to take a break or reschedule a later meeting to complete the 
assessment. If you become upset we may need to let your GP know. We can also provide 
you with information about other agencies or resources to access if you are worried about 
your memory or mood.  
 
Will my taking part in the study be kept confidenti al?  
The study is confidential. The only people allowed to see the data are myself, my 
supervisors, and anyone appointed by the Sponsor to check the study is being carried out 





We will inform your General Practitioner (GP) that you are taking part in this study. We will 
not inform your GP of any details about your performance on the assessment, unless: 
• You report any difficulties with your mood; 
• Your performance suggests that you may have be having significant problems with 
your memory.  
 
If you tell me anything that makes me think that you, or others around you, are at risk of 
harm, I would need to inform your GP and discuss with you how to address this. 
 
The information I gather from you will be kept for 3 years after the research has been 
completed, in accordance with NHS Research Ethic’s Guidelines.  
 
Will I find out the results of the study?  
If you wish to know the results of the study we can provide you with a written summary. The 
study will be completed in August 2013.  
 
What will happen to the results of the study?  
The information I collect will be written up as a Doctoral Thesis as part of my Clinical 
Psychology training course. I may also publish some of the data as a piece of research in a 
scientific journal. Any information collected will be kept anonymous and only myself and my 
supervisors will be able to identify the participants involved.  
 
Who is organising the research and why?  
I am conducting this study as part of my Doctorate in Clinical Psychology. It will be written up 
as my Doctoral Thesis.  
 
Who has reviewed the study?  
The study proposal has been reviewed by the University of Edinburgh Doctorate in Clinical 
Psychology course and my supervisors (Dr. Ken Laidlaw and Dr Sandy McAfee). Ethical 
approval has also been granted by South East Scotland Research Ethics Committee.  
 
What to do now?  
If you would like to know more about the study or are interesting in participating, please 
complete the tear off slip and send it to: 
 
Jo Phillips 
Trainee Clinical Psychologist 
Older Adults Clinical Psychology 
Psychology Department 
St John’s Hospital 
Livingston 
If you do not wish to participate in the study you do not have to do anything. Thank you for 





































Fig 1. Flow chart explaining participation process. 
 
I would like to speak to an independent advisor reg arding the study  
If you would like to speak to someone else about the study please contact: 
 
Dr Emily Newman 
Health Psychology Lecturer 
School of Health in Social Science 
Old Medical School 
University of Edinburgh 
Edinburgh EH8 9AG 
0131 651 3945 
 
I would like further information or 
would like to discuss how I can 
participate in the study 
Contact Jo Phillips or complete tear 
off slip and send to above address.  
 
You can contact Jo Phillips by phone 
to discuss the study (Tel No) 
Arrange a time/date to meet to 
complete the assessments. Your GP 
will be informed of your participation 
I would like to participate in the study 
I do not wish to take part in the 
study. Please inform Jo 
Phillips that you no longer 
wish to take part. You do not 
have to provide any reason.  
Attend appointment 
You will be sent a series of 
questionnaires to complete and bring 
with you to the appointment 
I do not wish to take part in 
the study 
If do not wish to take part in 
the study, you do not have to 
do anything. Thank you for 
reading the Participant 




Thank you for taking the time to read this informat ion sheet 
Jo Phillips, Trainee Clinical Psychologist 
 
If you would like to participate in the study, or w ould like further information, please 
complete the tear off slip below and send it to: 
 
Jo Phillips 
Trainee Clinical Psychologist 
Older Adults Clinical Psychology 
Psychology Department 





Tear off slip here 
 








I would like further information regarding the above study   
   
I would like to participate in the above study   
   
My preferred location for an appointment is: 
 
  
St John’s Hospital, Livingston   
   
Royal Edinburgh Hospital, Edinburgh   
   




Please contact me via  telephone  / email  / post (delete as appropriate)   
  







Email:                                                                                       Contact No: 
